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Abstract 
 
An organism can significantly increase its complexity through increasing its protein 
diversity. This can be achieved through applying post-translational modifications 
(PTMs) to proteins, altering its structure after synthesis. From all possible enzyme 
catalyzed modifications, phosphorylation is arguably the most important. O-
phosphorylation, the addition of a phosphate on a serine, threonine or tyrosine amino 
acid residue, can cause a dramatic change in protein function. Nowadays, more and 
more research is devoted to the less well understood amino acid N-phosphorylation. 
However, the relative chemical instability of the P-N bond makes it difficult to study. 
In particular histidine phosphorylation is now receiving more attention due to its high 
abundance in nature in general. Recently, antibodies against phospho-histidine have 
been reported and these tools will boost research in this field, like it did for phospho-
tyrosine. The enzymes involved in histidine phosphorylation, kinases and 
phosphatases, are also subject of research and besides the non-selective 
nucleoside-diphosphate kinases (NDPKs) a highly specific phospho-histidine 
phosphatase (PHP) has been identified. Unique in its class and expressed in high 
levels in many different cell types, this enzyme can be an alternative key in opening 
the door to the evaluation of the significance of N-phosphorylation in higher 
organisms.  
In order to investigate PHP function, enzyme knockdown through siRNA has shown 
great potential already. Chemical knockdown will be a valuable additional tool to 
reversibly inhibit the enzyme in a cellular setup. A small molecule inhibitor will also be 
useful in the evaluation of PHP as a potential drug target. PHP catalyzes the 
phospho-histidine hydrolysis reaction through activation of a water molecule (see 
figure). An imidazole equipped with a sulfonamide was hypothesized to mimic the 
transition state of PHP catalyzed phospho-histidine hydrolysis. This structural feature 
was explored as both small molecule inhibitor and peptide PHP inhibitor. In order to 
incorporate the imidazole sulfonamide in a peptide, the strategic building block 7 was 
prepared and successfully converted into several peptides using solid phase peptide 
synthesis (SPPS). For evaluation of the prepared compounds, biochemical assays 
were developed to assay the PHP inhibitory activity. Three different assaying 
techniques were successfully applied to study PHP activity and inhibition. A 
continues coupled enzyme UV absorption assay and a fluorescence assay utilizing a 
modest phospho-tyrosine hydrolysis activity of PHP were developed and successfully 
deployed to evaluate the prepared peptides and small molecules. Several small 
molecule inhibitors were identified with IC50 values ranging from 3 to 11 µM. In 
peptide form the sulfonamide imidazole failed to show inhibitory activity, indicating a 
different binding mode from what was hypothesized. 
The identified small molecules 53b, 53f, 60c and 86 were further evaluated with a 
Microscale Thermophoresis based binding assay and the solubility and cell 
permeability were assayed. Finally, the compounds were evaluated in a patch clamp 
ion channel whole cell assay and in a scratch type migration assay.  In both assays 
little effect was observed for most compounds except for compound 86. At 100 µM 
concentration 86 showed a significant inhibition of ion channel activation. This effect 
is different from expected as PHP inhibition was reported to increase channel activity. 
In the scratch assay no effect was observed besides occurance of cell death at a 
higher concentration of 86. This effect might be attributed to a carbonic anhydrase 
activity of the inhibitor compound. 
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Besides investigating PHP, the developed building block 7 is also suitable for 
investigating other aspects of histidine phosphorylation. Building block 7, and a 
phosphonate version developed earlier in our lab, was also incorporated into 
peptides derived from Histone H4. These peptides were designed to study the 
possible influence of histidine phosphorylation of epigenetic processed known to take 
place on the Histone H4. Lysine acetylation and methylation were studied on these 
peptides in order to see if a modification on an adjacent histidine, a known target for 
phosphorylation in vivo, would influence these processes. Unfortunately, no effect 
was found when comparing an N-phosphorylated target peptide to a non-
phosphorylated version. Additionally, pull-down probes, based on Histone H4 were 
prepared in order to identify phospho-histidine interacting proteins. Also here, the 
peptides failed to identify novel proteins involved in histidine phosphorylation. 
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Zusammenfassung 
 
Organismen können ihre Komplexität erheblich vergrößern, indem sie ihre 
Proteindiversität erhöhen. Dies kann zum Beispiel durch posttranslationale 
Modifikationen geschehen, die die Proteinstruktur nach der Synthese verändern. Von 
allen möglichen Modifikationen ist die Phosphorylierung die Wichtigste. O-
Phosphorylierung an Serin-, Threonin- oder Tyrosinresten kann die Funktion eines 
Proteins erheblich verändern. Jedoch wird heutzutage mehr und mehr Aufwand 
betrieben auch die weit weniger erforschte N-Phosphorylierung von Proteinen zu 
verstehen. Dies wird allerdings durch die chemisch relativ instabile Natur der P-N-
Bindung erschwert. Insbesondere die Histidinphosphorylierung steht dabei aufgrund 
ihrer Häufigkeit im Fokus. Kürzlich entwickelte Antikörper gegen diese Modifikation 
werden, ähnlich wie es vorher für Phoshotyrosin der Fall war, werden das Feld in 
Zukunft erheblich weiter bringen. 
Auch die Enzyme der Histidinphosphorylierung, Kinasen und Phosphatasen, sind 
Gegenstand der aktuellen Forschung. Neben nicht-selektiven Nukleosid-
Diphosphatkinasen (NDPKs) wurde eine hochspezifische Phosphohistidin-
phosphatase (PHP) identitifiziert. Einzigartig in ihrer Klasse und hoch exprimiert in 
vielen verschiedenen Zelltypen, könnte dieses Enzym der Schlüssel zur Evaluierung 
der N-Phosphorylierung in höheren Organismen sein. Bisher wurde das Enzym durch 
siRNA vermittelte Knock-Down-Experimente erforscht. Ein chemischer, reversibler 
Knock-Down durch kleine Moleküle würde eine wertvolle Erweiterung dessen 
darstellen. Darüber hinaus können kleine Moleküle als Inhibitoren dazu dienen, PHP 
als potentielles Zielprotein in der Medikamentenentwicklung zu evaluieren. 
PHP katalysiert die Hydrolyse von Phosphohistidin durch die Aktivierung eines 
Wassermoleküls (siehe Abbildung). Ein durch ein Sulfonamid modifiziertes Imidazol 
wurde als hypothetisches Pharmokphor und mögliches Übergangszustansmimetikum 
dieser Reaktion gewählt und sowohl als kleine Moleküle, als auch in Peptide 
inkorporiert und hinsichtlich potentieller PHP-Inhibition untersucht. Für die Synthese 
der Imidazol-Sulfonamidpeptide wurde der strategische Aminosäurebaustein 7 
hergestellt und mittels SPPS erfolreich in Peptide eingebaut. Zur Untersuchung der 
PHP-Inhibition wurde ein biochemischer Assay entwickelt und letztendlich wurden 
drei Assaytechniken erfolgreich angewandt. Es wurde sowohl ein enzymgekoppelter 
UV-Absorptionsassay als auch ein fluoreszenzbasierter Assay entwickelt, die auf der 
schwachen Phosphotyrosin-Hydrolyseaktivität von PHP basieren. So konnten einige 
kleine Moleküle als PHP-Inhibitoren mit IC50-Werten von 3 bis 11 µM identifiziert 
werden. Die getesteten Peptide zeigten keine Aktivität als PHP-Inhibitoren, was 
darauf schließen lässt, dass der ursprünglich vermutete Bindungsmodus nicht korrekt 
ist. Die kleinen Moleküle 53b, 53f, 60c und 86 wurden hinsichtlich ihrer Bindung an 
PHP weiter mittels Microscale Thermophoresis untersucht. Zudem wurden ihre 
Löslichkeit und die Zellpermeabilität bestimmt. Letztlich kamen Patch Clamp 
Ionenkanalexperimente und Zellmigrationsassays hinzu. In beiden zeigten die 
Moleküle nur geringe Aktivität, mit Ausnahme von Verbindung 86, welche bei einer 
Konzentration von 100µM eine signifikante Inhibierung der Ionenkanalaktivität zeigte. 
Dieser Effekt widerspricht den Erwartungen, da vorher bereits berichtet wurde, dass 
PHP-Inihibition die Ionenkanalaktivität erhöht. In den Zellmigrationsexperimenten 
zeigte die Verbindung keinen Effekt, mit Ausnahme von Toxizität in höheren 
Konzentrationen. Dieser Effekt könnte in Zusammenhang mit einer potentiellen 
Wirkung auf Carboanhydrasen erklärt werden. 
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Neben der Erforschung von PHP kann der Aminosäurebaustein 7 auch dazu dienen 
andere Aspekte der Histidinphosphorylierung zu untersuchen. Baustein 7 und auch 
ein vorher in unserem Labor entwickelter Phosphonat-basierter Baustein wurden in 
Peptide, die von Histon H4 abgeleitet wurden eingebaut um den möglichen Einfluss 
von Histidinphosphorylierung auf epigenetische Prozesse zu erforschen. Dazu wurde 
der Effekt von Histidinmodifikationen in Nachbarschaft zu Lysinen auf deren 
Acetylierung und Methylierung untersucht, da diese in vivo bekannt dafür sind, 
phosphoryliert zu werden. Dabei zeigte sich jedoch kein Unterschied zwischen N-
Phosphorylierten und nicht modifizierten Peptiden. Darüber hinaus wurden auch 
Sonden für Pull Down-Versuche hergestellt, die jedoch nicht zur Identifikation von 
neuen Proteinen, die in der Histidinphosphorylierung eine Rolle spielen, führten. 
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AA   amino acid 
Ac   acetyl 
All   allyl 
Alloc   allyloxycarbonyl 
aq   aqueous 
ATP   adenosine triphosphate 
Bn   benzyl 
Boc   tert-butoxycarbonyl 
br   broad 
Bu   butyl 
Bz   benzoyl 
°C   degrees Celcius (centigrade) 
calc.   calculated 
CAN   ceric ammonium nitrate 
Cbz  benzyloxycarbonyl 
CDI   carbonyldiimidazole 
m-CPBA  meta-chloroperoxybenzoic acid 
d (NMR)  doublet 
DABCO  1,4-diazabicyclo[2.2.2]octane 
dba   dibenzylidene acetone 
DBU   1,8-diazabicyclo [5.4.0]undec-7-ene 
dd (NMR)  doublet of doublets 
DDQ   2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
DCC   N,N-dicyclohexylcarbodiimide 
DCM   dichloromethane 
DIAD   diisopropyl azodicarboxylate 
DIC   diisopropyl carbodiimide 
DIPEA  diisopropylethylamine 
DMAP  4-dimethylaminopyridine 
DMB   2,4-dimethoxybenzyl 
DMF  N,N-dimethylformamide 
DMSO  dimethyl sulfoxide 
dppf   1,1'-bis(diphenylphosphino)ferrocene 
dt (NMR)  doublet of triplets 
EDC   3-(ethyliminomethyleneamino)-N,N-dimethyl-propan-1-amine 
Equiv  equivalents 
ESI   electrospray ionization 
Et  ethyl 
et al.   et alia (and others) 
Fmoc  9-fluorenylmethoxycarbonyl 
h   hours 
HATU  2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium 
hexafluorophosphate 
HBTU  O-benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate 
HOAt   3-Hydroxytriazolo[4,5-b]pyridine 
HOBt   N-hydroxybenzotriazole 
HPLC  high performance liquid chromatography 
HRMS  high resolution mass spectrometry 
iPr   isopropyl 
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HMDS  bis(trimethylsilyl)amine 
LCMS  high performance liquid chromatography mass spectrometry 
m (NMR)  multiplet 
Me   methyl 
MeCN  acetonitrile 
min   minutes 
MM  Magic Mixture (TLC): MeOH 3, H2O 2, AcOH 3, EtOAc 3 
mp   melting point 
MS   mass spectrometry 
Ms   mesyl 
m/z   mass to charge ratio 
NDPK  nucleoside diphosphate kinases 
NBS   N-bromosuccinimide 
NMP   1-methyl-2-pyrrolidone 
NMR   nuclear magnetic resonance 
Ns   4-nitrobenzenesulfonyl 
o   ortho 
OSu   hydroxysuccinimide 
p   phospho 
p   para 
Pbf   2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl 
Ph   phenyl 
PHP   phosphohistidine phosphatase 
ppm   parts per million 
PTM   posttranslational modification 
q   quartet 
quant  quantitatively 
Rf   retention factor 
rt   room temperature 
s   singlet (NMR) 
sat.   saturated 
S-Phos  2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl 
SPPS  solid phase peptide synthesis 
t (NMR)  triplet 
TBS   tert-butyldimethylsilyl 
tBu   tert-butyl 
Tf   trifluoromethanesulfonyl 
TFA   trifluoroacetic acid 
THF   tetrahydrofuran 
TIPS   triisopropylsilane 
TLC   thin layer chromatography 
TMP   2,2,6,6-tetramethylpiperidine 
TMS   trimethylsilyl 
Trt   trityl (triphenylmethyl) 
Ts   p-toluenesulfonyl 
XantPhos  4,5-bis(diphenylphosphino)-9,9-dimethylxanthene 
X-Phos  2-dicyclohexylphosphino-2’,4’,6’,-triisopropylbiphenyl 
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Amino acids 
 
Ala  alanine (A) 
Arg  arginine (R) 
Asn  asparagine (N) 
Asp  aspartate (D) 
Cys  cysteine (C) 
Gly  glycine (G) 
Glu  glutamate (E) 
Gln  glutamine (Q) 
His  histidine (H) 
Ile  Isoleucine (I) 
Leu  leucine (L) 
Lys  lysine (K) 
Met  methionine (M) 
Phe  phenylalanine (F) 
Pro  proline (P) 
Ser  serine (S) 
Thr  threonine (T) 
Trp  tryptophane (W) 
Tyr  tyrosine (Y) 
Val  valine (V) 
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1.1 Protein Phosphorylation 
 
1.1.1 Post-Translational Modification 
 
An important part of understanding the origin of life comes down to understanding the 
cell. All life on our planet and most likely in the universe, is based on this confined 
unit with a cell membrane that contains organic molecules, all having functions that 
are essential parts of the whole structure. Our deeper understanding started with 
unraveling the basics of genetics, the discovery of DNA, the relationship it has to 
proteins and finally mapping the entire genome. However, it is now clear that the 
relative small amount of genes (20,000 to 25,000) alone is by no means able to be 
responsible for the full complexity of higher order organisms like human beings.1 In 
principle, there are two major mechanisms for expanding the coding capacity of the 
genes to generate a higher order of diversity in the proteome (see figure 1). The first 
route of diversification of proteins is at the transcriptional level, by mRNA 
manipulation. Splicing the primary RNA into different RNAs allows the organism to 
generate similar proteins that differ in function or localization.2 Also, highly specific 
editing of RNA can be used to alter the RNA structure and therefore the protein 
outcome.3 The second route to proteome expansion is post-translational modification 
(PTM) of the protein gene products. As the name implies, PTMs are covalent 
modifications, introduced by enzymes after the DNA has been transcribed into RNA 
and translated into proteins. These highly specific enzyme-catalyzed modifications 
can occur on the side chain residues or on the protein backbone. Proteome 
diversification by covalent modification does occur in prokaryotes but is much more 
frequent and diverse in the nucleated cells of eukaryotes. About 5% of the genome of 
higher order eukaryotes is dedicated to enzymes that perform more than 200 types of 
PTMs on the proteome.4 The systematic investigation of the relationship between 
PTMs and functional changes is again a major undertaking, not unlike the human 
genome project in size and ambition. 
 
 
 
 
 
Figure 1: Increasing the proteomic diversity. The genome accounts for  20-25,000 genes however, 
the proteome is estimated to compass millions of proteins possessing a unique chemical identity. 
Manipulation of mRNA and the addition of post-translational modifications (PTMs) accounts for this 
added diversity. Figure adapted from www.piercenet.com.
5
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Besides hydrolytic cleavage of peptide backbones by proteases, all PTMs are 
enzyme-catalyzed covalent additions of a chemical group, usually an electrophilic 
fragment of a co-substrate, to a residue in a protein. The side chain that is modified is 
usually electron rich, thus acting as a nucleophile in the transfer.  
The five most common types of PTMs are acylation, alkylation, glycosylation, 
oxidation and phosphorylation. Thoroughly studied examples are the acetylation (on 
Lys) or methylation (Lys, Arg) of histones, seen as an integral part of controlling 
selective gene transcription (epigenetics).6 Myristoylation (N-terminal Gly) or 
palmitoylation (Cys) is a powerful modification to achieve membrane localization of 
proteins.7 Glycosylation, in the form of asparagine-linked (N-linked) or 
serine/threonine/tyrosine-linked (O-linked) oligosaccharides forming important parts 
of major structural components of many cell surface and secreted proteins.8 The 
sulfur containing amino acids cysteine and methionine are sensitive to oxidation.9 
The disulfide bonds that can occur between two cysteines often serve to stabilize 
protein structure in an intra-molecular fashion (e.g. insulin). And finally, there is 
protein phosphorylation, a well-known and studied modification of serine, threonine 
and tyrosine residues. Phosphorylation is arguable the most important of all PTMs 
and is for sure the most abundant. Introduction of the charged, di-anionic phosphate 
group on a neutral or positively charged amino acid induces a large change in the 
local protein microenvironment. Phosphorylation is often used as an on/off switch for 
enzyme activity, for instance in cellular signaling. 
 
 
1.1.2 Phosphorylation, an important Post-Translational Modification 
 
It is estimated that one-third of the proteins in the human proteome are substrates for 
phosphorylation at some point of their life time.10 Generally, post-translational 
modifications can occur simultaneously at multiple sites within the same protein. 
Phosphorylation is no exception. For example, the Abelson (Abl) tyrosine kinase can 
be found phosphorylated at eleven different sites, (nine times tyrosine, one serine, 
one threonine) spread over the different catalytic and regulatory domains of the 
protein.11 This results in a theoretical, 11! = 40420800 distinct isoforms possible for 
this particular protein alone. Potentially, every single added phosphorylation event 
can alter enzyme activity, localization and protein-protein interaction. 
In the late 19th century it was already known that proteins exist in a phosphate bound 
state. Most examples of these ‘phospho-proteins’ were found in milk (caseins) and 
egg yolk (phosvitin) and were simply considered to be a biological method of 
providing phosphorus as a nutrient. Therefore, the existence of phospho-proteins 
was seen as a consequence of metabolic reactions, and nothing more, for almost a 
century after their discovery.12 Regulation by protein phosphorylation was discovered 
by Edmund Fischer and Edwin Krebs who studied glycogen metabolism in the late 
1950’s.13 It was known that glycogen phosphorylase, the enzyme that degrades 
glycogen, exists in two forms, an active form (phosphorylase a) and an inactive form 
(phosphorylase b). Fischer and Krebs showed that the only difference is that 
phosphorylase a is phosphorylated on Ser14, transforming it into the active enzyme. 
They received the Nobel Prize in 1992 for their pioneering studies. Since then, 
phosphorylation has been identified on many proteins, often on the same family of 
enzymes that facilitate phosphorylation (the kinases) or de-phosphorylation (the 
phosphatases) itself. 
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The reversibility of protein phosphorylation makes this type of PTM ideal for signal 
transduction, which allows cells to rapidly respond to extracellular stimuli. Signal 
transduction cascades are characterized by one or more membrane bound proteins 
that are physically stimulated, either through ligand binding or some other response 
(see figure 2). The signal is passed on to second messengers and signaling 
enzymes. In the case of phosphorylation, the signal is passed on to downstream 
kinases, which then phosphorylate and activate their downstream substrates, 
including additional kinases, until a specific response is achieved. Signal transduction 
cascades can be linear, in which kinase A activates kinase B, which activates kinase 
C and so forth. Signaling pathways that amplify the initial signal have also been 
discovered; kinase A activates multiple kinases, which in turn activate additional 
kinases. Consequently, a single molecule, such as an extracellular growth factor, can 
activate complex cellular programs such as proliferation.14 
 
 
 
 
 
Figure 2: Cellular signaling and kinase activation through phosphorylation. Cellular signaling 
induced by binding of an external stimuli (like neurotransmitters, hormones or growth factors) to a 
ligand binding domain (LBD) of a membrane bound protein results in protein kinase activation through 
phosphorylation. Continuation of the signal is often a phosphorylation of one or more downstream 
kinases. Eventually, this signaling will result in a cellular response (e.g. protein expression, cell motility 
or cell division). 
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1.1.3  O-Phosphorylation, Kinases and Phosphatases 
 
The enzymes responsible for protein phosphorylation (kinases) collectively form one 
of the largest classes of PTM enzymes.15 This super-family of more than 500 protein 
kinases (PKs), referred to as the kinome, displays a large variety in its protein 
structure.16 Ranging from small cytosolic enzymes to large membrane bound proteins 
with multiple domains. However, all share a highly conserved kinase activity domain. 
This conservation is due to the necessity of binding the co-substrate adenosine 
triphosphate (ATP) that is required as phosphate donor. This domain conservation 
has helped the identification of PKs in the genome. Kinases are classified according 
to the amino acid residue they phosphorylate. Greater than 98% of O-
phosphorylation in eukaryotic cells occurs on serine and threonine residues by 
protein serine/threonine kinases (STKs). The remainder occurs on tyrosine residues 
by protein tyrosine kinases (TKs). A few PKs appear to phosphorylate tyrosine as 
well as serine/threonine residues and are classified as dual-specificity protein kinases 
(DSKs).17 Finally, the lipid kinase PI3K possesses protein serine/threonine kinase 
activities, in addition to phosphorylating lipid phospho-inositides.18  
As kinases often fulfill their role in tightly regulated signaling cascades, removal of the 
phosphate is of equal importance and justifies the presence of a large family of 
phosphatases. Protein phosphatases (PPs) are categorized by their selectivity for 
phospho-serine/phospho-threonine or phospho-tyrosine residues and are further 
categorized by sensitivity to endogenous inhibitors, requirements for cations, and in 
vitro substrate specificity. The major distinction is a protein serine/threonine 
phosphatase family (STPs) and a protein tyrosine phosphatase family (PTPs).19 
Additionally, a distinct family of dual-specificity protein phosphatases (DSPs) can be 
distinguished.20 STPs mediate the hydrolysis of the P-O bond of the phosphorylated 
protein residue using a bimetallic (zinc, manganese or magnesium) center, while 
tyrosine phosphatases form a covalent thio-phosphoryl intermediate that facilitates 
release of the tyrosine residue. The approximately 150 PPs found in eukaryotes are 
responsible for the de-phosphorylation of proteins that are targeted by over 500 PKs. 
This makes it likely that most phosphatases have multiple substrates.  
The use of phosphorylation/de-phosphorylation of a protein as a control mechanism 
has many advantages. It is fast; taking as little as a few seconds, it does not require 
new proteins to be made or degraded and is easily reversible. Disadvantages are 
there as well as aberrant regulation of phosphorylation can easily result in fatal 
diseases like cancer.21 Certain kinases and phosphatases are highly specific, 
potentially targeting only a few proteins, while others are able to act broadly on many 
proteins. The targets of phosphorylation include most protein components of the cell, 
including enzymes, structural proteins, cell receptors, ion channels and signaling 
molecules. If a protein is controlled by its phosphorylation state, its activity will be 
directly dependent on the activity of the kinases and phosphatases that act on it. It is 
common for a phosphate group to be added or removed from a protein continuously, 
a cycle that allows a protein to switch rapidly from one state to another. 
An important application of tyrosine phosphorylation, besides cell signaling, is 
facilitating interactions with proteins equipped with Src family homology domains 
(SH2 domains).22 These domains have been shown to bind strongly to specific 
patterns in proteins including a phospho-tyrosine. This interaction allows direct 
localization/recruitment of a protein. This is an important element of the formation of 
protein clusters and the direction of enzyme activity. 
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1.1.4 Amino Acids targeted by Kinases 
 
As stated earlier, several amino acid residues are known to be targets for 
phosphorylation (see figure 3). It is tempting to believe that it is mainly serine, 
threonine and tyrosine that are modified based on the large families of O-
phosphorylation kinases and phosphatases identified and the overwhelming amount 
of research devoted to O-phosphorylation. However, the highly important two-
component system in prokaryotes (see §1.2.1), with histidine and aspartate as 
substrates for phosphorylation, has been known for years. Initially, it was assumed 
that only O-phosphorylation is important for eukaryotes where N-phosphorylation is 
found exclusively in prokaryotes. Nowadays, more research effort is invested in the 
more exotic cases of N-phosphorylation in higher order species. Especially histidine 
phosphorylation seems interesting as it is estimated to be 10-100 fold more abundant 
in nature than phospho-tyrosine.23 The Gibbs free energy of hydrolysis for O-
phosphorylated amino acids is in the range of -6.5 to -9.5 kcal/mol. For a phospho-
histidine this is significantly larger with values ranging from -12 to -14 kcal/mol.24 This 
chemical instability is particularly evident at a pH lower than 7 where the half-life of a 
phospho-histidine species is in the order of seconds. This chemical instability makes 
histidine phosphorylation difficult to study and only recently phospho-histidine 
antibodies have been reported.25 It was an antibody against phospho-tyrosine that 
boosted the research on tyrosine phosphorylation and a similar increase in 
publications on histidine phosphorylation is to be expected in upcoming years. 
Reports on phosphorylation and de-phosphorylation of arginine, lysine, cysteine and 
glutamate residues are even more limited.26 
 
 
 
 
 
Figure 3: Chemical structures of phospho-amino acids. The structures of the well-known O-
phosphorylated amino acids phospho-serine, phospho-threonine, phospho-tyrosine and the instable 
phospho-aspartate and phospho-glutamate are shown. Also given are the less well known and studies 
N-phosphorylated amino acids phospho-lysine, phospho-arginine and both phospho-histidine regio-
isomers. Formation of phospho-cysteine is a reported but rare phenomenon. 
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1.2 Histidine Phosphorylation 
 
1.2.1  The Two-component System in Prokaryotes 
 
Intensive research performed the last twenty years has shown that bacteria use 
cleaver and quick signal transduction mechanisms to control specific gene 
expression. So-called two-component systems have been identified as the underlying 
mechanism. These signaling mechanisms allow the bacteria to respond to physical 
and chemical extracellular environmental changes by regulating osmolarity, nutrient 
uptake, redox potential, sporulation and the expression of virulence factors.27 
Histidine phosphorylation was found to be the key step in this process. 
As an example, the bacteria C. glutamicum harbors 13 different two-component 
systems and one of them (MtrBA) is directly related to transcription regulation of 
target genes involved in the response to hyperosmotic stress (see figure 4). Two-
component systems are in general a combination of a membrane bound sensor 
histidine kinase and a soluble response regulator protein located in the cytoplasm. A 
physical stimulus, related to a particular external stress factor, is sensed by the 
sensor kinase and transduced to an intracellular signal transduction cascade via 
auto-phosphorylation of a histidine on the sensor kinase. The activated phosphate is 
transferred to the response regulator (MtrA) and this activated transcription factor 
then interacts with specific binding sites near target genes on the DNA.28 
 
 
 
 
Figure 4: Representation of the two-component system MtrBA from C. glutamicum. Upon 
external stimuli the membrane bound histidine kinase MtrB auto-phosphorylates on a histidine (H). 
Interaction with the signaling molecule MtrA leads to phosphate transfer to MtrA on an aspartic acid 
(D) and consequent activation of this transcription factor. Figure adapted from www.kraemerlab.uni-
koeln.de.
28 
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The two-component system allows bacteria to take advantage of the chemically less 
stable nature of the N-P bond in the phosphorylated histidine. This quick phospho-
transfer reaction speeds up signaling and allows for a quickly initiated response. 
Two-component signal transduction systems are used not only by bacteria, but also 
by other prokaryotes and higher plants. However, higher eukaryotes including 
mammals, use distinct signal transduction systems that incorporate O-
phosphorylation as described in §1.1.2 and §1.1.3 rather than N-phosphorylation. 
 
 
1.2.2 Histidine Phosphorylation in Eukaryotes 
 
The overwhelming evidence found for histidine phosphorylation in bacteria (the two-
component system) and the identification of O-phosphorylation as key in cell 
signaling in eukaryotes suggests a clear distinction; N-phosphorylation is used by 
prokaryotes and O-phosphorylation by eukaryotes. Nevertheless, homologs of the 
two-component system have been found in yeast, plant and fungi, and O-
phosphorylation has also been found in prokaryotes.29 The lack of tools to study 
histidine phosphorylation, especially in mammals, still hampers progress in this field.  
In higher order eukaryotes phosphorylation of histidine on the β-subunit of trimeric G-
proteins has been the focus for research. This phosphate can be transferred directly 
to the GDP attached to the α-subunit of the G-protein and activating it. A lot of effort 
has been invested in further elucidating this mechanism but the phospho-histidine 
intermediate appears to be very short-lived making it difficult to study.30 
Histidine phosphorylation has also been shown to occur on the highly conserved 
histone H4 in various species.31 There is much evidence on PTMs that are performed 
on the histones that control cellular processes like gene transcription, DNA repair, 
replication and recombination.6 The two histidine residues on histone H4 that can be 
phosphorylated are in regions of the protein that form interactions with other histones 
in the nucleosome.32 Here, histidine phosphorylation has the potential to disrupt the 
formation of nucleosome structure and influence DNA transcription directly. However, 
definite proof supporting this hypothesis has not been found yet. 
ATP-citrate lyase (ACL) has been identified as a target of histidine phosphorylation.33 
In the cytosol, ACL cleaves citrate to form acetyl–coenzyme A (CoA) and 
oxaloacetate. Acetyl-CoA is used in the synthesis of acetylcholine, fatty acids, and 
cholesterol. Enzymatic removal of the histidine phosphate directly reduces its activity 
and slows down these metabolic pathways. An influence on acetylcholine synthesis 
suggests a role in the central nervous system (CNS). Indeed, an important role for 
ACL histidine phosphorylation has been found in the viability of neuronal cells.34 
The intermediate conductance voltage-insensitive potassium channel KCa3.1 is the 
best example for understanding the potential of protein regulation by histidine 
phosphorylation. KCa3.1 has been shown to play a critical role in the stimulation of 
calcium influx in a number of cells.35 Opening of the channel allows potassium to 
leave the cell and this facilitates influx of calcium from the endoplasmic reticulum 
(ER). His358, which resides in the C terminus of the channel, is known to be 
phosphorylated in CD4 T cells. This initiates channel activation, and vice versa, de-
phosphorylation leads to channel closing. T cell activation was shown to be directly 
influenced by the phosphorylation state of the KCa3.1 channel.  
The kinases and phosphatases responsible for all these histidine phosphorylations 
appear to be much more rare in number that their O-phosphorylation counterparts. 
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1.2.3 The Kinases and Phosphatases involved in Histidine Phosphorylation 
 
The before mentioned analytical difficulties to detect histidine phosphorylation has 
hindered research on the enzymes that are involved. Kinases and phosphatases 
involved in N-phosphorylation work mechanistically different from their O-
phosphorylation counterparts and are therefore not easily found through sequence 
homology. Nevertheless, genomic sequencing has been successful in finding two-
component like kinases in bacteria. Complete families of bacterial histidine kinases 
have been identified based on homology.36 Dedicated histidine phosphatases 
however, seem to be rare in prokaryotes although not completely absent.37 The 
kinases or the response regulator proteins of two component systems generally 
display aspartate phosphatase activity terminating the signal on their own. 
Well studied and fully characterized histidine kinases and phosphatases in mammals 
have been limited to a single type of kinase and a single phosphatase. The 
Nucleoside Di-Phosphate Kinases (NDPKs) were originally seen as housekeeping 
kinases. They play a key role in nucleotide metabolism and catalyze the transfer of a 
phosphoryl group from a nucleoside triphosphate to a nucleoside diphosphate. 
Additionally, more functions for these kinases have been found in regulation of tumor 
metastasis, cell differentiation and cell motility.30, 32 Of the nine different isoforms of 
NDPKs only two display intrinsic histidine phosphorylation activity. The NDPK-A and 
NDPK-B enzymes phosphorylate all target proteins mentioned in §1.2.2 in vivo, 
except for the histones in the cell nucleus. Here, the responsible kinases (Histone H4 
histidine kinases or HHKs) have not been fully characterized.30 
Several eukaryotic serine/threonine phosphatases have been shown to have 
moderate de-phosphorylation activity towards phospho-histidine. The histidine 
phosphorylation on histone H4 appears to be targeted by these phosphatases.31 Also 
here, its relevance in vivo and to what extend it is an artifact remains unclear. 
In 2002, a selective phosphatase was found and its primary structure fully 
sequenced. Until today this phospho-histidine phosphatase, or PHP (also known as 
PHP14 or PHPT1), remains the only fully evaluated enzyme that is truly dedicated to 
histidine phosphorylation in mammals. Its activity appears to be coupled to the 
NDPKs as it has the same realm of target proteins (see figure 5).  
 
 
Figure 5: Histidine phosphory-
lation/ de-phosphorylation of 
KCa3.1, the β unit of G proteins 
and ACL by NDPK and PHP 
respectively. Activation of the 
intermediate conductance voltage-
insensitive potassium channel KCa3.1 
by a histidine kinase (NDPK-A or 
NDPK-B) leads to opening of the 
channel and release of potassium. 
This process can be terminated by 
PHP through removal of the 
phosphate. The same enzymes have 
also been shown to be responsible for 
the phosphorylation/ de-phosphory-
lation of ACL and the β-subunit of G 
proteins in vivo. Figure adapted from 
Klumpp et al. 2009.
38
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1.3 Phospho-histidine Phosphatase (PHP)  
 
1.3.1 A mysterious enzyme 
 
In 2002, two groups independently reported on a mammalian phosphatase selective 
for phospho-histidine. Klumpp and co-workers used the bacterial protein [32P-
His]cheA as bait in rabbit liver soluble extract.39 Zetterqvist and co-workers used a 
synthetic phospho-histidine peptide to search for phosphatase activity in porcine liver 
cytosol extracts.40 Isolation, purification and sequencing revealed a 14 kDa protein, 
eventually found in numerous organisms (see figure 6), but without homologues in 
bacteria and fungi. The enzyme showed no sensitivity for general phosphatase 
inhibitors like okadaic acid, microcystin, vanadate or genistein. This protein, clearly 
part of a novel class of enzymes, was named Phospho-Histidine Phosphatase (PHP). 
PHP has no structural resemblance to other phosphatases and its activity is not 
affected by EDTA, indicating catalytical independence from metals, like Zn, Mg or Ca.  
After ten years, PHP still remains enigmatic and stands out since no similar enzymes 
have been found. Its means of regulation remains to be clarified and its role in cell 
homeostasis is not even slightly clear. The expression levels (northern blot) in 
different tissues, high in brain and neuronal cells and elevated in heart and skeletal 
muscle, also do not give away much of its secrets. However, high expression levels 
in tissues where the epithelial cells have a short half-life was found, suggests an 
involvement in cell proliferation.41 
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Figure 6: Alignment of human phospho-histidine phosphatase and interspecies homologous 
proteins. The amino acid sequence of human phospho-histidine phosphatase (PHP) compared with 
the homologous bovine, mouse and porcine sequences. Figure adapted from Ek et al. 2002.
40
 
 
 
1.3.2 PHP in Healthy Tissues 
 
PHP is found in virtually all vertebrates and tissue-types. Interestingly, it has been 
shown to be present in high quantity and activity in brain tissue and neurons.33, 42 
Already with its discovery by Klumpp and co-workers an important role for PHP in 
neuronal signaling was suggested. It was shown to be present in C. elegance 
exclusively in motor neurons along the ventral nerve cord.39 Research in this line was 
continued and the effect of PHP overexpression and its interaction with ACL was 
studied in various neuronal cells.42 A clear interaction was established between these 
two proteins and PHP was shown to de-phosphorylate ACL in vivo and by doing so 
reducing its activity. PHP can reduce neuronal cell viability through reducing the 
metabolic function of ACL and an increase in apoptosis was observed. It was 
suggested that excessive PHP activity can be linked to neurodegenerative diseases. 
A second study reporting the down-regulation of PHP with siRNA did not show an 
effect in human neuronal cell lines compared to untreated cells.34 
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PHP was also shown to have high expression levels in blood vessel walls.41 Again, 
over-expression and down-regulation of PHP was used to study its function in 
cultured human umbilical-vein endothelial cells (HUVEC).43 Over-expression led to 
reduced cell viability and increased levels of apoptosis. Down-regulation of PHP did 
not show an effect. The effect of over-expression is directly related to the enzyme’s 
histidine phosphatase activity since over-expression of a catalytically non-active PHP 
mutant, H53A, showed no reduced cell viability. 
In both studies siRNA was used for PHP down-regulation since there is no chemical 
inhibitor for PHP reported so far. An inhibitor could be used to more accurately study 
the effect of PHP and might even reveal PHP as a novel drug target in the treatment 
of neurodegenerative and cardiovascular disorders. 
 
 
1.3.3 PHP in Cancerous Tissues 
 
In 2003, the existence of an additional layer of N-phosphorylation on top of the O-
phosphorylation in cell signaling was suggested.44 This difficult-to-detect series of 
PTMs might be just as important in cell function and dysfunction as O-
phosphorylation. Indeed, recently PHP has been linked to cancer. 
In 2010, a study was published showing a relationship between PHP over-expression 
and metastasis of human lung cancer cell migration and invasion.45 In human lung 
adenocarcinoma CL1-5 cells, high expression levels of PHP were found. This was 
correlated with lymph node metastasis in the tissues of human patients with lung 
cancer. The CL1-5 cell line normally shows high levels of invasive potential, but not 
after PHP gene silencing with siRNA. To further support the theory that PHP directly 
influences lung cancer metastasis, PHP was over-expressed in human non-small cell 
lung carcinoma cells (NCI H1299) and also here an increase in invasiveness and 
migration was observed. Comparing the CL1-5 cells with the siRNA PHP knockdown 
showed a remarkable difference in the expression pattern of an array of proteins that 
are described as cytoskeletal modulators. This suggests that PHP regulates cell 
migration/invasion via the cytoskeletal reorganization signaling pathway. This was 
further supported by comparing the siRNA PHP knockdown CL1-5 cells with CL1-0 
cells. These CL1-0 cells are highly similar to CL1-5 but show poor metastatic 
properties. Knockdown of PHP expression from CL1-5 cells leads to an actin 
cytoskeletal rearrangement similar to that of the non-invasive CL1-0 cell line. How 
PHP activity influences cytoskeletal rearrangement is speculation but altering 
cytoplasmic calcium levels leads to cytoskeletal reorganization. PHP manipulation of 
G-proteins or KCa3.1 might very well be involved in this process. 
In 2012, it was shown that level of PHP expression in hepatocellular carcinoma 
(HCC) tissues and cell lines are elevated compared to non-cancerous human liver 
tissue and cells.46 HCC is an aggressive malignant tumor with high incidence and 
poor prognosis. A lentivirus-mediated delivery of siRNA targeting PHP was used to 
knockdown the enzyme. The results were more profound compare to the CL1-5 and 
NCI H1299 cells as both cell growth and proliferation were significantly inhibited. 
These two studies are the first steps in mapping the role of PHP and its over-
expression in cancerous tissues. There appears to be an important role for PHP in 
cell metastasis and a need for a chemical inhibitor to further elucidate PHP its role 
and function. It is even suggesting PHP as a possible drug target where small 
molecule inhibitors can be used as a novel chemotherapeutic. 
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1.3.4 The 3D Structure and Catalytical Mechanism of PHP 
 
In 2005, Zetterqvist and co-workers, published a mutational study providing the first 
insights in PHP activity related to its structure.47 In order to identify the active site, 
point mutations were introduced replacing conserved histidine and arginine residues 
for alanine. His53 and His102 were identified as being essential for catalytic activity as 
the mutations H53A and H102A lead to catalytically incompetent proteins. The 
mutations R45A and R78A decreased the activity by 89% and 50% respectively. 
In 2006, a 1.9 Å resolution crystal structure was published (pdb code 2HW4, figure 
7).48 Here, the enzyme was described as: “a 125-amino acid human cytosolic protein 
that folds into a compact elbow-shaped molecule of a mixed α/β fold with novel 
topology”. What was found by analyzing the surface of the protein around the 
essential His53 was a shallow pocket lined with AAs residues standing up from the 
protein surface (figure 7B). These residues show high conservation among the 
animal kingdom. Two distinct sets of conditions were used to crystallize the protein. A 
high concentration of sodium formate (pdb code 2HW4) or ammonium sulfate (pdb 
code 2NMM) was required to obtain diffracting crystals. The formate or sulfate anions 
were found well defined inside the active site of both structures (see figure 8A and 
8B) and are kept in place by similar, but different, hydrogen bond networks. The 
phosphate-group from a phospho-histidine substrate is likely to bind in a similar 
fashion in order to facilitate PHP catalyzed hydrolysis. 
 
 
Figure 7: Crystal structure of PHP (pdb code 2HW4). A, Ribbon representation of PHP revealing 2 
α-helices and 6 β-strands forming one folded β-sheet. B, Molecular surface representation with 
location of His
53
.  This residue is essential for catalytic activity, suggesting the catalytic site to be 
located in the shallow pocket above. The pocket is lined by several residues standing up from the 
protein surface. These residue show a high level of conservation among various species. Figure 
adapted from Busam et al. 2006.
48
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Figure 8: The proposed active site of PHP. A, A surface representation of the proposed active site 
with preserved formate ions (pdb code 2HW4). B, A surface representation of the proposed active site 
with preserved sulfate ions (pdb code 2NMM). C, A representation of the amino acids that line the 
active site and preserved water and formate ions. Figure adapted from Busam et al. 2006.
48
 
 
 
The cavity is restricted by the upright standing residues Lys21, Tyr52, Arg78, Ser94 and 
Met95 (see figure 8C). From these amino acids only Arg78 was subjected to mutation 
in the forth-mentioned study. The R78A-mutant showed a reduced enzyme activity of 
50% supporting the assignment of catalytic activity to this particular location. Lys21 
and Arg78 were suggested to serve as substrate anchors. Interestingly, the crystal 
structure does not support the observation that H102A and R45A are detrimental for 
enzyme activity. Both residues are located far from the putative active site. 
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In 2009, a more detailed mutation study in combination with an NMR solution 
structure analysis was reported.49 The active site was more accurately defined 
through NMR solution structure comparison of the free phosphate (Pi) bound versus 
non-bound version and a more extended point mutation study. Two possible catalytic 
sites, based on the NMR measurements were evaluated (see site I and site II in 
figure 9). Site I is in between the residues Tyr52, His53 and Ala54 on one side and 
Ser94, Met95, Ala96, Tyr97 and Gly98 on the other side. Site II can be found in between 
Lys21, Arg78, Ile79 and the residues Gly124 and Tyr125 on the flexible, in the X-ray 
structure non-visible, C-terminus. In both sites a conserved sulfate is present. Close 
examination of the Pi bound NMR solution structure shows a significantly larger 
influence on the residues from site I. This is further supported by point mutations of 
the majority of the amino acids forming the two sites. Indeed, H53A is completely 
inactive, but it has an enhancing effect on Pi binding. This suggests that the 
imidazole ring of His53 is not involved in substrate binding, but is essential for 
catalysis. The M95D and A96D mutations that were generated to introduce a 
negative charge at site I and the S94A mutation all show significant decreases in 
phosphate binding and catalytic activity. Ser94 is likely to form an H-bond with the 
phosphate, as is seen in crystal structure 2NMM, where the sulfate is coordinated 
with the serine OH. The mutations of site II residues, K21A and R78A show only poor 
effects on Pi binding or enzyme catalysis. Even a double mutant of these amino acids 
is still catalytically active. This clearly shows that these residues do not serve as 
substrate anchors as proposed before. Altogether, there is strong evidence for PHP 
exerting its catalytical activity at site I. Close analysis of chemical shifts in the Pi-
bound NMR solution structure suggest a tight coordination of the substrate 
phosphate by multiple H-bonds between the protein backbone N-H of His53, Ala54 and 
Ala96. As mentioned before, Ser94 is likely to contribute and forming a complex 
hydrogen bond network very similar to the one observed in 2NMM for a sulfate anion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: The location of the two proposed sites of catalysis (Site I and Site II) on X-ray 
structure 2NMM. Based on chemical shift information two possible active sites are proposed; Site I 
and Site II. See text for details. Figure adapted from Gong et al. 2009.
49
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Based on the suggested phosphate binding a mechanism of hydrolysis of phospho-
histidine was proposed with His53 as the catalytical residue (see figure 10). In 
general, a catalytic histidine can act as an attacking nucleophile, a general acid 
catalyst that protonates the leaving group or as a base, deprotonating a solvent 
molecule. His53 has a predicted pKa of 3.13, making it unlikely to be a hydrogen 
donor.48 Also, the distance to the sulfate (~3.7 Å) is too large for the histidine to act 
as a nucleophile. This strongly suggests activation of a water molecule by His53 (as 
depicted in figure 10). This mechanism is completely different from the mechanisms 
used by serine/threonine and tyrosine phosphatase families.  
 
 
Figure 10: Proposed catalytic 
mechanism of PHP induced phospho-
histidine hydrolysis. The amino acids 
His
53
, Ala
54
, Ser
94
 and Ala
96
 are likely 
involved in phosphate binding. His
53
, the 
only amino acids that is absolutely vital for 
catalytic activity, is too far away from the 
phosphate to serve as a nucleophile. His
53
 
can also serve as an activator of a water 
molecule. This water molecule, in close 
proximity to the phospho-histidine, can act 
as a nucleophile attacking the phospho-
histidine. The assumption is that the 
phospho-histidine will be ‘caught’ in the 
same hydrogen bond network that keeps 
the sulfate in 2NNM in place due to 
hydrogen bonds with residues Ala
54
, Ser
94
 
and Ala
96
. Figure inspired by Gong et al. 
2009.
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In 2010, Klumpp and co-workers suggested the presence of an ATP binding site on 
PHP.50 This would be next to a glycine rich region. Indeed it was shown that PHP can 
be reversibly labeled with [α-32P]ATP. However, close examination of the crystal-
structures makes this highly unlikely. The supposedly responsible triple glycine 
motive (Gly75-Gly76-Gly77) is located inside the protein underneath the catalytic site. 
More likely, ATP binds inside the catalytic site and mutations G75A and G77A simply 
re-model the active site indirectly, explaining the loss of ATP binding and enzyme 
activity. His53 might be pushed up by these mutations altering the solvent exposed 
catalytical site. It is not unlikely that ATP, with a series of three negatively charged 
phosphates, will bind to the basic active site directly. More interestingly, this study 
also looked into the three cysteine residues that are located closely together far away 
from the active site. Mutation of these residues to alanine did not affect enzyme 
activity. Truncation of the enzyme from the N-terminus side was possible till amino 
acid 9 after which amino acid deletion resulted in almost complete loss of catalytic 
activity. The C-terminus appears to be more important since only 4 amino acids could 
be deleted without loss of activity. 
An extensive survey of tyrosine phosphorylation of proteins isolated from human 
mammary epithelial cells published in 2009 revealed Tyr116 and Tyr125 from PHP as 
targets of phosphorylation.51 The meaning and relevance of this feature was not 
addressed and remains to be investigated.  
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2.1 Prospects and Challenges in Chemical PHP Inhibition 
 
The efforts so far in studying the physiological role of PHP clearly show the need for 
tools that biology alone cannot provide. These tools can be obtained through 
chemical means. Especially a small molecule/peptidomimetic inhibitor for PHP can 
be useful to further elucidate the role that PHP plays in complex processes in cells. 
Since PHP activity has been linked to neurodegenerative and cardiovascular 
disorders and cancer, a cellular active PHP inhibitor might be more than a 
biochemical tool. It can be regarded as a potential therapeutic agent. 
For a long time, it was assumed that targeting phosphorylation related enzymes with 
a small molecule for therapeutic purposes was physiologically impossible. However, 
the success of the BCR-Abl kinase inhibitor Imatinib (approved in 2001 as Gleevac®) 
showed that issues of selectivity and related toxicity can be overcome.52 Since then, 
several kinase inhibitors successfully reached the market, although the field of 
phosphatase inhibitors has not taken such a high flight. For inhibition of 
phosphatases with small molecules, selectivity and poor pharmacokinetic properties 
remains problematic.53 The catalytical domains of phosphatases are generally highly 
conserved and these enzymes exert selectivity in substrate through regulatory 
domains or subunits and not so much through direct protein-protein selection. Also, 
localization of the required phosphatase through protein-protein interactions or PTMs 
(e.g. palmitoylation to achieve membrane binding) is likely to occur and will 
compartmentalize enzyme catalysis to where it is required.54 This selectivity issue is 
less likely to occur with a potent PHP inhibitor. The enzyme uses a unique 
mechanism of action (as explained in §1.3.4) and lacks the family resemblance to 
other enzymes in cells. This significantly raises the possibility of a phosphatase 
inhibitor, selectively targeting PHP, succeeding as a tool and/or drug compound. 
 
 
2.2 A Strategic Building Block as a Starting Point for PHP Inhibitors 
 
As suggested by molecular modeling, substrate peptides can have significant 
interaction with the proposed catalytic site of PHP.48 However, the proposed 
mechanism and the point mutations reported later, as presented in §1.3.4, suggest 
otherwise.49 It remains to be seen how big (or better, how small) and solvent exposed 
(how ‘drug-able’) the catalytic site of PHP really is. Also, it is unclear to what extend a 
peptide sequence will contribute to ligand binding.  
Without hits from a high-throughput screen, using a rational design is an attractive 
option, e.g. a phospho-histidine mimic that cannot be hydrolyzed by the enzyme. This 
unit would preferably be ‘dressed up’ in the shape of a Solid Phase Peptide 
Synthesis (SPPS) compatible building block. Such a strategy has been deployed 
before, with limited success until recently, in the efforts to generate antibodies 
against phospho-histidine. The native phospho-histidine (figure 11, 1) has been 
mimicked by the use of a furan or pyrrole functionalized as a phosphonate (figure 11, 
2 and 3).55 Here, the non-hydrolysable C-P bond replaces the acid sensitive N-P 
bond in 1 in order to prevent the acid catalyzed hydrolysis during the immunization of 
an animal that is used to generate antibodies. Only the pyrrole 3 has been reported 
to be used to generate antibodies that recognized the native epitope. The generated 
antibodies did recognize a peptide with 3 incorporated; however, the native phospho-
histidine 1 was not, rendering these antibodies useless. 
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Figure 11: The structures of phospho-histidine (1), reported phospho-histidine mimics 2-5, the 
novel sulfonamide based mimic 6 and the derived SPPS building block 7. Building block 7 
represents a target molecule that can be incorporated in peptides designed as PHP inhibitors. 
Alternatively, the sulfonamide imidazole motive indicated in red represents a possible starting point for 
small molecule PHP inhibitor design. 
 
 
The triazole moiety 4 was used successfully as the generated antibodies indeed 
recognized the native phospho-histidine 1.25 However, the selectivity over phospho-
tyrosine was not reported. In our laboratory, similar efforts are ongoing with an 
imidazole based mimic 5 as a tool to generate antibodies.56 Improved selectivity over 
tyrosine is expected based on a more accurate protonation state. The imidazole of 5 
will be positively charged under physiological conditions like 1 and unlike 4. 
Using a phospho-histidine mimic (like 2-5) as a starting point for PHP inhibitors 
seems reasonable. However, a negatively charged phosphate is likely to give poor 
cell penetration. Therefore, it was decided to look into the possibility of using a 
sulfonamide mimic 6 for the transition state of a PHP catalyzed phospho-histidine 
hydrolysis. In this project the synthesis of a strategic building block 7 is presented. 
This synthetic amino acid can be incorporated into peptides and upon deprotection 
these peptides can be tested for PHP inhibition activity. Alternatively, the possibility to 
generate small molecule inhibitors with this approach is explored. The sulfonamide 
decorated imidazole motive (indicated in red in figure 11) can serve as a good 
starting point for small molecule inhibitors as peptide based inhibitors might prove to 
be too large. Overall, the first steps in this project are the production of the enzyme, 
setup of biochemical screening and binding assays (described in Chapter 3) and the 
synthesis/evaluation of building block 7 (described in Chapter 4). The design, 
synthesis and evaluation of small molecule inhibitors are described in Chapter 5. 
Chapter 6 is dedicated to the further evaluation of small molecule inhibitors, including 
cellular experiments. Chapter 7 describes the synthesis and evaluation of several 
peptides prepared to investigate the histidine phosphorylation of Histone H4. Chapter 
8 presents the concluding remarks and future prospects. Finally, the experimental 
section is described in Chapter 9. 
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3.1 Introduction 
 
In order to identify molecules with enzyme inhibitory activity, functional assays are 
required that are simple, robust and reproducible. A phosphatase assay requires, 
besides the enzyme, an appropriate substrate that can be de-phosphorylated. Both 
products of this reaction, the de-phosphorylated substrate or the released phosphate, 
can be used as readout for enzyme activity (see figure 12).  
 
 
 
 
Figure 12: Reaction scheme of a phosphatase catalyzed substrate de-phosphorylation 
reaction. Both substrate and phosphate can be used as a measure for reaction. In the rectangle are 
shown the structures of well-known substrates that show fluorescence upon phosphate hydrolysis. 
 
 
For phosphatases, different activity assaying techniques have been described. 
Traditionally, phosphatase assays were ‘discontinuous’, measuring phosphate 
release after quenching of the reaction using malachite green, 32P-labelled substrates 
or a second enzymatic reaction.57 Such an approach is elaborate and does not allow 
‘real-time’ reaction monitoring. More recent, assays have been developed that rely on 
direct detection of changes in UV absorbance, fluorescence or fluorescence 
polarization due to the de-phosphorylation of substrate. These assays are called 
‘continuous’ as the readout is measured instantly. For tyrosine phosphatases, 
substrates like p-nitrophenyl phosphate (pNPP), fluorescein diphosphate (FDP) and 
6,8-difluoro-4-methylumbellyferyl phosphate (DiFMUP) are the substrates of choice 
and allow a direct readout (see figure 12).58 Also, for serine/threonine phosphatases 
appropriate fluorescence readout systems have been developed that allow direct 
continuous detection.59 As an example, a cleaver chemical instability built into a non-
fluorescent peptide is used to release the fluorescent 7-hydroxycoumarin anion upon 
serine de-phosphorylation (see figure 13). 
For PHP activity assaying, only discontinuous methods have been used, e.g. 
malachite green to detect and quantify the released phosphate. However, for 
research purposes, a continuous PHP assay is desirable. A continuous assay will 
allow us to determine important parameters (e.g. KM) and direct analysis of enzyme 
inhibition by inhibitors. Both substrate and phosphate readouts were considered and 
successfully pursued in a continuous set-up (see §3.4 and §3.5). 
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Figure 13: A: Reaction scheme of a Ser/Thr phosphatase assay. A non-fluorescent substrate is 
de-phosphorylated by the phosphatase of interest and the product is unstable and releases a 
fluorescent coumarin upon degradation. This anion can be used as a continuous readout. Figure 
adapted from Xue et al. 2010.
59
 
 
 
3.2 Cloning and Expression of PHP 
 
The development of PHP assays requires easy access to the non-commercially 
available enzyme itself. The gene encoding for PHP was supplied to us by Prof. 
Zetterqvist (Dept. Medical biochemistry, Uppsala University) in the form of a pBADNK 
vector. This modified expression vector lacked a tag suitable for affinity purification. 
The gene was cloned into 5 different pBADM expression vectors (see table 1) using 
the technique of ligation-independent cloning (LIC). These vectors produce the gene 
product with N-terminal attached His-tag and fusion proteins with different sizes that 
can increase solubility and expression.60 Besides the included His-tag the fusion 
proteins can also be used for affinity chromatography to purify the construct. By use 
of a TEV cleavage site the fusion protein can be removed leaving just an additional 
glycine and alanine attached to the N-terminus of the expressed target protein. The 
cloning and expression in Escherichia coli TOP10 cells upon arabinose addition was 
successful in all cases as figure 14 shows. The pBADM-60 construct was used for 
protein production. After His-tag purification (lane 7) the construct was treated with 
TEV protease (lane 8) and purified using size exclusion chromatography (SEC) as 
shown in lane 9. Also the product of pBADM-11 was purified but the His-tag was not 
removed through TEV digestion. This construct was used exclusively for protein X-
ray crystallography as described in §3.7. 
 
 
  
 
Table 1: overview of the pBADM vectors used for PHP cloning and expression.
60 
 - 47 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: SDS-PAGE gel showing the overexpressed constructs as indicated in Table 1 and 
the purification and TEV cleavage product: the purified PHP. Lane 1: Protein marker, 2: pBADM-
11 product His-PHP, 3: pBADM-20 product His-TrxA-PHP, 4: pBADM-30 product His-GST-PHP, 5: 
pBADM-40 product MBP-PHP, 6: pBADM-60 product His-NusA-PHP, 7: His-NusA-PHP after Ni-NTA 
purification, 8: PHP, TEV and His-NusA after TEV cleavage, 9: PHP after SEC purification.  
 
 
Sequencing confirmed successful cloning in case of all five vectors and the mass of 
the pBADM-60 expressed and purified PHP, with the addition of two N-terminus 
amino acids, was confirmed using ESI-MS. 
 
 
3.3 Enzyme activity 
 
The expressed and purified enzyme was aliquoted as 100 µM stock solutions and 
stored at -80 0C. To test the viability of the protein and these storage conditions the 
enzyme activity from a defrozen sample was determined and compared to literature. 
With the discovery of PHP in 2002, Zetterqvist and co-workers reported a specific 
activity of 9 µmolmin-1mg-1 at pH 7.5 towards a synthetic phospho-histidine peptide.40 
Using a synthetic 20 amino acid phospho-peptide (see §7.3 for details on structure 
and synthesis) a specific activity of 6.7 µmolmin-1mg-1 was established. An anion 
exchange column was used to separate phosphorylated from non-phosphorylated 
peptide and determination of conversion. 
An interesting issue concerning PHP activity is the question of higher order protein 
structures. It has been suggested that PHP is active not as a monomer but as a 
trimer.38 The X-ray structure 2NMM (as mentioned in §1.3.4) also seems to suggest 
this (see figure 15). To investigate this, the protein was concentrated to ~100 mg/mL 
to force quaternary protein structure formation and was analyzed using analytical 
SEC. The concentrated protein solution was run and compared with a marker 
solution (see figure 16). A single population of PHP was observed with a molecular 
weight slightly less than 20 kDa. This strongly suggests that the enzyme is active as 
a monomer. 
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Figure 15: A: X-ray structure 2NMM as submitted to the Protein Database. PHP is crystallized in a 
clear trimeric shape with the individual catalytic sites (as described in §1.3.4) in close proximity. The 
lineup of the protein molecules suggests the existence of a quaternary structure. 
 
 
 
 
 
Figure 16: Analytical size exclusion run of PHP. Red line: Marker (Mw: from left to right, 66, 45, 31, 
20 and 6.5 kDa). Blue line: PHP (Mw: 14 kDa). 
 - 49 - 
 
 
3.4 Continuous Fluorometric Assay 
 
For a PHP activity assay the very sensitive and ‘continuous’ technique of 
fluorescence is preferred. For a continuous fluorescence readout generated by an 
enzyme with a unique mechanism of catalysis (like phospho-histidine phosphatase), 
the development of new substrates needs to be considered. A phospho-histidine 
substrate that changes its fluorescence properties upon enzymatic de-
phosphorylation is required. A phospho-imidazole analogue of fluorescein (8) or 
coumarin (9) can be considered (see figure 17). Such molecules are synthetically not 
straightforward and it is doubtful that de-phosphorylation of these substrates will 
indeed display a significant change in fluorescence. Also the approach presented 
earlier in figure 13 (§3.1) is not feasible for a weak nucleophile like histidine. 
 
 
 
 
Figure 17: Structure of proposed phospho-histidine fluorescent substrate molecules 8 and 9. 
 
 
PHP has been reported to have some activity towards p-nitrophenyl phosphate (see 
pNPP in figure 12) but, it was used in a discontinuous fashion (in combination with 
addition of base before end point measurement).49 6,8-difluoro-4-methyl-2-oxo-2H-
chromen-7-yl dihydrogen phosphate or DiFMUP (13), a known substrate used in 
tyrosine phosphatase assays, is functional in a large pH range (5 to 8) and 
represents an interesting alternative if PHP does remove the phosphate.61 
This substrate was easily prepared from 6,8-difluoro-7-hydroxy-4-methylcoumarin 
(11) in two steps (see scheme 1). Introduction of the benzyl protected phosphate was 
achieved using an in-situ generated dibenzylphosphoryl chloride and hydrogenation 
of 12 yielded 13 in 76% yield (over two steps). 11 was synthesized from 2,3,4,5-
tetrafluor nitrobenzene (10) by Thilo Walther as described in his dissertation.62  
 
 
 
 
 
Scheme 1: Synthesis of DiFMUP (13). a: CCl4, DiPEA, DMAP,dibenzyl phosphite, ACN, -15 
o
C.  b: 
H2, Pd/C, EtOH/toluene, rt, 76% (over two steps). 
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Potential substrate DiFMUP (13) was subjected to the enzyme and fluorescence was 
monitored at 455 nm upon excitation at 355 nm at 37 °C. Conditions were chosen as 
reported in literature.62 The pH was set at 8 at which the enzyme is most active.40, 49 
Indeed the substrate proved sensitive to PHP enzymatically induced hydrolysis. To 
generate a functional assay useful for inhibitor identification significant optimization is 
required. First, the linearity of detection was established for the plate reader 
instrument that was used. Plotting the signal obtained against the product (compound 
11) concentration identified a linear range useful for kinetic measurements and a 
maximal signal beyond where linearity is slowly lost (see figure 18). Above 5 μM of 
product formation linearity clearly starts to deviate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Fluorescence plotted against the concentration of de-phosphorylation reaction 
product (11). Testing the linearity of signal showed that above a concentration of 5 μM linearity starts 
to deviate. 
 
 
When using a setup with a single enzyme (E) and substrate (S), the kinetics can be 
described by equation 1. ES is the enzyme-substrate complex that is formed prior to 
the enzyme catalyzed reaction occurring. k1 is the rate constant for ES formation and 
k-1 the dissociation rate. The overall rate-limiting step in the reaction is the breakdown 
of the ES complex to yield product (P), which proceeds with rate constant k2. 
Assuming rapid equilibrium between reactants (E and S) and the enzyme-substrate 
complex (ES), the kinetic behavior of enzymes based on the substrate concentration 
can be described by equation 2. Here, initial velocity of the reaction is related to the 
substrate concentration [S]. This equation is generally known as the Michaelis-
Menten equation.63 
 
                                                         k1                 k2 
[E] + [S]              [ES]            [E] + [P] 
                                                         k-1 
 
Equation 1: General equation describing an enzymetic reaction. [E] = the enzyme concentration, 
[S] = substrate concentration, [ES] = concentration of a enzyme-substrate complex and [P] = the 
concentration of the product of the processed substrate. 
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    [S] * Vmax   
                                                      V = 
  [S] + KM 
 
 
Equation 2: Michaelis-Menten equation. V = the rate of the reaction, Vmax = maximal reaction rate, 
[S] = substrate concentration and KM = the Michaelis-Menten constant. 
 
 
The parameter Vmax is the maximum velocity of reaction that can be reached under 
substrate saturation conditions. KM is the Michaelis-Menten constant and represents 
the concentration of substrate where the velocity of reaction is half the Vmax (see 
figure 19). Establishing these parameters is important when identifying enzyme 
inhibitors. It is essential to run the assay at a substrate concentration at or below the 
determined KM value. A higher concentration of substrate will saturate the enzyme 
and prevent sufficient inhibitor binding to be noticed. Assuming rapid equilibrium 
between reactants (E and S) and the enzyme-substrate complex (ES) also makes k2 
= kcat. The turnover number (kcat) expresses the number of substrate molecules that 
is being converted to product by the enzyme per second.  Also, the parameter kcat/KM 
is useful to determine and represents the efficiency of the enzyme towards the 
substrate and has a physical upper limit of 108-1010. Such an enzyme is referred to 
as superefficient or perfect enzyme.64 
To determine the KM the reaction needs to be run at different concentrations of 
substrate and the initial velocity plotted against the concentration. The equation is 
only true if the [S] >> [P] and that requires initial velocities to be measured where only 
a fraction of substrate has been converted to product. This yields a graph like figure 
19. KM and Vmax can be visually determined from this graph, however this is 
inaccurate. Nonlinear regression analysis software is preferred in determination of 
these parameters. The assay was performed at different substrate concentrations 
ranging from 50 to 1000 μM. The initial velocities were measured and by using the 
software program XL Fit. A KM of 765 ± 59 μM and a Vmax of 8.3 ± 0.6 μM/s was 
established. kcat/KM was determined to be 1.08 ± 0.2 .10
5 M-1.s-1. 
 
 
 
 
Figure 19: example of the initial velocity plotted against substrate concentration. This graph 
illustrates an enzyme reaching its maximum rate of substrate conversion Vmax when increasing the 
substrate concentration (enzyme saturation). KM is the concentration of substrate at half the Vmax. 
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3.5 Continuous Coupled Enzyme Assay 
 
The assay described in the previous paragraph allows for quick screening and 
evaluation of PHP inhibitors however, a phospho-tyrosine mimic like DiFMUP (13) 
does not qualify as a physiologically relevant PHP substrate. A control assay utilizing 
a real phospho-histidine will be required. Consequently, the enzymatically produced 
‘free’ phosphate must be considered as readout. A system to detect phosphate in a 
continuous fashion has been reported and successfully used in a variety of assays 
testing for phosphatase, ATPase, GTPase and other enzymatic activity.65 In this so 
called coupled assay setup, the enzyme purine nucleoside phosphorylase (PNP, 
Bacillus cereus) rapidly processed free phosphate when provided with cofactor 2-
amino-6-mercapto-7-methylpurine riboside (MESG) (see figure 20). This synthetic 
nucleotide is converted by the enzyme to 2-amino-6-mercapto-7-methylpurine (MES) 
and the UV absorption of this product can be measured directly at a wavelength of 
360 nm. This system is functional in a pH range of 6.5 to 8.5. This is compatible with 
the pH range required for an acid sensitive phospho-histidine (pH > 7). This assay 
procedure does require three additional ingredients in the form of a suitable phospho-
histidine substrate, the enzyme PNP and the purine derivative MESG.  
 
 
Figure 20: Principle of the coupled assay. The phosphate produced by PHP induced substrate 
hydrolysis is detected through a second enzyme reaction catalyzed by PNP producing MESP. The 
formation of this assay product can be monitored through absorption at 360 nm. 
 
 
Obtaining a phospho-histidine substrate is synthetically feasible. Chemical 
phosphorylation of histidine itself (or residues in peptides/proteins) has been 
described in literature as early as 1991.66 The reagent potassium phosphoramidate 
(PPA) phosphorylates histidines readily on both the 1- and 3-position. Over time the 
predominant 1,3-diphospho-histidine is not stable and converts to the more stable 1-
phospho-histidine (15a see figure 21) and the predominant 3-phospho-histidine 
(15b). Nevertheless, obtaining a chemically pure product is important to guarantee a 
reproducible stable readout. This procedure requires a purification step upon 
phosphorylation. Using a single amino acid histidine 14 rather than a peptide seems 
plausible since the mechanism proposed as PHP catalysis (see §1.3.4) does not 
necessarily require a substrate peptide recognition. Purification of a single amino acid 
phospho-histidine 15 has been described using anion exchange chromatography. 
Indeed chemical phosphorylation of histidine using PPA and purification proved 
possible and the product 15b was isolated in pure form. 
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Figure 21: Chemical phosphorylation of histidine. The single amino acid histidine (14) was 
chemically phosphorylated by potassium phosphoramidate (PPA) and 1-phospho-histidine (15a) and 
3-phospho-histidine (15b) were obtained. Purification was performed using a Mono Q anion exchange 
column. 
 
 
To generate sufficient quantities of PNP enzyme, a pET-28 vector coding for BcPNP 
was obtained from Prof. Miller (Cornell University). Expression in Escherichia coli 
TOP10 gave excess to sufficient amounts of working enzyme.  
The PNP substrate MESG (16) was prepared according to a modified literature 
procedure from 2-amino-6-chloro-purine ribonucleoside 17 (see scheme 2).67 
Methylation with MeI yielded the ionic intermediate 18. A reaction with thiourea and 
methanolic ammonia gave the desired substrate 16 in 64 % yield. 
 
 
 
 
 
Scheme 2: synthesis of MESG (16). a: MeI. DMF, 18h, rt. b: thiourea, NH3, 30 min, rt, 64% (two 
steps). 
 
 
Mixing all components together in a PNP required buffer and starting the reaction by 
addition of the phospho-histidine substrate yielded a reaction curve that compared to 
a background signal (no PHP added) clearly registered the release of phosphate 
(see figure 22). The pH was set at 7.6 and not 8 due to the increasing instability of 
MESG at higher pH. 
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Figure 22: Graphs of the UV absorption at 360 nm plotted against the time. a: the reaction as it 
runs over time compared to a background reaction (no PHP present). b: The reaction run at various 
amounts of PNP (from left to right 5, 2.5, 1.25, 0.5 μM) in order to eliminate the lag phase. The insert 
shows a zoom in of the lag phase (see text for details). 
 
 
A reaction takes place and is clearly detected however, it is unclear from figure 22A 
which of the two enzymatic reactions is rate limiting. The rate of formation of 
phosphate is of interest and not the rate of MES formation. To assure this, the PNP 
reserve should be sufficient to make the phosphate production the limiting factor. 
This requires an analysis of the reaction at various PNP concentrations. As figure 
22B shows, an initial lag phase can be observed at insufficient PNP concentration. 
Increasing the concentration to 10 μM resulted in a negligible lag time required for 
conditions of ideal coupled enzyme systems.68 To further validate this, initial 
velocities were plotted for reactions with increasing PHP enzyme concentration and 
found to be linear (see figure 23A and B). This shows that the system is in agreement 
with Michaelis-Menten kinetics. 
In a similar fashion, as described in the previous paragraph, the KM and Vmax were 
determined. A KM of 3.6 ± 0.2 μM and a Vmax of 213 ± 12 μM/s was established. 
kcat/KM was determined to be 5.9 ± 1.2 .10
8 M-1.s-1. Clearly the enzyme turns over the 
phospho-histidine 15b significantly more efficient compared to DiFMUP (13) in the 
fluorescence assay described in the previous paragraph. 
 
 
 
Figure 23: Graph of the reaction run at different concentrations of PHP. plotting the initial 
velocity against the concentration of PHP yields a straight line. The concentrations of PHP that 
were used are, from left to right; 175, 150, 125, 100, 75, 50 and 25 μM. 
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3.6 Determination of Kd with Microscale Thermophoresis 
 
Besides the functional assays suitable for determining IC50 values, described in the 
previous paragraphs, access to a binding assay for PHP is desirable. Determining a 
binding affinity for PHP inhibitors will be an orthogonal technique to establish 
interaction between the enzyme and the molecules that are identify as PHP 
inhibitors. The two enzyme activity assays can be classified as relatively insensitive 
due to high enzyme concentrations required. A binding assay will not suffer from this 
and will generate a Kd (dissociation constant) value, describing an affinity 
independent of enzyme activity and concentration. 
Microscale Thermophoresis (MST) is a technique well suited for a sensitive and 
quantitative analysis of protein-ligand interaction.69 By means of a nanotemper® 
device, binding affinity can be determined for either protein-protein interactions but 
also protein-small molecule interactions. MST is based on applying an infrared laser 
to homogeneous solutions of a constant concentration of fluorescent labeled protein 
with a varied ligand concentration added. The laser induces a local temperature 
gradient in the glass capillaries that contain the sample, and the labeled protein 
moves away as registered by decrease in fluorescence signal (see figure 24). After 
reaching steady-state equilibrium, where laser induced motility equals general mass 
diffusion in the opposite direction, the laser is turned off and back-diffusion restores 
sample homogeneous distribution. Three different stages of the process are recorded 
for each sample; the initial fluorescence before laser, the thermophoresis process 
upon laser initiation and the back diffusion after switching the laser off. The rate of 
movement is related to the amount of ligand binding (see figure 25). 
 
 
 
 
 
Figure 24 Principle of Nanotemper. The fluorescently labeled protein moved away from a laser 
induced temperature gradient (thermophoresis) till a steady state is reached. After turning the laser off, 
the protein moves back (back-diffusion). This process is influenced by ligand binding.
69b
 Figure taken 
from http://www.nanotemper-technologies.com. 
 
 
This technique is highly sensitive and detects all types of ligand binding induced 
changes, in size, charge, hydration shell or conformation. Molecular changes in 
protein structure as small as phosphorylation can be detected using MST. The 
protein is labeled with an appropriate fluorescent dye, or intrinsic fluorescence (e.g. 
due to tryptophan) can be used as well. This is especially useful if a protein is to be 
studied in its native unmodified form.70 
 - 56 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Dependent on ligand binding, the rate of migration of protein away from the laser 
induced gradient is affected. Figure taken from http://www.nanotemper-technologies.com. 
 
 
Additionally, there is a complete freedom of buffers and additives (detergents or 
DMSO) to choose from as it in principle does not affect the MST measurement. Even 
the use of complete cell lysates has been suggested to be possible mimicking in vivo 
conditions closely.71 
The Biophysics Department of the Ludwig-Maximilians-University Munich (LMU) 
studied the principles of MST extensively and identified the solvation entropy and the 
hydration shell of molecules as the driving force. A change in a primary, secondary, 
tertiary or quaternary structure due to ligand binding will change the hydration shell 
around the protein of interest and influences its behavior under MST (see figure 
26).72  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: A change in the hydration shell around the fluorescently labeled protein has been 
found as the mechanism behind MST. Figure taken from http://www.nanotemper-technologies.com. 
 
 
The availability of a blue/green filter machine limits the possibilities to a small group 
of possible fluorophores. It was decided to label PHP with a single equivalent of 
fluorescein by use of a Fluorescein-OSu labeling protocol. The protein was purified 
with a SEC column and the mass of the mono labeled protein was confirmed with 
ESI-MS. The protein proved to be stable in the same buffer as used for the non-
labeled protein and was stored at 4 0C. 
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3.7 PHP Crystallography 
 
The work described in this paragraph has been performed together with Arthur Porfetye under 
supervision of Dr. Ingrid Vetter. 
 
The X-ray crystal structures published for PHP (described in §1.3.4) have allowed for 
the development of better models describing PHP its activity and function. However, 
there is still a lot that remains to be discovered about this protein. This generated a 
need to have access to in-house crystallization possibilities and to be able to produce 
crystals of PHP with peptide/protein substrates or small molecule inhibitors.  
The X-ray structures published are based on an artificial construct. The enzyme was 
crystallized as a His-tag labeled protein with ‘only’ the amino acids 5-125 of the 
native protein present. This means that the first four amino acid are deleted. For the 
in-house efforts, crystallization of the native protein construct (with the added Gly-Ala 
N-terminal amino acids as the only deviation from wild type PHP) and the pBADM-11 
derived His-tag labeled PHP construct were attempted. A full screen was launched 
using commercially available screens and a Mosquito pipetting robot. Two conditions 
were found that yielded branches of thin needles for the construct without tag (see 
figure 27A). Optimization led to thicker needles that showed significant diffraction at 
the Swiss Light Source (SLS, Paul-Scherer Institut Villigen, Switzerland) (see figure 
27B). In house, with a less focused X-ray source, no diffraction was observed. 
 
 
 
Figure 27: Crystallography results from screening (A) and optimization (B). Conditions for A: 
Co(II)Cl2 0.01 M, MES 0.1 M, NH4SO4 1.8 M, pH = 6.5 (taken from Core III nr.50). Conditions for B: 
Co(II)Cl2 0.01 M, MES 0.1 M, NH4SO4 1.6-1.8 M, pH = 6.5-8.5. 
 
 
Comparing the generated structure with the reported structure with pdb code 2HW4 
showed an identical fold except for one remarkable difference. The complete C-
terminal end of PHP till Tyr125 was visible where it is not in 2HW4 (see figure 
28B/28C compared to 28A). Due to a more tightly packing, this part of the enzyme 
becomes visible and leads to a remarkable feature. It significantly reduces the size of 
the cavity that comprises the active site and it leaves open only a small patch filled 
with a sulfate ion and a water molecule as shown in figure 28B. This is in good 
agreement with the proposed catalytic mechanism as presented in §1.3.4, figure 10, 
and the sulfate is exactly there were the phosphate is proposed (see figure 28D). 
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Figure 28: Crystal structure with pdb code 2HW4 compared to the in-house generated 
structure. A: structure 2HW4 top view, B: own structure top view, C: own structure top view with C-
terminal end amino acids visible. The carboxylic acid from Tyr
125
 forms a salt bridge with Arg
78
. D: side 
view with a phospho-imidazole placed inside where ligand binding is proposed (as described in 
§1.3.4). The insert shows a zoom-in. 
 
 
Different from the proposed model, the water molecule appears to come from the 
other side and no space is present in between His53 and the substrate phosphate.  
Tyr123 covers His53 completely with no space for a water molecule (as suggested in 
figure 10) and the tyrosine phenol forms a hydrogen bond with the substrate 
phosphate group. The C-terminal carboxylic acid shows a distance to the guanidine 
of Arg78 that justifies the assumption that it is involved in a salt bridge (see figure 
28C), as already predicted by the NMR solution structure study reported earlier (see 
figure 9). Unfortunately, this novel structure does suggest that only a small part of 
protein can be used for developing a substrate competitive inhibitor. This depends on 
the role and function of this, likely to be, flexible C-terminal end. In solution, does this 
4 amino acid part bend away or is it involved in catalysis? A role in catalysis seems 
unlikely since deletion of the C-terminus has been reported to be allowed until amino 
acid 121 (see §1.3.4). Also addressed in that paragraph is the fact that Tyr125 is 
known to be subjected to phosphorylation in a cellular setting. Addition of this 
phosphate to the tyrosine would block the active site completely! This suggests the 
presence of a build-in enzyme inhibitory mechanism. Considering the close proximity 
of the Tyr125 phenol group to the substrate-phosphate bound inside the catalytic site, 
it is also possible that this residue is auto-phosphorylated (see chapter 8 for ongoing 
research on this topic). 
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4.1 Introduction 
 
The use of peptidomimetics as phosphatase inhibitors is a well-proven concept. In 
the case of tyrosine phosphatases, potent peptide derived inhibitors have been 
developed. Originally, a peptide substrate was used and equipped with a non-
hydrolysable phosphate mimic, or bioisostere, like difluoro-phosphonomethylphenyl 
(see compound 19 figure 29; a nanomolar inhibitor for tyrosine phosphatase 
PTP1B).73 Drug molecules with negative charges usually display poor cell 
permeability and 19 is no exception. Ever since the focus has been on developing 
other phosphate mimics that display improved pharmacodynamic properties. A 1,2,5-
thiazolidin-3-one-1,1-dioxide is a well-tolerated alternative (as used in PTP1B 
inhibitor 20).74 Phospho-tyrosine mimics like these, and others, clearly make use of 
the generally positively charged tyrosine phosphatase active sites. Recently, more 
and more mimics have been reported usually on small molecules rather than peptide 
derived structures (see also §5.1).53b, 75  
 
 
 
 
 
Figure 29: The structures of published phosphatase inhibitors bearing a phospho-histidine 
mimic. 
 
 
Based on the proposed mechanism of phospho-histidine hydrolyses presented in 
§1.3.4 a similar approach can be adopted (see figure 30). A substrate phospho-
histidine is recognized by PHP through several H-bond interactions. Then, an 
activated water molecule acts as a nucleophile that attacks on the phosphorus atom 
and breaks the N-P bond (figure 30A). Suggested is a synthetic mimic of the 
transition state of PHP that induces phospho-histidine hydrolysis (figure 30B). Here, 
the imidazole is maintained and the phosphate is replaced for a non-substituted 
sulfonamide that mimics the phosphate and the water molecule. In order to prevent 
hydrolysis the histidine imidazole nitrogen is shifted one position, resulting in a stable 
and synthetically feasible moiety. To allow incorporation of this transition state mimic 
into peptides, a building block suited for Fmoc solid-phase peptide synthesis (SPPS); 
equipped with N-terminal Fmoc and further orthogonal protection, relying on global 
acidolytic protective group removal (Pg1 and Pg2), is required. To our knowledge, a 
terminal sulfonamide as a phosphate mimic is rare and only a single report has been 
published.76 A peptide equipped with different phospho-tyrosine mimics, including a 
methylene sulfonamide tyrosine (see compound 21 figure 31), was tested as an 
inhibitor for the phosphatases PTP1B and YopH, a phosphatase from Yersinia pestis. 
Indeed peptide 21 proved active against YopH but not to PTP1B. 
 - 62 - 
 
 
 
 
Figure 30: Representation of the recognition of a phospho-histidine substrate by PHP (A), a 
sulfonamide-based TS-mimic (B) and the corresponding target building block 7 suited for 
Fmoc SPPS (C). 
 
 
 
Figure 31: Structure of peptide 21. This peptide was prepared as an inhibitor of phosphatase PTP1B 
and YopH.
76
 The methylene sulfonamide serves as a phosphate isostere. 
 
 
A sulfonamide has the advantage of bearing no charge at physiological pH. However, 
until today only this one example employing this group as a phosphate mimic has 
been reported. There have been many reports on terminal sulfonamides as key 
elements of carbonic anhydrases inhibitors (see §5.1). 
 
 
4.2 Synthesis of Building Block 7 
 
A retrosynthetic analysis for the synthesis of this fully protected building block 7 was 
carried out (see figure 32). Focus is on a linear approach with the formation of a non-
saturated amino acid 22 from aldehyde 23 and subsequent asymmetric 
hydrogenation as key steps in acquiring the amino acid functionality. The imidazole 
2-position aldehyde can be introduced by lithiation and quench with DMF. The 
sulfonamide imidazole is protected with acid labile protective groups (Pg), compatible 
with the following synthesis steps. A Boc, trityl or similar group can be used for the 
imidazole. Bis(2,4-dimethoxybenzyl)amine will be used to acquire a protected 
sulfonamide by direct coupling with the imidazole sulfonyl chloride 24 at an early 
stage of the synthesis. The 2,4-dimethoxybenzyl protective group has been proven to 
be an excellent choice for protection of sulfonamides, as well as for carboxamides, 
and can be removed easily under acidolytic cleavage conditions, similar to Boc or 
trityl removal.77 
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Figure 32: Retrosynthetic analysis of building block 7. 
 
 
The key step is the asymmetric hydrogenation of the N-formyl dehydroamino ester 
22. This method is a proven strategy towards enantiopure natural and unnatural 
amino acids.78 Reduction of a dehydro-amino acid derivative is an elegant method to 
acquire amino acids and can easily be achieved using a rhodium catalyst and a chiral 
BINOL derived phosphoramidate like PipPhos (see figure 33A).79 The α-acetamido 
group, the C=O moiety in particular, is generally believed to be essential in obtaining 
high enantioselectivity by directing the catalyst. An acyl group is often used but is 
difficult to remove after reduction of the double bond without harming the obtained, 
often delicate, amino acid stereochemistry and substitution pattern. A formyl group 
has been shown to be an attractive alternative that is effective and easily removed 
afterwards.80 Also, the introduction is easily achieved by use of an elegant Schöllkopf 
procedure combining an aldehyde of choice (in this case aldehyde 23, see figure 33B 
for the mechanism) and methyl isocyanoacetate. Through a 2+3 cycloaddition, a 
Schöllkopf 2-oxazoline is formed and under basic conditions this rearranges into the 
dehydroamino acid derivative 22. 
 
  
 
 
Figure 33: General scheme of an asymmetric hydrogenation (A) and the mechanism of the 
formation of a Schöllkopf 2-oxazoline and rearrangement into compound 22 (B). 
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The synthesis of 22 as shown in scheme 3 commenced by heating imidazole (25) in 
chlorosulfonic acid and subsequent addition of thionyl chloride yielded 4(5)-imidazole 
sulfonyl chloride 24 in 62% after quenching and filtration from water.81 Reaction of 24 
with N,N-bis(2,4-dimethoxybenzyl)amine (DMB2NH) in the presence of DIPEA in 
DCM at 0 °C resulted in sulfonamide 26 in high yield (90%). It was found to be 
necessary to protect the imidazole (26) at N(1) before introducing the aldehyde in 2-
position through deprotonation and DMF quench. Several protective groups were 
investigated; tosyl, phenylsulfonyl and N,N-dimethylsulfonamine, which all resulted in 
poor regioselectivity in the deprotonation step (5- vs 2-position), as well as low 
reproducibility in terms of isolated yield. An N(1)-Boc protective group was 
investigated with good result, but was found to be non-compatible with peptide 
synthesis.56 Scrambling of the Boc group between the imidazole and the Nα-position 
upon Fmoc deprotection during peptide synthesis terminated the peptide synthesis 
prematurely with significantly reduced yield as a result (see figure 34). Eventually, 
incorporation of a trityl (Trt) group at N(1) according to standard conditions, resulted 
in compound 27 (83%), which underwent complete regio-selective deprotonation on 
the 2-position with n-butyl lithium at -30 °C. Quenching of the lithiate with DMF 
yielded aldehyde 23. The condensation with methyl isocyanoacetate proved viable 
but 22 was obtained in low yield.  
 
 
 
 
 
 
Scheme 3: Synthesis of intermediate 22. a: ClSO3H, 140 
0
C, 16h, SOCl2, 5h, till 125 
0
C, 62% b: 
N,N-bis(2,4-dimethoxybenzyl)amine (DMB2NH), DiPEA, DCM, 2h, rt, 90% c: KOtBu, TrtCl, DMF, 18h, 
rt, 83% d: n-BuLi, DMF, THF, 1h, -30 
0
C, 91% e: methyl isocyanoacetate, Cu2O, KOtBu, 2h, rt, 33%. 
 
 
 
 
 
 
 - 65 - 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: Mechanisms of Boc group scrambling during peptide synthesis. After coupling a 
building block like 7 on a peptide attached to a resin and the Fmoc is removed from the N terminal 
amine, scrambling of the Boc group takes place and results in partial termination of SPPS and 
formation of side-products.
56
 
 
 
No significant attempts to optimize the methyl isocyanoacetate condensation towards 
22 were undertaken since this olefin proved completely immune to hydrogenation. 
Both asymmetric and symmetric methods were tried in attempts to reduce the double 
bond but all failed in producing product 28. The compound was subjected to both 
homogenous and heterogeneous catalysts and hydrogen pressures up to 28 bar and 
temperatures up to 60 oC were applied only to determine complete resistance of 21 
to reduction (see table 2 for details). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Overview of the attempts that were performed to reduce 22 by hydrogenation. The 
olefin 22 proved stable towards high temperatures and very high hydrogen pressure. Eventually, 
increase of temperature and pressure resulted in degradation of starting material (SM) rather than 
product formation. All reactions were given 18 hours of reaction time. 
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This inability to reduce the double bond required the development of a new synthetic 
strategy and a suitable alternative was found in a convergent route where 
intermediate 27 and 2-position functionalization could still be used (see figure 35). 
Introduction of iodine instead of an aldehyde gives access to intermediate 29. This 
iodine is suitable for an approach where a zinc-iodine serine amino acid derivative 30 
can be coupled via a Negishi cross-coupling reaction. Many different unnatural 
phenylalanine derivatives have been prepared in this fashion.82 To acquire target 
molecule 7, a final step, the orthogonal cleavage of the amino acid methyl ester by 
trimethyltin-hydroxide (Me3SnOH) treatment, is required. This non-acidic nor basic 
methodology should leave both the acid labile protective groups of the imidazole 
sulfonamide moiety as well as the base-labile Fmoc protection of the Nα-position 
unaffected.83  
 
 
 
 
 
Figure 35: Second retrosynthetic analysis of building block 7 with key intermediate 28. 
 
 
Indeed, applying the n-BuLi deprotonation as for aldehyde 23 but quenching with I2 
yielded iodine 29 (see scheme 4). After optimization, the procedure resulted in good 
yield (85%) of 29 on multigram scale. Next, with this intermediate in hand, the 
Negishi cross coupling with (R)-Nα-Fmoc-3-zinc iodoalanine methyl ester (30) was 
investigated. This amino acid derived zinc intermediate was prepared from 
commercially available serine methyl ester 31 (see scheme 5).  
 
 
 
 
 
 
Scheme 4: Introduction of an iodine on the 2-position of intermediate 27, obtaining the product 
29. a: n-BuLi, I2, THF, 1h, -30 
0
C, 85%.  
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Scheme 5: Negishi coupling based synthesis of building block 7. a: NaHCO3, H2O, Fmoc-OSu, 
dioxane, 1h, rt, 98% b: pyridine, TsCl, 40h, 4 
0
C  c: NaI, acetone, 18h, rt, 90% (over two steps) d: 
Zn(0), DMF, I2,  e: 29, Pd2(dba)3, XPhos, 2h, 40 
0
C, 53% f: Sn(Me)3OH, DCE, 18h, 65 
0
C, 86%. 
 
 
After Fmoc protection of 31, and conversion of the hydroxyl into iodine 33, zinc 
species 30 was generated by insertion of activated elemental zinc. Several methods 
to achieve this conversion have been described.82a Zn-activation through ultrasonic 
treatment or through Knochel’s procedure using 1,2-dibromoethane and 
chlorotrimethylsilane gave variable/irreproducible results. Direct in-situ activation of 
Zn by addition of a small amount of iodine was found to be the best method.84 In line 
with earlier reports, a general increase in yield was observed when the reaction was 
performed in DMF instead of THF.82a These serine derived Negishi intermediates are 
very useful in the preparation of unnatural phenylalanine analogues, although 
coupling with ortho-substituted arylhalides have been reported to be difficult 
substrates.84 Our trityl protected iodoimidazole 29 proved to be a very difficult 
substrate as well, and significant catalyst screening and optimization was required in 
order to reach isolatable amounts of product. For the Negishi cross-coupling reaction 
leading to arylalanines, a number of different palladium sources and ligand 
combinations have been reported in literature. With our substrate (29), a strong 
preference for reduction of the 2-iodo imidazole was observed, leading to rapid 
formation of the 2-H imidazole 27 as a competing reaction (see figure 36). This is 
caused by preferential β-hydride elimination/reduction competing with product 
forming reductive elimination as previously by Buchwald and coworkers.85 A 
correlation was found between the amount of equivalents of zinc-reagent added and 
the yield for the palladium catalyzed coupling reaction. Raising the amount of zinc-
reagent usually led to higher yields indicating that the β-hydride elimination/reduction 
is quick compared to effective coupling.  
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Figure 36: The desired reductive Pd elimination (in green) vs undesired β-elimination (in red). 
After palladium insertion in the arylhalide and attack of the zinc species intermediate 35 is formed. 
This complex will collapse and releases the palladium catalyst that can undergo a new catalytic cycle. 
The collapse of 35 can take place through two distinct mechanisms yielding two different possible 
products 34 or 27. A desired reductive Pd elimination will eliminate the catalyst while forming the 
desired carbon-carbon bond as shown in green. An undesired β-elimination will form an α-β double 
bond in on the amino acid and eliminates the palladium with the imidazole attached as shown in red. 
The α-proton is on the palladium and reductive elimination will render the 2-H imidazole 27 as product 
together with the amino acrylic acid 36.  
 
 
Eventually, two equivalents was chosen as a reasonable compromise between 
higher yield and excessive use of the iodoalanine precursor. For the coupling 
reaction, different palladium catalysts and ligands were investigated (Table 3). 
Pd(PPh3)4 generally showed only traces of product formation at room temperature, at 
40 oC, 8% conversion was obtained. At this temperature, complete consumption of 
the iodo-imidazole (29) was usually achieved after 2 hours. Use of PdCl2(PPh3)2 also 
did not result in useful amounts of the coupling product. It appeared that only a single 
turnover took place per equivalent of catalyst (entry 4 and 5). Increasing the 
temperature to 80 °C (entry 3 and 6) resulted in rapid decomposition of organozinc 
reagent 30 and no significant product formation was observed. A well-documented 
palladium catalyst-ligand combination described for Negishi coupling reactions is 
Pd(OAc)2 or Pd2(dba)3 with P(o-tol)3. Again, only reasonable yields were obtained 
when using higher loading of palladium catalyst.  Next, electron-rich biaryl phosphine 
ligands were investigated. Such ligands have been reported to perform well and with 
high substrate tolerance even for the more sterically hindered (mainly ortho-
substituted) aryliodides.86 A ratio between palladium and ligand of 1:1 was 
maintained.84 JohnPhos, SPhos and XPhos showed large differences when used in 
combination with Pd(OAc)2 or Pd2(dba)3. In both cases, XPhos showed the highest 
conversion (entries 13 and 16). This is not entirely in agreement with the results from 
earlier studies where SPhos was shown to be superior over XPhos concerning 
product formation over β-hydride elimination / reduction.85 Eventually, entry 16 gave 
the best result with acceptable catalyst loading, while lowering the amount of 
palladium resulted in reduced product formation (entry 17). Next, scale up of the 
reaction to multi-gram scale was performed, resulting in consistent yields. Cleavage 
of the methyl ester functionality of 34 with trimethyltin hydroxide proved viable, thus 
providing building block 7 in 86% yield. Overall, the synthesis sequence resulted in 
18% of building block 7 over six steps. 
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Table 3: Optimization of the Negishi reaction towards 34.  a: HPLC-based as detected (absolute 
intensity) by a corona CAD detector. % conversion into coupling product = area coupling product / 
(area coupling product +area reduction product)x100. Starting material was fully converted in all 
cases. b: Isolated yield after silica gel purification.  
 
 
4.3 Synthesis of Peptides 37 and 38 
 
Next, building block 7 was evaluated in standard SPPS according to the Fmoc 
protocol. It was decided to prepare a peptide with the sequence AH*PFG originating 
from Zetterqvist and co-workers original studies on PHP (scheme 6, peptide 37).40 
The peptide was synthesized on Tentagel-resin functionalized with a RAM-anchored 
Fmoc-glycine (Scheme 6, A-D). Coupling of the Fmoc-amino acids (step A and C) 
was carried out using standard HBTU/HOBt activation, except for the protected 
sulfonamide building block 7 (step B), which was coupled employing HATU/HOAt as 
activating reagents. Capping after coupling of building block 7 was not possible as 
treatment with acetic anhydride/HOBt resulted in imidazole N-acetylation and Trt 
removal at the imidazole moiety, leading to acyl migration from the imidazole core to 
the Nα-position after subsequent Fmoc removal (mechanism similar to described for 
Boc scrambling in figure 34). This shift stopped further amino acid coupling and 
significantly reduced yield. Cleavage from the resin (D), as well as global 
deprotection, was carried out by applying a mixture of trifluoroacetic acid 
(TFA)/triisopropylsilane (TIPS)/H2O (90:5:5).  
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After preparative reverse phase HPLC purification (C18) and subsequent 
lyophilization, peptide 37 was isolated in 42% yield (from resin loading). An additional 
peptide sequence carrying the sulfonamide histidine was synthesized (RH*RKG, 
peptide 38, 59% yield). This peptide was based on the sequence from histone H4 
and carries positively charged amino acids rather than neutral amino acids as in 
peptide 37. A distinction in ligand binding should be expressed in IC50 values if the 
peptide sequence is of importance for substrate recognition. 
 
 
 
 
 
 
 
Scheme 6: The peptide synthesis performed with building block 7 to yield the PHP peptide 
inhibitors 37 and 38. 
 
 
4.4 Evaluation of Peptides 37 and 38 as PHP Inhibitors 
 
The two peptides were tested in both fluorescence as the enzyme coupled activity 
assay at a concentration of 100 µM and failed to show any effect. This suggests that 
either the presentation of the sulfonamide histidine in a peptide form is not working or 
the sulfonamide is not a good mimic. The de-protected amino acid itself (see scheme 
7, compound 39) also failed to show any activity at all. Clearly peptide based 
inhibitors with this sulfonamide imidazole moiety are not suited as a basis for PHP 
inhibitor design. 
 
 
 
 
 
 
Scheme 7: The deprotection of building block 7 that yielded the non-natural amino acid 39. a: 
piperidine, DMF, 1h, rt b: TFA, water, TiPS, 2h, rt, 34% (over two steps). 
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5.1 Introduction 
 
As already introduced in the previous chapter, the development of inhibitors bearing 
groups that serve as phosphate bioisosteres is a common theme in medicinal 
chemistry programs directed at phosphatases. The difficulties that are associated 
with peptide based inhibitors did move the focus from peptidomimetics to small 
molecule inhibitors. Also, the discovery of allosteric sites boosted the development of 
inhibitors that do not directly compete with substrate binding.53a Nevertheless, the 
use of mimics for phosphate is still very common for substrate competitive inhibitors. 
Small molecule inhibitors generally use the same or similar phospho-tyrosine mimics 
as the peptide inhibitors. Mimics like difluoro-phosphono-methylphenyl or 
difluoromethylene sulfonic acid (used in PTP1B inhibitors 40 and 41, see figure 37) 
found their use in various small molecule phosphatase inhibitors. The mimics based 
on heterocyclic rings generally display improved stability and effectiveness compared 
to phosphonic or sulfonic acids. Popular examples are 1,2,5-thiazolidin-3-one-1,1-
dioxide (compound 42) and various thiazolidinone derivatives (e.g. compounds 43 
and 44).53b 
 
 
Figure 37: The structures of small molecule phosphatase inhibitors 40-44, bearing various 
phospho-histidine mimics, and imidazole sulfonamide general structure 45.  
 
 
The failure of peptides 37 and 38 to show PHP inhibitor activity made us look into the 
possibility of exploring small molecules based on the same 4-sulfonamide imidazole 
bioisostere principle (structure 45). To our knowledge a terminal sulfonamide has 
never been reported as a part of a small molecule phosphatase inhibitor but this 
feature is common for inhibitors targeting carbonic anhydrases (CAs).87 These 
ubiquitously expressed enzymes catalyze the reversible reaction of hydration or 
formation of bicarbonate ions to or from CO2. In humans, fifteen different isoforms 
have been identified. Important roles for these enzymes have been addressed for 
many of them and inhibitor development has received considerable attention in this 
field. Today the largest class of CA inhibitors that have been reported are indeed 
sulfonamides, as exemplified by binding of benzene sulfonamide in CA II (figure 
38A). The anion form has a direct interaction with the zinc cation conserved inside 
the active site of the CA. In terms of catalysis, this zinc is responsible for activation of 
the water molecule that attacks the CO2 molecule to form the bicarbonate enzymatic 
product. The Zn sits at the bottom of a conical cavity lined partially by hydrophobic 
and hydrophilic amino acid residues and is stabilized by three histidines. A terminal 
sulfonamide serves as a mimic for the water molecule as well as the CO2 molecule.
88 
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Figure 38: Representation of benzene sulfonamides binding inside the catalytic site of human 
CA II. Both a simple benzene sulfonamide (A) or more decorated inhibitors (B), inducing selectivity, 
have been reported. Figure redrawn from Alterio et al. 2012.
88
 
 
 
Optimization around the benzene sulfonamide theme led to the identification of 
extended series of CA inhibitors. Especially functionalization patterns like 46 and 47 
were reported (figure 39). The R-group represents a substituent varying from a 
peptide tail to an aliphatic spacer. Selectivity within the family of carbonic anhydrases 
can be achieved by modifications in this position as well as optimization of 
physicochemical properties. Also, urea (example 48) and thiourea (example 49/figure 
38B) derivatives have been reported. Several carbonic anhydrase inhibitors are 
currently in clinical trials but no compound has been FDA approved so far.87  
Besides benzene ring based inhibitors many different sulfonamide functionalized 
heterocyclic rings, like 50-52, have found their way into CA inhibitor design as well. 
Surprisingly, a functionalized imidazole, like compound 45 (figure 37), has never 
been reported. Important to keep in mind is that the design of an imidazole 
sulfonamide PHP inhibitor like 45 can come with additional activity towards members 
of this CA enzyme family. This is not necessary a problem as carbonic anhydrase 
inhibitory activity is associated to antitumor activity but can limit its usefulness as a 
tool compound.88 
 
 
 
 
Figure 39: Examples of carbonic anhydrase inhibitors bearing a sulfonamide motive. Many 
different aromatic rings found their way into carbonic anhydrase inhibitors. However, a sulfonamide 
directly attached to an imidazole has never been reported as a carbonic anhydrase inhibitor. 
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5.2 Synthesis and Evaluation of Imidazole Sulfonamide PHP Inhibitors 
 
The chemistry that was developed to synthesize building block 7 included the 
intermediates 27 and 29. Removal of the protective groups gives access to small 
molecules 53a and 53b (see scheme 8). Using the same 2-position lithiation protocol 
and quenching with various electrophiles, introduction of various groups 
(intermediates 54c-f) was proven to be possible. Immediate acid treatment and 
HPLC purification gave direct access to a set of four additional small molecules, 53c-
f (see table 4 for structures). To broader scan the imidazole 2-position, aromatic rings 
were introduced by performing palladium catalyzed cross-coupling reactions on 
iodine 29. The products 55a-d were continued without purification in an TFA 
deprotection step and products 56a-d were isolated upon HPLC purification. This set 
of compounds was tested in the continuous fluorometric assay and remarkable 
results were obtained (see table 4). Small 2-position substituents like H, Me, Et and 
Cl failed to show significant activity at 100 µM concentration whereas larger 
substituents like bromine (53f) or iodine  (53b) do give 100% inhibitory activity at this 
concentration. An IC50 value of 11.1 ± 5.9 µM and 6.2 ± 2.5 μM respectively was 
determined. The aromatic substituents 56a-d showed little activity with a phenyl 
substituent showing as little as 34% inhibition at 100 μM as best. 
 
 
 
 
 
Scheme 8: Deprotection of building block 27 and 29 and synthesis of derivatives 53a-f and 56a-
d. a: BuLi, I2, THF, 1h, -30 
0
C, 85% b: BuLi, electrophile, THF, 1h, -30 
0
C c: Pd(PPh3)4, K2CO3, 
dioxane/water, 80ºC (for 54d: Zn(0), BnI, DMF, PdCl2(PPh3)2, 40 ºC) d: TFA, water, TiPS, 18h, RT. 
 
 
These results were clearly encouraging and also the activity assay showed 
consistent and reproducible results. Clearly the 2-position substituent is of major 
influence but limited in what size substituent is allowed by the enzyme. To further 
investigate the imidazole 2-position it was decided to exploit the versatile possibilities 
of the metallation protocol and functionalize with more polar oxygen containing 
substituents. 
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Table 4: Yield and inhibitor activity of compounds 53a-f and 56a-d. a: yields over two steps. 
 
 
Aldehyde 23, another intermediate prepared originally for the synthesis for building 
block 7, represents a useful starting point and the aldehyde was easily converted into 
57 with MeMgBr. A reduction of 23 with NaBH4 gave access to intermediate 58 that 
could be methylated directly using MeI, yielding 59. The general TFA deprotection 
protocol used on the previous set of molecules was also used here and the 
molecules 60a, 60c and 60d were isolated in good yield. 60b was not isolated 
successfully, most likely due to chemical instability. 
 
 
 
 
 
Scheme 9: The aldehyde functionality of 23 was manipulated to yield 57-59 and general TFA 
deprotection yielded the compound series 60a,c,d. a: NaBH4, MeOH, 45 ºC, 96% b: MeMgBr, 
THF, 1h, 0 
0
C c: NaH, MeI, THF, 0 ºC d: TFA, water, TiPS, 18h, RT. 
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Furthermore, a carboxylic acid was introduced on the imidazole 2-position through 
quenching of the lithiated imidazole by canuling it into a stirred slurry of dry ice in dry 
THF (see scheme 10). Upon isolation of the product the trityl protective group proved 
instable, most likely due to internal protonation of the imidazole by the carboxylic 
acid. Eventually, the non-protected imidazole 61 was isolated in high yield. Removal 
of the DMB groups from 61 yielded carboxylic acid 62. Additionally, the carboxylic 
acid was converted into three small amides, 63a-c (see table 5 for structures). The 
unprotected imidazole did not interfere with amide formation as conversion was 
generally complete after one hour. Deprotection of 63a-c yielded amides 64a-c. 
 
 
 
 
 
 
Scheme 10: Introduction of a carboxylic acid on the 2-position, the instability of the trityl 
protective group and the derived small molecules 62 and 64a-c. a: BuLi, CO2, THF, 1h, -30 
0
C, 
93% b: R1R2NH, PyBOP, DiPEA, DMF, RT c: TFA, water, TiPS, 18h, RT. 
 
 
Compounds 60a-d, 62 and 64a-c were subjected to the fluorescence activity assay 
and 60c, bearing a methylhydroxy substituent, showed full inhibition at 100 μM. An 
IC50 value was determined for this compound and a value of 9.9 ± 4.0 µM was found. 
The methoxymethyl (60d) and dimethylcarbonamide (64c) substituents showed 
significantly less activity with 37 and 31 % respectively. Among the other substituents 
very little activity was established (see table 5).  
The initial results of screening the 2-position substituent showed encouraging results 
and the available X-ray structures were investigated in an attempt to explaining the 
established SAR. It is unclear whether the fully visible C terminal end X-ray structure, 
as was generated in-house, is a better model compared to the structure as reported 
in literature. It is clear that the in-house generated ‘closed’ structure shows little 
space for substituent binding compared to the reported structure 2HW4 (see figure 
28b-d compared to 28a). Therefore it was decided to use 2HW4 as the basis for in 
silico modeling. 
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Table 5: yield and inhibitor activity of compounds 60a-d, 62 and 64a-c. a: yields over two steps 
 
 
Docking experiments performed using X-ray structure 2HW4, with 60c as the ligand, 
showed a strong preference for two possible binding conformations. The inhibitor can 
adopt a conformation with the sulfonamide in the same pocket as where the binding 
with a phospho-histidine was predicted (figure 40A). Alternatively, an inverse binding 
mode was proposed (figure 40B) where the sulfonamide interacts with Arg78 (see 
also figure 40A and 40B inserts for an interaction graph). Interestingly, the results 
from such a docking exercise are very similar when using a rigid receptor or an 
induced fit method when amino acid residue flexibility is taken into consideration. The 
tautomerisation of the imidazole seems to be of little influence on the docking 
experiment outcome and again these two possible binding modes are favored. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40: Two possible binding modes for compound 60c as predicted by docking 
experiments. See text for details. 
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In both cases, the essential His53 is covered by the ligand and is non-accessible for 
interaction with a phospho-histidine substrate. This clearly suggests competitive 
inhibition of the enzyme as the mechanism of action for these molecules. 
For compound 53b no clear trend was found when docking experiments were 
performed in the pdb reported structure 2HW4. This is likely to be caused by the 
under appreciation of the van-der-waals interaction possibilities compared to 
hydrogen bond formation possibilities in the strongly polar protein surface of the 
catalytic site. The relatively lipophilic iodine will give less strong interactions 
compared to the polarized methylene hydroxyl substituent in the 2-position of 
compound 60c. One predicted conformation seems particularly attractive. This is 
where the large iodine is locked nicely in between the residues Met95, Ser94, His53 
and Tyr52 (see figure 41). The imidazole is lying flat on the bottom of the pocket 
forming one hydrogen bond with the backbone amine of Met95. The sulfonamide 
hydrogens are lined up perfectly for the formation of a pair of hydrogen bonds with 
Arg78. The -NH2 of the sulfonamide finds its way into a tunnel formed by the standing 
upright residues Arg78 and Tyr93. 
 
 
 
 
Figure 41: proposed binding mode based on docking studies for compound 53b. In this 
proposed binding mode the inhibitor lies flat on the bottom of the catalytic cavity locked in place by 
three hydrogen bonds with Arg
78
 and Met
95
. The insert shows a graph of the identified ligand-receptor 
protein interactions. 
Arg
78
 
Tyr
93
 
Met
95
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Next, it was decided to look into the possibility to further functionalize the sulfonamide 
or move to a sulfonyl derivative. Expanding the molecule in this direction is an 
opportunity to reduce the polarity of the molecule by increasing the logP value 
together with increasing the surface area of the ligand interaction with the protein. 
Low logP values are generally associated with poor cell permeability. The 
compounds 53b and 60c display clogP values of 0.11 and -1.64 respectively, 
rendering them likely to suffer from poor cell permeability (calculated using the 
software MarvinSketch 6.0.6). Addition of a methyl or benzyl group attached to the 
sulfonamide of 53b will raise this value to 0.33 and 2.05 respectively. For 60c these 
modifications will lead to values of -1.08 and 0.31. The arrow in figure 42 shows the 
space in between the upstanding residues Arg78 and Tyr93. The conformation of 
these residues forms a tunnel that seems suited for ligand extension. 
 
 
 
 
 
Figure 42: the proposed binding mode of 53b predicts space for extension on the sulfonamide, 
as indicated by the arrow. Substitution of the sulfonamide nitrogen with alkyl or aromatic groups will 
give access to such molecules.  
 
 
A strategic building block like sulfonyl chloride 65 was required to provide easy 
access to a series of compounds with substituted sulfonamide (see scheme 11). A 
bromine or iodine substituent on the imidazole 2-position is favored over the methyl 
hydroxyl substituent due to synthetic feasibility. The possibility to directly introduce a 
bromine or iodine at the 2-position of intermediate 24 was investigated but failed due 
to the instability of the product (65) during formation. The protection of the imidazole 
was considered and a benzyl chloromethyl ether (BOM) group was successfully 
introduced on the imidazole. Subsequently, bromination on the 2-position of 66 was 
possible in reasonable yield. The introduction of iodine failed and did not yield 
isolatable amounts of product. Again, instability of the product was observed and this 
significantly lowered the yield. Reacting sulfonylchloride 68 with different amines 
yielded compounds 69a-f.  
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Scheme 11: The synthesis of compounds 69a-f and 70a-c through strategic intermediate 68. a: 
BOMCl, MeCN, 18h, RT, 79% b: NBS, CHCl3, 4h, 50 
o
C 43% c: HNR1R2, DiPEA, DCM, 18h, RT d: 
Na2SO3, NaHCO3, water, tetra-n-butylammonium bromide, R1X, 18h, RT e: TFA, water, TiPS, 18h, 
RT. 
 
 
An interesting procedure described by King and Beatson, using Na2SO3 as a 
reducing agent and an alkylhalide, gave excess to alkyl sulfonyl derivatives 70a-c.89  
Unfortunately, inhibitory activity was lost in almost all entries (see table 6). In this 
series a methyl sulfonyl substituent (entry 70a) showed some activity with 16% 
inhibition at the highest concentration of 100 μM. 
 
 
 
 
Table 6: activity of compounds 69a-f and 70a-c. a; yields over two steps 
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It is clear that there is little room for improvement and the molecule appears to bind in 
a small pocket making the proposed binding mode of figure 42 less plausible. This 
suggests that the X-ray structure generated in-house (see §3.7) is a better basis for a 
model. However, the exposed pocket is too small to fit even the small molecules like 
53b or 60c. The question is how does the C-terminal Tyr125 behave in solution and 
does the C-terminal end pressed against the active site represent a relevant 
conformation or is it an artifact caused by tight crystal packing? Closer analysis of the 
X-ray structure and comparing it to 2HW4 does show significant movement of the 
amino acids Arg78 and Lys21. These residues seem to be pressed in a tight 
conformation next to Tyr52 due to Tyr125 being pushed into the catalytic site. Lifting up 
this tyrosine residue just a few angstrom exposes a deepened binding pocket that fits 
the identified inhibitors remarkable well. Further underneath the lifted Tyr125, appears 
to be more space but this is likely to be filled with a water molecule present in the 
non-manipulated X-ray structure. Figure 43 shows a representation of iodine 53b 
docked inside the Tyr125 lifted structure. 
 
 
 
Figure 43: The proposed binding mode of 53b in the in house generated X-ray structure. A 
single manipulation was made in lifting up the C-terminal Tyr
125
 slightly. In doing so, an ideal binding 
pocket for these small molecules was obtained. 
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For the final stage of optimization, focused was on smaller variations directly on the 
imidazole core since larger substituents on the premises of the molecule led to 
significant loss of activity. Three methyl variations (1-,3- or 5-methylimidazole) were 
pursued in order to see if such additions are allowed (see figure 44, entries 71, 72 
and 73). Again, a bromine or iodine as 2-position substituent is preferred over the 
methyl hydroxyl substituent. 
 
 
 
 
 
 
 
Figure 44: The structures of the methyl imidazole regioisomers 71, 72 and 73. 
 
 
The synthesis of the 1-methyl regioisomer commenced with commercially available 
1-N-methylimidazole 74 (see scheme 12). In line with the previously described 
synthesis of the 1-H version the sulfonyl chloride moiety was readily introduced using 
chlorosulfonic acid and thionyl chloride. Conversion of the sulfonylchloride 75 into a 
sulfonamide was again achieved by the use of a dimethoxybenzyl protected amine. 
Introduction of the 2-position halide on 76 proved more difficult as selectivity during 
lithiation between the 2- and the 5-position was completely lost with the small 1-
position methyl substituent compared to the earlier used trityl group. The 2,5-dihalide 
77 was readily obtained, unlike the desired 2-position mono iodide. It has been 
reported in literature that a 5-position halogen-imidazole is not stable under acidic 
conditions.90 This would allow for the synthesis of the desired 2-position mono-halide. 
Indeed upon acid treatment to remove the DMB protective groups, the 5-positon 
iodide was nicely removed and only the desired mono iodide 71 was identified as 
product. 
Synthesis of 72 proved difficult due to instability problems. Precursor 24 could be 
methylated selectively on the 3-position using dimethyl sulfate in formic acid. 
However, converting the sulfonylchloride 78 into sulfonamide 79 was not possible 
and methylated amine 81 was isolated as the only product. A mechanism for this 
unforeseen instability is proposed in the box in scheme 13. 
The 5-methyl regioisomer 73 was prepared in a method similar to the preparation of 
the compounds 69a-f. Here, a commercially available 4/5-methylimidazole (82) was 
used as starting material and the sulfonylchloride and BOM protection group were 
introduced successfully and in similar yield as compared to compound 68. For entry 
73 it was decided to prepare the bromide since introduction of the iodide failed before 
(see scheme 11). Introduction of the bromide on the 2-position was achieved and 
consequent conversion into sulfonamide gave compound 85. Final acidic cleavage of 
protective groups yielded the desired 5-methyl derivative 73. 
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Scheme 12: Synthesis of compound 71. a: ClSO3H, 140 
0
C, 16h, SOCl2, 5h, till 125 
0
C, 31% b: 
N,N-bis(2,4-dimethoxybenzyl)amine (DMB2NH), DiPEA, DCM, 2h, 0 ºC - rt, 82% c: BuLi, I2, THF/ 
HMPA, 18h, -30 ºC, 83% d TFA, water, TiPS, 18h, rt, 41%.  
 
 
 
 
 
 
Scheme 13: Attempt of synthesis of compound 72. a: 78% formic acid, Me2SO4, 18h, RT, 58% b: 
N,N-bis(2,4-dimethoxybenzyl)amine (DMB2NH), DiPEA, DCM, 2h, 0ºC-rt. Instead of obtaining the 
desired 79, compound 81 was isolated. The mechanism explaining this product involves a nucleophilic 
attack of the (DMB)2N on the adjacent methyl. Byproduct 80 is quenched upon aqueous workup and 
lost during extraction. 
 
 
 
 
 
 
Scheme 14: Synthesis of compound 73. a: ClSO3H, 140 
0
C, 16h, SOCl2, 5h, till 125 
0
C, 39% b: 
BOMCl, MeCN, 18h, rt, 50% c: NBS, CHCl3, 3h, 50 
o
C, N,N-bis(2,4-dimethoxybenzyl)amine 
(DMB2NH),, DiPEA, DCM, 3h, 0 ºC - rt, 16%  d TFA, water, TiPS, 18h, rt, 50%.  
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Besides adding substituents to the imidazole core, the role of imidazole core 
tautomerism needs to be investigated. The imidazole proton can be on the 1- or on 
the 3-position (see figure 45A and 45B respectively). The model proposed in figure 
43 shows the formation of a hydrogen bond between the imidazole core and the His53 
lining the bottom of the cavity. If this assumed interaction is important for inhibitor 
activity the tautomeric form that the inhibitor adopts, becomes essential. His53 is 
under physiological conditions not protonated.48 The imidazole inhibitors have a 
hydrogen bond donating proton but due to tautomerism the hydrogen can point the 
wrong way. Also, the pKa will be of influence on the imidazole protonation state. 
Imidazole itself has a pKa of 6.9. The electron withdrawing groups generally found on 
the inhibitor 2-position and the sulfonamide will lower the pKa significantly, assuring a 
non-charged imidazole at physiological pH. This means that the imidazole 3-position 
is not necessarily a hydrogen bond donor when the ligand meets the enzyme in 
solution. To establish a constitutive proton on the imidazole 3-position, a molecule 
like compound 86 (figure 45) was considered. Introduction of a hetero-atom directly 
on the 2-position will generate a molecule that is likely to adopt a urea-like 
conformation resulting in a constitutively protonated 1- and 3-position nitrogen. A 
thiourea (X = S) would be preferred due to the larger size compared to an oxygen or 
nitrogen. 
 
 
 
Figure 45: Influence of tautomerisation and pKa on the form an imidazole is in and structure 86 
the can lock the ring in a urea form. The urea of 86 will generate a molecule with permanent 
protonation on both imidazole nitrogens. 
 
 
To introduce the sulfur on the 2-position of the imidazole the lithiation protocol 
deployed so successfully before can also be used. Quenching the 2-position lithiate 
with elemental sulfur led to disappearance of starting material 27 and formation of a 
variety of sulfurated compounds due to the use of an excessive amount of S8. 
Treatment with trifluoro acetic acid yielded only a single compound, the desired 
thiourea 86. H- and F-NMR analysis showed no sign of molecule protonation by a 
TFA counter ion that indeed could be observed for all the other imidazoles. This 
shows that 86 is indeed only present in the thiourea form. 
 
 
 
 
Scheme 15: Synthesis of compound 86. a: BuLi, S8, THF, 30min, -30 ºC d TFA, water, TiPS, 18h, 
RT, 12% (over two steps).  
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Eventually, the compounds 71, 73 and 86 were subjected to the fluorescence activity 
assay and remarkably, the entries 71 and 73 failed to show any activity. Perhaps 
these substituents interfere with an important hydrogen bond. Entry 86 however, 
showed full inhibition at 100 µM and an IC50 value of 3.1 ± 1.7 µM was determined. 
 
Thiourea 86 is indeed the most active compound that was identified during this 
synthesis and testing campaign. The explanation on the previous page stating that 
the permanent protonation of both imidazole nitrogens will be beneficial seems very 
plausible and is supported by docking experiments. Using the Tyr125 lifted structure, 
described earlier in figure 43, it becomes evident that 86 fits convincingly in the same 
configuration as found for 2-iodo inhibitor 53b. The added 2-position sulfur shows 
multiple possibilities for hydrogen bond formation, either as a thiourea or as a 2-
position –SH tautomer. However, it is doubtful that this will be of mayor contribution 
to the binding affinity. Sulfur has been reported to be a poor hydrogen bond acceptor 
and a moderate hydrogen bond donor.91 It is more likely that the tautomeric 
permanent 3-position NH hydrogen bond donor is the major contributor in this case. 
This constitutive hydrogen bond donation to the underlying His53 (see insert of figure 
46) will lock the compound more tightly inside the enzyme active site.  
 
 
 
 
 
 
 
Figure 46: The proposed binding mode of 86 as predicted by docking. The insert shows the 
multitude of H-bond interaction possibilities between ligand and protein and also a conserved water 
molecule underneath Tyr
125
. 
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5.3 Synthesis and Evaluation of Phosphonate and Carboxamides/Carbonic 
Acid Derivatives as PHP Inhibitors 
 
The success of the sulfonamide functionality raises the question if other bioisosteres 
for phosphate would also be allowed. A phosphonate group (compound 88, figure 47) 
would be desirable but also a carboxylic acid (89) or amide (90) are interesting 
substituents. The phosphonate and carboxylic acid are not very attractive options 
since such negative charges often prevent drug molecules from diffusing through a 
cell membrane. However, both the phosphonate and carboxylic acid have been 
employed successfully as phosphate mimics in numerous occasions, unlike the 
sulfonamide or amide bioisosteres.75 It is interesting to see the scope of the 
enzyme‘s sensitivity towards these small molecule inhibitors when decorated like the 
sulfonamide series. It was decided to use iodine as the 2-position substituent. 
Introduction of the iodo group is easily achieved and the acidic instability of a 5-
position iodine, described in the synthesis of 71, can also be used in the synthesis of 
these compounds when regioselective introduction of the iodine is problematic. 
 
 
 
 
 
Figure 47: Translating the sulfonamide based inhibitors to phosphonate (88), carboxylate (89) 
and amide (90) versions. 
 
 
To substitute the sulfonamide for a (benzyl protected) phosphonate, a halogen metal 
exchange on the 4-position of trityl protected 4-iodo imidazole 92 (see scheme 16) is 
required. This chemistry was employed successfully before, in our group, in an 
attempt to synthesize a phosphonate based phospho-histidine building block 98 (see 
figure 48). For this compound, the same chemistry was used that was developed for 
the sulfonamide based mimic 7 synthesis (as described in chapter 4).56 Nevertheless, 
the introduction of an iodine on the 2-position of 93 through n-butyllithium induced 
lithiation failed. The presence of the phosphonate heavily influenced the 
regioselectivity of the deprotonation and the 5-position iodo imidazole isomer (95) 
was formed instead. Indeed acidic removal of the benzyl protective groups gave 97 
as the sole product rather than 96 (or 88), indicating that the iodine was indeed 
introduced on the 5-position and lost upon acid treatment. 
To achieve the desired 2-position lithiation over the favorable 5-position lithiation on 
intermediate 93, the thermodynamically favored lithiation (93b, figure 49) needs to be 
overcome to achieve the kinetically favored 2-position lithiation (93a). Lowering the 
temperature during lithiation from -30 ºC to -78 ºC did not change regioselectivity nor 
did replacing the n-BuLi by s-BuLi, LDA or Li-TMP. 
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Scheme 16: Synthesis of compound 88. a: TrtCl, DiPEA, THF, 18h, 60 ºC, 84% b: iPrMgCl:LiCl, 
bis(diethylamino)phosphine chloride, 2h, -78 ºC - rt, BnOH, MeCN, tetrazole, 0 ºC - rt, 18h, 53% c: t-
BuLi, I2, THF, 2min, -100 ºC, 62% d: BuLi, I2, THF, 30min, -30 ºC, 53%
67
  e: TFA, water, TiPS, 18h, rt, 
(88 from 94: 64% and 97 from 93: 29%). 
 
 
 
 
 
 
 
Figure 48: Retrosynthetic analysis of compound 98 with intermediate 93 and 94. This synthesis 
is described in the thesis from Bart van Vliet.
56 
 
 
 
 
 
 
 
Figure 49: Lithiation of 93 going either kinetically on the 2-position (93a) or thermodynamically 
on the 5-position (93b). 
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An elegant method for influencing the regioselectivity of lithiation of 2-
methoxypyridine 99 was described by Caubere and coworkers (see figure 50).92 
Treating this heterocycle with different lithiating reagents and quenching with an 
electrophile generally failed to give the desired 6-position substituted product 100. 
For example, LDA yielded the 3-position lithiate 101 due to the directing effect of the 
methoxy group. Use of n-BuLi resulted in nucleophilic addition yielding lithiate 102. 
The in-situ generated non-nucleophilic reagent complex BuLi-Me2N(CH2)2OLi (BuLi-
LiDMAE was used successfully on 99, generating lithiate 103, and desired pyridine 
100 could be isolated with E being a variety of substituents. The formation of a 
complex as shown in figure 50 (insert 1) was given as explanation for the obtained 
regioselectivity. Hypothetically, this sterically hindered and non-nucleophilic complex 
can also use the presence of the imidazole nitrogen and phosphonate P=O to 
coordinate and facilitate deprotonation on the adjacent carbon in a similar fashion as 
with 99 (see figure 50, insert 2). Unfortunately, when applying this method, no 
desired 2-position deprotonation of 93 was observed and again, only 5-position iodo 
product was found after quenching.  
 
 
 
Figure 50: The lithiation of 2-methoxypyridine. Successful 2-position lithiation of pyridines can be 
achieved by using BuLi-DMAE. This complex associates with the pyridine nitrogen and methoxy 
oxygen and directs a second equivalent of BuLi towards the pyridine 2-position hydrogen.
92 It was 
hypothesized that 2-position lithiation of 93 could be achieved in a similar fashion.  
 
 
A more successful method was found in the use of a stronger and more kinetic base 
like t-BuLi. Simply replacing n-BuLi from the original protocol by t-BuLi yielded the 
desired iodo regioisomer 94. Optimization of the protocol by lowering the temperature 
to -100 ºC and addition of the iodine immediately upon t-BuLi addition resulted in a 
62% yield with no formation of the 5-position isomer observed. Indeed, acidic 
removal of the protective groups from 94, showed stability of the halide and allowed 
us to acquire the desired phosphonate 88. 
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To complete the set of alternative bioisosteres the commercially available 4-
carboxylic acid imidazole 104 was protected with a trityl group. The carboxylic acid 
105 was reacted with the same double dimethoxybenzyl protected amine used for the 
sulfonamides, obtaining compound 106. Like for the sulfonamide the DMB protective 
group is a suitable protection for a terminal amide group.93 With these two building 
blocks in hand the lithiation and regioselectivity of these carbonyl attached imidazoles 
was investigated. Again, regioselectivity proved to be an issue for the lithiation. In 
both cases a clear lack of selectivity was observed as both 2- and 5-position isomers 
were formed in similar amounts. Using n-BuLi or t-BuLi did not influence the ratio 
much in both cases. The mixture of isomers also seemed hard to separate by normal 
or reversed phase chromatography. However, this was assumed not to be a serious 
issue since the 5-position isomers were likely to be unstable under acidic 
deprotection conditions. This was already observed for the sulfonamide and 
phosphonate compounds. Indeed upon TFA treatment and HPLC purification only 
the 2-position iodo-imidazoles, 89 and 90 were isolated in pure form. 
 
 
 
 
 
 
 
Scheme 17: Synthesis of compounds 89 and 90. a: TrtCl, pyridine, DMF, 18h, rt, 73% b: N,N-
bis(2,4-dimethoxybenzyl)amine, HOBt, EDC.HCl, DiPEA, 2h, rt, 95%  c: t-BuLi, I2, THF/HMPA, 2 min., 
-100 ºC, TFA, water, TiPS, 18h, rt, 45% d: t-BuLi, I2, THF, 2 min., -100 ºC, TFA, water, TiPS, 18h, rt, 
38%.  
 
 
Compounds 88, 89, 90 and phosphonate 97 were tested for PHP enzyme inhibition 
and remarkably, showed no enzyme inhibitory activity. The sulfonamide is clearly 
superior to carboxylic acid, carboxamide and even the phosphonate. This result 
suggests a binding mode for the imidazole sulfonamides different to the way a 
phospho-histidine substrate binds to the enzyme prior to enzymatic hydrolysis. This is 
in line with the various binding modes already proposed predicting the 2-position 
substituent of the imidazole sulfonamide inhibitors at the place where substrate 
phosphate is likely to bind.   
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5.4 Encore: Structure Based Design: 3,5-diphenyl-isothiazolidine-dioxides as 
      PHP inhibitors? 
 
The availability of X-ray structures for PHP allows the application of structure based 
(ligand) design as an alternative means of novel inhibitor identification. With this 
technique, the structural information available directs the design of new ligands.  
X-ray structure 2HW4 shows a significantly larger catalytic cleft compared to the in-
house generated structure (see figure 28). Assuming that 2HW4 is a real, in situ, 
conformation for PHP, an inhibitor design can be envisioned that contains a central 
core with two aromatic rings attached (see figure 51). The most convincing binding 
modes for the imidazole sulfonamides place the sulfonamide in the center close to 
Arg78. This sulfonamide is easily incorporated in a ring system. This ring should be 
able to position the aromatic ring features correctly to fill the two pockets on both left- 
and right-hand side. Preferably, this center ring is saturated to induce a certain 
amount of flexibility. An isothiazolidine 1,1-dioxide ring presents a viable option and a 
3,5-diphenyl decoration as the best orientation for the phenyl rings. This test 
compound, 107 in figure 52, can be prepared in a racemic fashion to obtain a total of 
4 different stereoisomers. Docking experiments were performed and all four possible 
isomers, SR, RR, SS and RS were docked inside 2HW4. Three out of four 
compounds were docked convincingly, placing the ligand nicely in the catalytic site 
(see figure 53). The RS isomer poses a problem as the cis-orientation prevents the 
ligand from adopting a suitable conformation. For the other cis-isomer, SR, this was 
not a limitation. 
 
 
 
 
Figure 51: Depiction of a proposed layout for novel PHP inhibitors based on pdb 2HW4. 
Performing a structure based ligand design, the available binding pocket can be filled with a molecule 
based on a cyclic ring structure containing a sulfonamide. The two additional spaces can be filled with 
a phenyl ring attached to the central ring. 
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Figure 52: Structure of the proposed compound 107 and the structures of the in literature 
reported compounds 108, 109 and 110. 
 
 
 
 
 
Figure 53: Docking of the four different stereoisomers of 107 in pdb 2HW4. Isomers SR, RR and 
SS dock well inside the active site, obtaining the configuration as designed with the sulfonamide in 
close proximity to Arg
78
. Isomer RS did not fit in the protein due to the cis configuration. 
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Unlike for the 3,5-diphenyl-isothiazolidine-dioxides, the mono-phenyl versions 108 
and 109 are known in literature and their synthesis reported.94 Also, a benzyl 
decorated alternative, compound 110, has been reported before.77 Nevertheless, 107 
would be an interesting, and above all, feasible target for synthesis and a promising 
scaffold for novel bioactive molecules. Alternatively, the phenyl substituents can be 
replaced by heterocyclic or aliphatic substituents when 107 shows promising activity 
In order to design a synthetic procedure to prepare 107, the reported synthesis of 
108 and 109 proved useful. These compounds were prepared by two different 
synthetic routes disconnecting the centre isothiazolidine 1,1-dioxide either in between 
the C3 and C4 atom or in between the C5 and N1 atom (see figure 54). 
Disconnecting in between C3 and C4 of 107 and disconnecting further to sulfonyl 
chloride 112 and amine 113 leads back to a non-natural amino acid, phenylglycine 
114.94a This route allows for a quick optimization program starting from various 
commercially available sulfonyl chlorides and (un)natural amino acids if the test 
compound shows inhibitory activity. Alternatively, 107 can be prepared from a Boc 
protected sulfonamide 116 and epoxide 117, derived from styrene 118.94b The readily 
availability of starting materials and the absence of protective groups strongly favors 
the first synthetic strategy. 
 
 
 
 
 
 
 
Figure 54: Retrosynthetic analysis for 107. Either a disconnection in between C3 and C4 or in 
between C5 and N1 will generate a synthetic procedure starting from commercially available starting 
materials. Favorable is the route starting from amino acid 114. This route starts with easily available 
starting materials and does not require the use of protective groups. This route is also more suitable 
for parallel synthesis if compound 107 is followed up by an optimization program  
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Commercially available racemic phenyl glycine 114 was treated with an excess of 
LiAlH4 (see scheme 18). The primary alcohol product was immediately reacted with 
benzyl sulfonylchloride 112. Two equivalents of the sulfonyl chloride were used in 
order to directly obtain the chloride 111 rather than a primary alcohol. A ring closure 
induced with two equivalents of n-BuLi allowed the isolation of 107 in moderate yield. 
Care was taken in isolating the two pairs of diastereomers that were formed 
separately. After the final ring closure four different products are formed when a 
racemic amino acid starting material 114 is used. The trans-enantiomers were 
isolated separately from the cis enantiomers (see figure 55). 
 
 
 
 
 
 
Scheme 18: Synthesis of compound 107. a: LiAlH4, THF, 18h, 0 
o
C - rt b: 112, TEA, THF, 8h, 0 
o
C - 
rt, 68% (over two steps)  c: diisopropylamine, BuLi, THF, 3h, -70 ºC – 0 
o
C, 64%. 
 
 
 
 
 
 
Figure 55: Depiction of all possible stereoisomers of 107. Using ordinary straight fase 
chromatography the diastereoisomers were obtained separately. The compounds were tested as two 
sets of enantiomers. 
 
 
Both enantiomeric mixtures were isolated in pure state and assayed separately for 
PHP enzyme inhibition. Unfortunately, both compound mixtures failed to show any 
inhibition at a 100 µM concentration. 
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6.1 Introduction 
 
The biochemical screening assay results presented so far are based on the 
fluorescence assay described in §3.4. The substrate used in this assay is DiFMUP 
and this phospho-tyrosine mimic cannot be considered a realistic substrate for a 
phospho-histidine phosphatase. A phospho-histidine containing substrate would be a 
more realistic probe in a biochemical assay setup. The development of this assay 
was described in §3.5 and phospho-histidine itself was successfully prepared and 
used for this assay. The assay is significantly less ‘high throughput’ but perfectly 
suitable as a backup assay to validate the results from the fluorescence screening 
assay. Based on the results of this secondary assay, a subset of compounds was 
continued and investigated in the Microscale Thermophoresis (nanotemper) binding 
assay described in §3.6. 
The next step is profiling in cellular assay systems. An important requirement for 
cellular active compounds is good water solubility and cell membrane permeability. 
This was assayed for the compound selection using a PAMPA type permeability 
screen as described in §6.4. The cellular assays that were performed are a patch 
clamp ion channel current experiment with HCT116 colon cancer cells and a scratch 
type migration assay with MCF-7 breast cancer cells. The results are described in 
§6.5 and §6.6 respectively. Monitoring the behavior of these compounds inside living 
cells using fluorescence microscopy is a very attractive alternative technique to use. 
It will allow pinpointing the location of increased concentrations of fluorescently 
labeled compound in vivo. It can also show the interaction between a labeled inhibitor 
compound and a labeled receptor protein in live cells. The efforts to obtain a 
fluorescently labelled imidazole sulfonamide are described in §6.7. 
Finally, structural information regarding the interaction between the inhibitors and the 
enzyme would be a great achievement. Attempts to co-crystallize and soak the 
developed inhibitors with the PHP enzyme are discussed in §6.8. 
 
The compounds that were selected for further profiling, based on the fluorescent 
screening assay results, are 53f, 60c and 86 (see figure 56). These compounds all 
display inhibitory activity in the 1-10 µM IC50 range. Added for solubility and cell 
permeability assaying, is the structurally different sulfonyl compound 70a. This 
compound displays only minor PHP inhibitory activity but is different in chemotype, 
since it is lacking the sulfonamide that can lead to poor cell permeability properties. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 56: Structures of the compounds 53f, 59c, 70a and 86. This set of compounds was selected 
for further profiling. 
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6.2 Continuous Coupled Enzyme Assay 
 
The continuous coupled assay that was developed as a control assay (see §3.4) 
uses phospho-histidine as a substrate and a second enzyme reaction to generate a 
readout. However, the principle is the same as for the fluorescence screening assay 
used during the synthesis and testing cycles described in chapter 5. Consequently, 
the inhibitory results should be in the same range. The compounds 53f, 60c, 70a and 
86 were subjected to a full IC50 determination. The results are presented in table 7. 
As expected, the determined IC50 values are indeed comparable underlining the 
robustness of both assay systems. Generally, activity is lower in the coupled assay 
but clearly within the margin of error. A typical IC50 curve is shown in figure 57. 
 
 
 
 
Table 7: Comparison of the activity determined in both biochemical assay for the selected 
compounds. 
 
 
 
 
 
 
´ 
 
 
 
 
 
 
 
 
 
 
Figure 57: Typical inhibition curve shown for compounds 60c. Figure generated using the 
software Prism 5.0. 
 
 
To provide a full perspective of the assay, a complete screen was performed. All 
compounds that were synthesized in the project were tested at a 100 µM 
concentration comparing both active and inactive compounds on both assays. 
Indeed, no surprises were obtained and compounds that failed to show inhibitory 
activity in the fluorescence screening assay did not show inhibition in the coupled 
assay (data not shown). 
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6.3 Determination of Kd values using Microscale Thermophoresis (MST) 
 
Unlike a biochemical assay, where the substrate conversion is used as readout, a 
binding assay will give direct information about the interaction between protein and 
ligand.  As described in §3.6, PHP was labelled with fluorescein in order to measure 
equilibrium binding constants between protein and the inhibitor molecules. 
 
In the selection of compounds used for Kd determination, 70a was replaced by 53e 
(see figure 58). This compound is structurally more similar to the other three 
imidazole sulfonamides but, completely inactive in both functional assays. This 
compound serves as a negative control and should not show any binding with the 
fluorescein labelled PHP protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 58: Structures of the compounds 53f, 60c, 86 and 53e. These compounds were selected for 
MST Kd determination. 70a was replaced by the structurally more similar but inactive chloride 53e. 
 
 
The determined dissociation constants are given in table 8. The Kd values match well 
to the IC50 values generated in the two biochemical functional assays. 60c displays a 
somewhat lower binding. Also, for the continuous coupled assay this compound was 
less active compared to the fluorescence assay. Negative control 53e clearly 
underlines the validity of the binding assay showing no effect even at the highest 
concentration of measurement, being 200 µM. 
 
 
 
 
 
Table 8: Comparison of the inhibitory activity determined in the fluorescence biochemical 
assay and the Kd values for the compounds 53f, 60c, 86 and non-active negative control 53e. 
 
 - 100 - 
 
 
6.4 Solubility and Cell Permeability 
 
As mentioned in the introduction of this chapter, solubility and cell permeability for the 
compounds  is essential for obtaining useful data from cellular assays. The intention 
is to show cellular efficacy, making these parameters essential for forwarding these 
compounds into more complex assays using living cells. The selected compounds 
were subjected to measurements determining kinetic solubility and Parallel Artificial 
Membrane Permeability Assays (PAMPA).95 The obtained results are outlines in 
table 9.  
 
 
 
 
Table 9: Determination of the kinetic solubility as determined by a direct LCMS based 
measurement (assay wall: 500 µM) and PAMPA permeability. a: %Flux defined as concentration 
(test well)/concentration (control well) x 100. Solubility and PAMPA data generated by the Lead 
Discovery Center, Dortmund. b: calculated using the software MarvinSketch 6.0.6. 
 
 
The kinetic solubility is excellent for all compounds and can be considered higher 
than the assay maximum of 500 µM. The low molecular weight and high polarity of 
these compounds assure good water solubility. The passing over a membrane as 
expressed by %Flux is very low for entries 53f and 60c. For these molecules a 
relatively acidic sulfonamide and an extremely low lipophilicity respectively, 
negatively influences their ability to passively diffuse through a membrane. This is 
underlined by entries 70a, lacking the sulfonamide, and 86, with a much higher pKa 
for the sulfonamide. These compounds display significantly better cell permeability. 
This clearly sets apart compound 86 as the prime candidate for further investigation.  
In an attempt to improve the cell permeability of 60c the preparation of prodrugs was 
considered. Decided was to acylate and benzylate the primary hydroxyl group and 
resubmit these esters for permeability measurements. The compounds were 
prepared as shown in scheme 19. Hydroxyl precursor 58 was converted into the 
esters 119 and 120. Fortunately, acidic removal of the protective groups did not harm 
the ester functionality and the compounds 121 and 122 were isolated in good yield.  
As shown in table 9, addition of a large lipophilic group significantly improved cell 
permeability for entry 122 compared to 60c. Addition of a simple acyl group however, 
did not affect the PAMPA permeability as compound 121 did not display increased 
membrane passing compared to 60c.  
Compounds 121 and 122 were also tested in the fluorescence biochemical screening 
assay and were found to be inactive. 
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Scheme 19: Synthesis of prodrugs 121 and 122. a: pyridine, RCOCl, DCM, 2h, 0 
o
C - rt b: TFA, 
TiPS, 18h, rt, 56% and 76% respectively (yield over two steps). 
 
 
6.5 KCa3.1 Ion Channel Patch Clamp 
 
The experiments described in this paragraph have been performed by Prof. Dr. Frank Wehner (Max 
Planck Institute, Dortmund) 
 
The potassium channel KCa3.1 is the prime known example where histidine 
phosphorylation is essential for a physiological event in eukaryotes. This calcium-
activated potassium channel is vital in CD4 T cells for maintaining the cell membrane 
potential relatively negative. This is the driving force for Ca2+ influx when required 
inside the cell upon T cell activation. PHP negatively regulates channel activity 
through dephosphorylation of His358 (see §1.2.2).35 As mentioned in §1.3.3, PHP 
activity has also been related to human lung cancer cell migration and invasion.45 
The cells that were used in this study are highly metastatic lung cancer CL1-5 cells. It 
was suggested that the mechanism involves an effect on cytoskeletal rearrangement 
but KCa3.1, as a possible target for PHP in this process, was not mentioned. 
To investigate if KCa3.1 is involved in cell metastasis, whole cell patch clamp 
experiments were performed with readily available, highly metastatic, HCT116 colon 
cancer cells. Upon treatment of the cells with either a KCa3.1 channel activator 
(DCEBIO, figure 59A) or inhibitor (TRAM-34, figure 59A), a significant difference in 
current was observed compared to untreated cells (see figure 59B, red trace and 
green trace respectively compared to the blue trace representing untreated cells). 
Clearly the ion channel is present and fully functioning in this cell line. 
Secondly, the influence of PHP inhibition on the ion channel behavior was 
investigated. The same experiment was now performed with 10 µM of inhibitor 53f, 
86 or 122 pre-incubated cells. No effect was observed except with inhibitor 86 
present. Unexpectedly, the effect of addition of channel activator DCEBIO seems to 
be impaired by the PHP inhibitor. The experiment was repeated with a concentration 
of 100 µM (see figure 59C) and indeed the compound significantly inhibited the 
action of channel activator DCEBIO (red trace). This is different than expected as 
PHP inhibition was reported in T cells to activate channel flow. A PHP inhibitor would 
be expected to increase the channel current of untreated cells (blue trace). With the 
current knowledge this different effect cannot be explained. A direct antagonistic 
action of the compound on the ion channel is a possible mechanism. To investigate if 
86 influences channel activity through a different mechanism the experiment needs to 
be repeated with PHP siRNA knock-down. This experiment has not been performed 
yet. 
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Figure 59: Investigation of the role PHP has in KCa3.1 channel activity in HCT116 colon cancer 
cells. A: The chemical structures of ion channel activator DCEBIO and channel blocker TRAM-34. B: 
The current-voltage (i-v) plot of the HCT116 cells. The effect on channel current at different voltage 
membrane potential is plotted with the presence of a channel activator DCEBIO (red trace) or channel 
blocker TRAM-34 (green trace). Untreated cells are represented by the blue trace. C: The current-
voltage (i-v) plot of the HCT116 cells pre-incubated with 100 µM concentration of PHP inhibitor 86. 
Again, the effect on channel current at different voltage membrane potential is plotted with the 
presence of a channel activator DCEBIO (red trace) or channel blocker TRAM-34 (green trace). 
Untreated 86 pre-incubated cells are represented by the blue trace. Surprisingly, the presence of PHP 
inhibitor 86 has no effect on the cells except when channel activator DCEBIO is added. Here, the 
channel remains predominantly in a closed state.  
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6.6 Wound Healing Scratch Assay 
 
The work described in this paragraph has been performed by Dr. Rosemarie Marchan in the lab of 
Prof. Dr. med. Jan G. Hengstler (Leibniz Research Centre for Working Environment and Human 
Factors) 
 
A wound healing scratch assay is a widely used assay testing for the ability of cells to 
migrate in vitro under the influence of chemical compounds or applied genetic 
changes, e.g. gene knockdown, under carefully chosen conditions.96 The role of a 
particular protein in the migration of cells can be studied in detail using this 
technique. A monolayer of cells is grown on a plate under medium and a scratched 
opening is created using a pipet tip. The closing of this gap is monitored in time. The 
increased or decreased rate of closing can be quantified and related to the added 
chemical (concentration dependent) or genetic change. 
The vital role that has been found for PHP in CL1-5 lung cancer cell lines, was also 
investigated in a wound healing scratch assay as reported by Dacheng and 
coworkers.45 In order to investigate PHP through means of chemical inhibition, CL1-5 
cells were requested and obtained from Pan-Chyr Yang, Dean and Professor of 
Medicine at the National Taiwan University College of Medicine. The obtained cells 
were also subjected to the scratch assay protocol, however growing a monolayer of 
the CL1-5 cells in our lab proved impossible. A tendency to grow on top of each other 
rather than creating a monolayer was observed. It was decided to test the PHP 
inhibitors in MCF-7 breast cancer cells instead. These cells are known to behave well 
in this type of scratch assay and do express detectable levels of intracellular PHP 
(data not shown). 
The compounds selected for the assay were the same as used for the patch clamp 
experiments, 53f, 86 and benzylic prodrug 122. The compounds were tested at 5 and 
10 µM concentration and compared to non-treated cells. Pictures were taken at time 
points 0,1,2 and 3 with 24 hour increments. The results were disappointing as none 
of the three compounds showed a significant effect at either 5 or 10 µM 
concentrations. Increasing the concentration, as was required for the patch clamp 
experiment, was also no option as cell toxicity was observed for compound 86 at a 10 
µM concentration (see figure 60). This is in line with the higher cell permeability that 
was established for this compound and supports a conclusion that this compound is 
cytotoxic for MCF-7 cells. Possibly, compounds 53f and 122 have a similar toxicity 
but fail to enter the cell. The mechanism to this toxicity is unknown and not 
necessarily PHP mediated. Also, the outcome of the patch clamp experiments 
suggests an unexpected pharmacology for 86. The cytotoxicity might also be an 
expected effect as sulfonamides like 86 can possess carbonic anhydrase inhibitory 
activity (see §5.1). Several carbonic anhydrase inhibitors are indeed being evaluated 
as anti-tumor drugs.88 Also the role of certain carbonic anhydrases in breast cancer is 
being investigated.97 In MCF-7 cells, upregulation of carbonic anhydrase XII by 
various growth factors has been established.98 
Besides the PHP knockdown experiments performed in CL1-5 lung cancer cells, 
siRNA PHP knockdown has been shown to inhibit both cell growth and proliferation in 
hepatocellular carcinoma (HCC) cell lines.46 This suggest that also selection of the 
right cell line is essential for a successful outcome in an experiment to study the 
effect of PHP inhibition. Additionally, the cytotoxic properties of the PHP inhibitors 
should be considered as a subject of investigation next to their alleged ability to 
impair cell migration. 
 - 104 - 
 
 
New experiments with different cell lines are currently being considered in order to 
further study PHP in cells and the cellular effectiveness of the inhibitors. 
Overexpression of PHP might be required to distinguish the effect of PHP inhibition 
from compound related side effects. CL1-5 cells do express the enzyme in far higher 
concentrations compared to other many other cell lines that are more readily 
available. Additionally, the inhibitory effect of the compounds on carbonic anhydrases 
needs to be evaluated. This activity can limit the usefulness of these compounds as 
tools to investigate PHP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 60: Results for compound 86 in the wound healing scratch assay. The experiment was 
performed in full media (FM), with DMSO or at a concentration of 5 or 10 µM. At concentrations of 5 
and 10 µM the rate of scratch closing was monitored using microscopy in time. At 5 µM concentration 
the created opening closed just as rapidly as for the untreated and DMSO control experiments 
indicating no effect at this concentration. Raising the concentration of inhibitor compound 86 to 10 µM 
resulted in immediate cell death. 
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6.7 Fluorescence Microscopy 
 
A powerful technique that can yield solid evidence for an interaction between two 
(bio-)molecules in living cells is Förster (or Fluorescence) Resonance Energy 
Transfer (FRET). What made this technique possible was the discovery of an entire 
class of auto-fluorescent proteins, e.g. Green Fluorescent Protein (GFP), found in 
jellyfish.99 A protein of interest can be labelled through cloning of the protein gene 
into an expression vector linking a fluorescent protein to the N- or C-terminal end. 
This vector can then be transfected into the cell of interest. Energy transfer from one 
excited fluorophore (donor) to another (acceptor) when in close proximity (10 to 100 
Å) leads to an emission of light from the acceptor fluorophore (see figure 61).100 
 
 
 
 
 
 
Figure 61: Principle of Förster Resonance Energy Transfer (FRET). Excitation of the fluorophore 
acceptor leads to energy transfer to the fluorophore donor when in close proximity due to interaction of 
molecule 1 and 2. The amount of emitted light by the donor is a measure for the interaction of 
molecule 1 and 2.  
 
 
Besides an interaction between two biomolecules, interaction between a small 
molecule inhibitor and a target molecule can also be visualized if the right 
fluorescently labelled tools can be obtained. Labelling the PHP inhibitor molecule 
with a fluorescent tag and generating a PHP-fluorescent protein construct can 
generate an interesting opportunity to study the inhibitor-enzyme interaction in 
various cellular set-ups.  
The spectroscopic properties of the two fluorophores need to be considered in 
selecting the right labels in order to obtain a workable FRET pair. It is essential that 
there is sufficient separation in excitation spectra to achieve selective stimulation of 
the donor fluorophore. Also, an overlap is required (approximately 30%) between the 
emission spectrum of the donor and the excitation spectrum of the acceptor to obtain 
efficient energy transfer. Finally, a reasonable separation in emission spectra 
between donor and acceptor is required to allow independent measurement of the 
fluorescence of each fluorophore.101 A good combination of fluorophores for this 
approach is an mCitrine labelled PHP and the inhibitor molecule labelled with 
fluorescein derivative TAMRA (see figure 62). In this combination all requirements 
are met. 
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Figure 62: Excitation and emission spectra from mCitrine and TAMRA. blue: mCitrine excitation 
spectrum; red: mCitrine emission spectrum; light blue: TAMRA excitation spectrum; light red: 
TAMRA emission spectrum. Generated online through www.chroma.com 
 
 
Besides FRET there is the possibility to use Fluorescence Lifetime Imaging or 
FLIM.102 With this technique the unique properties of either the fluorophore donor or 
acceptor is being used. A fluorophore is not only characterized by its excitation and 
emission spectrum, but also by its unique lifetime. This lifetime is defined as the 
average time that a fluorophore remains in an excited state before returning to the 
ground state. FLIM does not depend on changes in fluorophore molecule 
concentration, excitation intensity and other factors that limit intensity-based 
measurements. The fluorescence lifetime is influenced by changes in the cellular 
environment including the occurrence of FRET, which shortens the excited state 
lifetime. Also, the use of FLIM allows the monitoring of intracellular events at very 
high resolution, allowing accurate pinpointing of the event.103 Combination of FRET 
and FLIM data provides direct evidence of interactions between labelled molecules. 
By measuring the donor lifetime in the presence and the absence of acceptor it is 
possible to accurately calculate the distance between the donor- and acceptor-
labeled molecules.104 
 
PHP was N- and C-terminal labelled with mCitrine using standard cloning techniques. 
TAMRA is a suitable label for a small molecule since it is commercially available as 
N-hydroxysuccinimide ester and is superior to many other fluorescent labels 
regarding loss of fluorescence due to bleeding during experiments.105 
Adding a fluorescent label to the imidazole sulfonamide PHP inhibitors is challenging. 
Trivial from a synthetic point of view, but analyzing the SAR that was established 
around the imidazole sulfonamides, showed that only minor structural modifications 
are allowed around the core without significant loss of activity. Adding a large 
additional molecule in the form of a fluorophore is likely to disrupt the binding to PHP. 
60c did show some activity (37% at 100 µM) and attaching the TAMRA through a 
linker would result in target molecule 123 (see figure 63). 
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Figure 63: Structures of the compounds 53f, 60c and TAMRA labeled target molecule 123. 
Compound 60c forms a small opening in the SAR around 53f. The oxygen of 53f is the only site where 
a linker can be attached without losing all activity.  
 
 
For the TAMRA labelled sulfonamide imidazole compound 123, synthesis started 
with triethylene glycol 124 (see scheme 20). Converting one alcohol into an azide 
was achieved by applying methanesulfonyl chloride and secondly, sodium azide.  
From 125, the other terminal alcohol was activated as a tosylate and used to alkylate 
synthetic intermediate 58 obtaining azide 127. To convert the terminal azide in a 
primary amine, triphenylphosphine was used and attaching the TAMRA fluorophore 
was achieved through coupling with the commercially available OSu ester. The 
protective groups were removed using TFA and preparative HPLC afforded target 
molecule 123 in 10% yield from 127. The low yield was caused by significant 
cleavage of the first ether bond from the linker under the acidic protective group 
removal conditions. During purification, a large amount of 53f was observed 
indicating acid catalyzed degradation of the product. 
 
 
 
 
 
Scheme 20: Synthesis of fluorescently labelled imidazole sulfonamide 123. a: MeSO2Cl, TEA, 
THF, 18h, 0 ºC - rt, b: NaN3, EtOH, 6h, 80 ºC, 45% over two steps c: TsCl, pyridine, DCM, 18h, rt, 
66% d: 58, NaH, DMF, 18h, rt, 41% e: PPh3, H2O, THF, 24h, rt f: TAMRA-OSu, TEA, DMF, 18h, rt g: 
TiPS, H2O, TFA, 2h, rt, 10% over three steps . 
 
 
The labelled PHP was obtained through cloning of the PHP gene into two mCitrine 
PET vectors attaching the fluorescent label at both terminal ends. This work was 
performed by the Dortmund Protein Facility.106 The cellular experiments, transfecting 
the labelled enzyme into CL1-5 cells and monitoring FRET and/or FLIM upon addition 
of compound 123, has not been performed yet. 
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6.8 X-ray Co-Crystallization and Soaking  
 
The work described in this paragraph has been performed together with Arthur Porfetye under 
supervision of Dr. Ingrid Vetter. 
 
The successful crystallization of the wild type PHP in-house initiated trials for co-
crystallography and soaking of the identified inhibitors. However, despite extensive 
screening of conditions no structure was obtained showing the inhibitors bound in the 
catalytic site. What was observed in the X-ray structure was an electron density in the 
active site that can be assigned with high likelihood to a sulfate ion. All conditions 
that were used for successful PHP crystal formation contain concentrations of sulfate 
ions in excess of 1.5 molar.  
Close examination of the X-ray structures that were obtained in-house revealed a 
network of hydrogen bonding to this sulfate ion from catalytically essential amino 
acids like His53 and Lys21 (see figure 64). The adjacent PHP molecule in the tightly 
packed matrix revealed a glutamine residue (Gln84) making contact with the sulfate. 
This renders the sulfate essential in forming important contacts from one PHP 
molecule to another stabilizing the protein matrix. This interaction can be considered 
to be essential for obtaining crystals that diffract well. Competition between the 
inhibitors and the excessively high sulfate concentration will render attempts to obtain 
a co-crystal nearly impossible. Also soaking did not result in a replacement of the 
sulfate by inhibitor underlining the sulfate as a key element of the crystal matrix. 
 
 
 
 
 
Figure 64: The importance of a conserved sulfate ion in the X-ray matrix. The electron density 
found in the active site matches a sulfate ion. Besides hydrogen bonds between the sulfate and the 
protein catalytic cavity, an additional interaction with Gln
84
 from an adjacent PHP molecule is 
observed. This interaction shows that the sulfate plays an essential role in the protein stacking of the 
X-ray matrix. This explains why a high concentration of sulfate is so important for obtaining crystals.  
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7.1 Introduction 
 
Building block 7 was designed as a tool that can be incorporated into different 
peptides. Depending on the chosen amino acid sequence, these peptides can be 
used to study different aspects of histidine phosphorylation. Besides the attempts to 
create PHP inhibitor peptides as described in chapter 4, the sulfonamide imidazole 
mimic of phospho-histidine can be incorporated into peptides that are designed as 
pull-down probes. Such tools are then used to extract previously unidentified 
phospho-histidine interacting partners out of various cell lysates. Clearly more 
important in this set-up is a genuine phospho-histidine mimic. The building block 128 
(as depicted in figure 65) would be required and peptide synthesis and protective 
group removal would result in a peptide 129 carrying the desired phospho-histidine 
mimic. This non-hydrolysable phosphonate building block 128 was prepared 
previously in our group and has already been used successfully in raising antibodies 
that recognize native phospho-histidine peptides as represented by 130.56 
 
 
 
 
 
 
Figure 65: The structures of previously described building block 7, phospho-histidine mimic 
building block 128 and its peptide incorporated form 129, and a true phospho-histidine 130 as 
topic of investigation. 
 
 
The days when histones were seen as proteins used just for storage of DNA are far 
behind us. Histones and their post-translational modifications are now fully 
recognized as integral parts of the genetic information stored in a cell nucleus.6a As 
mentioned in §1.2.2, histone H4 is known to be phosphorylated on two histidine 
residues, His18 and His75. These PTMs were discovered a long time ago but did not 
receive the same attention dedicated to other histone PTMs like acetylation, 
methylation and O-phosphorylation.6b Therefore, the physiological function and 
importance remains to be discovered. Also here, the proper tools are essential for 
successful investigation of N-phosphorylation.107 
It has been shown that O-phosphorylation on histones is an essential part of DNA 
repair and transcription regulation.108 Additionally, a phospho-serine or phospho-
threonine  can directly influence the activity of other PTM applying enzymes, e.g. 
Histone Acetyl Transferase (HAT) on adjacent residues.109 The phosphorylation of 
histones can also serve for the generation of docking sites for proteins involved in 
DNA expression like transcription factors.110 In this line it is easily hypothesized that 
the N-phosphorylation on histone H4 His18 can serve a similar purpose. 
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In investigating this hypothesis, the identification of interacting partners for histone H4 
with the phospho-histidine of interest is essential. Two pull-down probes, peptides 
with building blocks 7 and 128 incorporated, were designed and prepared. These 
peptides were deployed to identify proteins from various cell lysate mixtures. To 
eliminate false positive protein hits, a negative control, an analogous peptide with 
non-modified histidine, was prepared as well. This work is described in §7.2.  
Alternatively, the role of Histone H4 His18 phosphorylation was studied in an in vitro 
set up enzyme assay. The rate of lysine acetylation or methylation by either HAT or 
histone H4 Lys20 specific lysine methylase Suv420h1 is measured on a His18 
phosphorylated peptide and compared to the non-phosphorylated peptide 
counterpart. This work is described in §7.3. 
 
 
7.2 Preparation and Evaluation of Sulfonamide and Phosphonate Containing 
Pull-down Probes 131 and 132 
 
The design of the pull-down probe peptides is based on 20 amino acids 
corresponding with AAs 9-28 from histone H4 (indicated in red in figure 66). Besides 
the two phospho-histidine mimics, replacing His18, a desthiobiotin attached through a 
linker was added in the design. This moiety will allow pulling the construct out of a 
cell lysate mixture through the use of streptavidin on magnetic beads.111 To prevent 
the linker and desthiobiotin from interfering with the protein recognition, it is attached 
to an additional lysine at the C terminal end of the peptide. Finally, a glycine with 
amide end is added in the design for synthetic purposes preventing problems with 
detaching the finished peptide from the resin. The Rink Amide (RAM) Tentagel resin 
was selected as it is a suitable resin for a challenging SPPS campaign. Peptides 131 
and 132 are intended to solely identify proteins that interact with a native phospho-
histidine. This requires a control probe 133 that contains a normal histidine to identify 
proteins that bind to other parts of the peptide besides the phospho-histidine mimic. 
These proteins can then be excluded from a list of hits (see figure 67 for a detailed 
description of the experiment). 
 
 
 
 
 
 
Figure 66: The structures of pull-down probes 131 and 132, and control peptide 133. In red are 
the amino acids derived from histone H4 (AAs 9-28). Probe 133 bears a normal histidine and serves 
as a negative control to eliminate false positive hits. 
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Figure 67: Principe of the pull-down experiment as exemplified with probe 132. Premixing probe 
132 with streptavidic coated magnetic beads gives a complex (A) that can bind to a protein that 
interacts with phospho-histidine. Addition of a cell lysate protein mixture will lead to complex B that can 
be retrieved by using a magnet. Washing will release the target protein that can be identified by mass 
analysis. Any protein that is identified by probe 131 or 132 and not by control probe 133 interacts with 
the phospho-histidine mimic. This identified protein is worth further investigation. 
 
 
Before the synthesis of the probes on the resin could begin, the desthiobiotin linker 
attached to Fmoc protected lysine was prepared. Synthesis of building block 134 is 
described in scheme 21. Starting from triethylene glycol 124 a tert-butylester was 
introduced by 1,4-addition to tert-butylacrylate. Conversion of the second terminal 
alcohol into an azide gave 136 in good yield. The azide was reduced using PPh3 and 
the desthiobiotin was attached. 137 was coupled to an Fmoc protected lysine through 
the succinimide activated carboxylic acid 138 obtaining building block 134. 
For the SPPS a Tentagel RAM resin was selected. These low loading (0.24 mmol/g) 
resins are suited for complex peptide synthesis. After loading of the resin with Fmoc-
glycine and Fmoc deprotection, building block 134 was coupled to the functionalized 
resin 139 using standard HBTU coupling conditions (see scheme 22). Unfortunately, 
coupling to the resin was unsuccessful. A test cleavage of 140 failed to show the 
Fmoc protected dipeptide in analysis. Also, an Fmoc protected glycine was not found 
indicated that the coupling reaction of 134 with 139 failed. Coupling with an alloc 
protected Fmoc lysine towards 141 was successful showing that the biotin linker of 
134 interfered with peptide coupling. The alloc of the obtained 141 can be removed 
selectively and this allows for attachment of the desthiobiotin linker at a later stage. 
 - 114 - 
 
 
 
 
 
 
Scheme 21: Synthesis of building block 134. a: t-butyl acrylate, Na, THF, 18h, rt, 29% b: MsCl, 
TEA, DCM, 4h, 0 
o
C - rt c: NaN3, DMF, 18h, 60 ºC, 87% over two steps d: PPh3, dioxane/H2O, 18h, rt 
e: desthiobiotin, EDC.HCl, DMAP, DMF, 18, rt, 43% over two steps f: TFA, DCE, 30min, rt g: N-
hydroxysuccinimide, EDC.HCl, DCM, 18h, 0 ºC - 25 ºC h: Fmoc-lysine, dioxane/NaHCO3(aq), 3h, 0 ºC 
- rt, 31% over three steps. 
 
 
 
 
 
 
 
Scheme 22: Initiation of peptide synthesis on the resin. a: 134, HOAt, HATU, DiPEA, DMF, 3h, rt 
(coupling performed 2x) b: Fmoc-allyl lysine, HOAt, HATU, DiPEA, DMF, 2h, rt (coupling performed 
2x). 
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The three peptides were synthesized, starting from 141 using SPPS and ten more 
amino acids were coupled using an automated peptide synthesizer (see scheme 23). 
Before manual coupling of the building blocks, the resin material was split in three 
batches. Besides coupling of the two building blocks, a normal Fmoc histidine was 
attached for the synthesis of peptide 133. The three peptides were completed 
separately and for the final amino acid a Boc protected glycine was used. The alloc 
from the lysine was removed using Pd(PPh3)4 and the desthiobiotin linker was 
attached using carboxylic acid 138 with HATU as coupling reagent. In this fashion, all 
three peptides 142a-c were prepared. The peptides were cleaved from the resin and 
deprotected in one step using TFA. Peptides, 131, 132 and 133 were purified using 
preparative HPLC and isolated in 22 %, 20 % and 17 % overall yield respectively. 
 
 
 
 
 
Scheme 23: Synthesis of peptides 131, 132 and 133. a: piperidine, DMF, 10 min, rt (performed 3x) 
b: Fmoc-AA, HOAt, HATU, DiPEA, DMF, 1h, rt (coupling performed 2x) c: 7 or 131 or Fmoc-histidine, 
HOAt, HATU, DiPEA, DMF, 1h, rt (coupling performed 2x) d: Pd(PPh3)4, DMF, 2h, rt (performed 2x) e: 
TFA, H2O, TiPS, 1h, rt (performed 3x). 
 
 
The peptides were used in pull-down experiments performed in the lab of Prof. Dr. 
Robert Schneider at the Max-Planck-Institute of Immunobiology Freiburg. For these 
experiments Hela cell nuclear extracts were used. These cells are easy to grow and 
a large amount of nuclear extract can be obtained. The potential interacting partners 
are supposed to reside in the nucleus and discarding the cytosolic proteins reduces 
the chance of obtaining false positives. Unfortunately, comparing the results from the 
control peptide equipped with a natural imidazole with both modified histidine 
peptides, did not result in the identification of proteins that interact with a phospho-
histidine. It can be hypothesized that the 20 amino acid peptide does not mimic the 
tertiary structure of the 102 amino acid histone H4 properly. Alternatively, the two 
mimics might simply fail to be a good mimic for the native phospho-histidine. 
However, building block 128 has been used successfully to generate antibodies 
recognizing the native phospho-histidine. These antibodies can be used as a positive 
control but, this control experiment has not been performed yet. 
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7.3 Preparation and Evaluation of Histone H4 Derived Peptides 143 and 144 
 
The peptidic fragment of histone H4 that contains His18 is rich in lysines (containing 
Lys5, Lys8, Lys12, Lys16 and Lys20) that are targeted by HATs for acetylation and 
methyl transferases (MTs) for methylation.112 This modification releases the attached 
DNA from the histone. If the His18 phospho-histidine is influencing HAT activity, the 
rate of lysine acetylation should be affected by offering a phosphorylated peptide 
(144, figure 68) to a HAT and compare it with a non-phosphorylated peptide (143, 
figure 68). These peptides need to be prepared synthetically through SPPS. 
Phospho-peptide 144 is prepared from 143 through chemical phosphorylation. As 
previously demonstrated in §3.5, chemical phosphorylation of peptides with 
potassium phosphoramidate (PPA) is a powerful procedure for obtaining chemically 
pure phospho-histidine peptides.  
The experiment was performed in the presence of 14C-labelled acetyl-CoA. The 
relative amount of incorporated radioactivity is a measure for the amount of 
acetylation and allows for acetylation reaction rate determination. This experiment 
was also performed with recombinant human lysine methylase Suv420h1. Here, the 
influence of His18 phosphorylation on lysine methylation is investigated.  
 
 
Figure 68: The principle of probing the influence of the N-phosphorylation of histone H4 on 
His
18
. By comparing the rate of peptide acetylation by human Histone Acetyl Transferase (HAT) with 
(peptide 144) and without (peptide 143) the presence of the phosphate on His
18
, the influence of N-
phosphorylation of histone H4 is assayed. 
 
 
Again the amino acids 9-28 from the histone H4 were chosen and phospho-histidine 
peptide 144 is obtained by chemical phosphorylation of 143. For analytical purposes 
a strong UV absorbing 4-nitroaniline, attached to glutamic acid 26, is incorporated in 
the design (see figure 69 for the detailed structure of the peptides). 
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Figure 69: The structures of peptides 143 and 144. Peptide 143 is based on the amino acids 9-28 
from histone H4. Glu
26
 is equipped with a 4-nitroaniline for analytical purposes. Chemical 
phosphorylation of 143 on His
18
 gives access to peptide 144. 
 
 
Peptide 143 was synthesized using automated SPPS on a Tentagel glycine 
preloaded resin (0.25 mmol/g). The synthesis was performed in a similar fashion as 
was described for peptides 131-133 (scheme 23). The Fmoc protected 4-nitroaniline 
glutamic acid 145 was prepared starting from commercially available Boc/tertbutyl 
protected glutamic acid 146 (see scheme 24).  Attachment of the 4-nitroaniline was 
achieved through the activation of the carboxylic acid using HOAT. The Boc and 
tertbutyl protective groups from 147 were removed using strong acid and the Fmoc 
protective group was attached to obtain the required building block 145 in 40 % 
overall yield. 
 
 
 
 
 
Scheme 24: Synthesis of building block 152. a: HOAt, EDC.HCl, DCM, 18h, 0 
o
C - rt b: 4-
nitroaniline, DBU, DCM, 18h, 0 
o
C – 35 ºC, 68% over two steps c: TFA, H2O, DCM, 4h, rt d: Fmoc-
OSu, NaHCO3, dioxane/H2O, 18h, 0 
o
C - rt, 57% yield over two steps. 
 
 
Phosphorylation of peptide 143 with potassium phosphoramidate followed the 
familiar pattern that is always observed for chemical histidine phosphorylation.66 
Rapid formation of the 1- and 1,3-diphosphate isomer, 148 and 149 respectively, was 
initially obtained (see figure 70). Upon standing the 3-isomer, the desired mono 
phospho-peptide 144, became dominant due to the instable nature of the 1-position 
isomer 148. After 48 hours, peptide 144 is the main component and purification using 
a Source 15S cation exchange column was performed. An increasing gradient of 
NH4HCO3 salt solution was used to separate the components. A second run was 
required to obtain chemically pure material (purity >95%). 
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Figure 70: Purification of phospho-histidine peptide 144. The incubation of 143 with potassium 
phosphoramidate generates three products; the quickly formed 1-isomer 148 and 1,3-isomer 149. 
Upon standing the more stable 3-isomer 144 becomes predominant. 144 was purified using a Source 
15S cation exchange column and a NH4HCO3(aq) gradient to elute the peptide. 
 
 
The biochemical experiments, investigating the influence of phosphorylation of His18 
on HAT and Suv420h1 activity, were also performed in the lab of Prof. Dr. Robert 
Schneider at the Max-Planck-Institute of Immunobiology Freiburg. For the HAT 
activity, cell extracts were used and Suv420h1 was obtained from a commercial 
recombinant source. The AcCoA and SAM cofactors are radioactively labeled 
allowing the quantification of lysine modification. Again, for both the HAT and HMT 
assays there was no significant effect comparing the His18 phosphorylated peptide 
with the control non-modified histidine peptide.  For the HAT assay, it can be 
proposed that the possible effect is diluted, since there are multiple targeted lysines 
in the peptide masking the impact. Potentially all lysines in the peptide are targets for 
the enzyme and a smaller peptide incorporating a single lysine close to the His18, e.g. 
only Lys20, would be a better substrate to investigate the effect of histidine 
phosphorylation on HAT. Alternatively it can again be proposed to use the complete 
histone H4 for this study in order to obtain the entire tertiary protein structure as for 
the pull-down experiments. However, obtaining such a selectively phosphorylated 
protein is not trivial. Other than for the HAT activity, the Suv420h1 is specific for Lys20 
and also here no alteration in lysine methylation was observed with or without the 
phosphate present on His18.  
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The systematic unraveling of the secrets of N-phosphorylation has only recently 
begun. It still remains to be seen if it will be found to be just as important as O-
phosphorylation. Clear examples of vital roles for N-phosphorylation are still scarce. 
Essential for revealing more N-phosphorylation driven processes is the development 
of the right tools to identify N-phosphorylation events in vitro and in vivo. Antibodies 
that can recognize phospho-histidine have only recently been reported and are likely 
to boost the research in this field in the next coming years.25, 56 Also, inhibitors for the 
kinases and phosphatases involved in N-phosphorylation can improve our 
understanding of the role of these enzymes. Besides using these compounds as 
tools to investigate the role of an enzyme, there might be opportunities to further 
develop them as therapeutics for various illnesses. The kinases involved are known 
to be promiscuous and do not limit themselves to N-phosphorylation alone. Many 
enzymes that are known to be out there have not been isolated and characterized 
yet. For now, Phospho-histidine Phosphatase (PHP) remains the only dedicated N-
phosphorylation related enzyme.  
The assays described in this thesis, probing PHP phosphatase activity, are the first 
continuous assays for this enzyme to be reported. Methods that were used so far 
required a purification step before determination of phosphate release.40, 49-50 The 
validation that was performed on these novel assays, the hits that were identified and 
the reproducibility underline the value for further research in this field.  
Synthesis of building block 7, an imidazole sulfonamide based phospho-histidine 
mimic, proved viable and two peptide molecules, designed as PHP inhibitors, were 
prepared. Unfortunately, these peptides failed to inhibit the enzyme. More successful 
was the approach of using small molecules based on the same imidazole 
sulfonamide feature. Figure 71A shows the SAR that was established around the 
imidazole sulfonamide core. Initially, optimization focused on the imidazole 2-
position. Here, significant steepness in SAR was found and various substituents 
showed activity in the range of 5-12 µM. Halogens I (compound 53b, 6.2 ± 2.5 µM) 
and Br (53f, 11.1 ± 5.9 µM) were identified (see figure 71B). A smaller halogen like a 
Cl or only hydrogen showed no inhibitory activity at 100 µM. Larger 2-position 
substituents like phenyl, furan or benzyl failed to show significant inhibition even at a 
concentration of 100 µM. A methylhydroxy group was the third substituent displaying 
significant activity (compound 60c, 9.9 ± 4.0 µM). A methyl or ethyl substituent was 
not allowed, showing that the hydroxyl group of 60c is an essential feature for 
activity. The possibility of forming a hydrogen bond is likely to cause this potency 
gain. Other hetero atom containing groups at the imidazole 2-position, like ether, 
carboxylic acid or amides did not lead to active compounds. Attempts to gain more 
potency focused on the substitution pattern on both the sulfonamide nitrogen and the 
imidazole ring. Surprisingly, addition of alkyl groups to the sulfonamide nitrogen is not 
allowed as all potency was lost. Also, the addition of a methyl to the 1-position 
nitrogen or 5-position resulted in complete loss of activity. Here, the influence on the 
tautomerism of the imidazole can be considered. It can be hypothesized that 
essential for activity is the presence of a proton on the 3-position nitrogen. This would 
allow for a hydrogen bond to the imidazole of His53 (see figure 43, §5.2). To test this 
concept, compound 86, containing a 2-position sulfur substituent, was designed. This 
compound was shown to be completely in the thiourea form resulting in a 
constitutively protonated 3-position nitrogen. 86 is the most active compound 
identified with an IC50 of 3.1 ± 1.7 µM. Finally, replacement of the sulfonamide by 
phosphonate, amide or substituted sulfonyl resulted in complete loss of activity. 
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Figure 71: The established SAR around the imidazole sulfonamide core and the identified µM 
active PHP inhibitors. In general, addition of substituents led to complete loss of activity. The only 
exception is the imidazole 2-position were the substituents I, Br, CH2OH and =S resulted in activity 
ranging from 3 to 12 µM inhibitory activity. 
 
 
The identified inhibitors were tested in an alternative functional assay, using a more 
native phospho-histidine as substrate, and similar activities were established. Also in 
the MST binding assay very similar values for Kd were established. Overall 
biochemical assay results appear to be remarkable reproducible and universal for the 
different assay systems. 
The solubility was measured and generally these compounds are highly soluble in 
aqueous media. This is due to the small and polar nature of the compounds. Cell 
permeability was also established using a PAMPA assay and found to be low for all 
compounds except for imidazole sulfonamide 86, that showed significant cell 
permeability with 66%. Altogether, 86 displays the best combination of properties 
making it our prime PHP inhibitor for use in cellular assays. 
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Testing the compounds in cellular assays did not yield promising results so far. 
Compounds 53f, 60c and 86 were tested in the patch clamp assay and an effect was 
observed at a 100 µM concentration of 86 but the effect seems contrary to what was 
expected. With the current stand in science it cannot be explained as KCa3.1 activity 
was blocked rather than activated with compound 86. Overexpression of PHP can 
overrule a different side effect caused by the inhibitors and might be required for 
further studies. It can also be argumented that a 1-10 µM activity is insufficient for 
achieving cellular activity. However, the optimization program that was performed 
suggests little room for optimization. The available X-ray structures and the proposed 
catalytic site reveals a shallow pocket predominantly lined with polar substituents. X-
ray structures of PHP were also generated in-house and revealed a remarkable 
feature. The C terminal end was visible as not seen before in published structures. A 
significant part of the catalytic cleft is then occupied by this loop rendering only a 
small pocket that fits little substrate beyond a single phosphate group (see figure 28, 
§3.7). This is in line with the small nature of the active inhibitors that were identified. 
Obtaining sub-micromolar activity generally requires lipophilic patches or deep 
pockets to obtain a strong binding affinity. PHP lacks this and the already small 
catalytic site is completely solvent exposed. This is also reflected by the promiscuous 
nature of the enzyme. In the literature, there is only a single example of a phospho-
histidine containing peptide that was shown to be not a substrate for PHP.107 Also in 
our hands the enzyme was able to dephosphorylate various substrate peptides. It is 
likely that the localization of either substrate or PHP determines selectivity rather than 
structure and mechanism of the PHP-substrate interaction in vivo. In general, this is 
not uncommon for phosphatases.113 Put together, is seems that achieving sub-
micromolar PHP inhibitory activity is a near impossible task. 
Alternatively, activity of the sulfonamide inhibitors might be improved by covalent 
attachment to the enzyme. The catalytic site contains a residue that can be used for 
covalent attachment of a substrate. An electrophilic ligand, if presented properly, can 
react with Lys21 found in the active site. Introducing a CF3 group on the 2-position of 
the imidazole is likely to yield a compound with an intrinsic liability (see figure 67). 
Deletion of HF in 150 generates an electrophile (151) that forms an easy target for a 
nucleophile like a lysine. Essential is that the inhibitor binds to the enzyme, and so 
that the lysine can react, generating 152. Taking into consideration the binding mode 
that was proposed, this is not the case. However, no definite structural proof for a 
particular binding mode has been found so far. Compound 150 has not been 
prepared yet. 
 
 
 
 
Figure 72: Structure and suggested mechanism of action of proposed inhibitor 150. Compound 
150 is expected to be able to eliminate HF and form the reactive intermediate 151. Reaction with Lys
21
 
can give covalently inhibition of PHP as represented by structure 152. 
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A powerful alternative technique that can be deployed to identify inhibitors for PHP is 
High Throughput Screening (HTS).114 The continuous fluorescence assay that is 
described can easily be adapted to a 384 well plate format and used to screen large 
numbers of compounds in an automated fashion. This approach can generate new 
chemical structures able to inhibit the enzyme and a new optimization program can 
be commenced. 
 
X-ray crystallography of the PHP protein was performed successfully in order to 
investigate the enzyme its shape and function. Co-crystallization with the inhibitors, 
unfortunately, did not lead to successful crystal formation. Also, soaking experiments 
failed to trap the inhibitor into the matrix and obtain a binding conformation. All 
conditions established for successfully obtaining crystals, required a high 
concentration of sulfate ions in the excess of 1.5 molar. Analysis of the structures that 
were obtained showed a highly conserved sulfate ion in the active site of the enzyme 
that facilitates protein stacking. In order to obtain an X-ray structure that shows the 
ligand bound, a modification of the enzyme will be required. Only then new conditions 
can be found for crystallizing the enzyme without a sulfate blocking the active site. 
The amino acid Gln84 was found to be involved in hydrogen binding to the sulfate 
found in the catalytic site from an adjacent PHP molecule. Modification of this amino 
acid to a different one can alter the crystallography dynamics for this enzyme and 
might give a micromolar active ligand a chance to appear in the crystal grid. 
 
The phospho-histidine peptides that were prepared to study histone H4 did not lead 
to a major breakthrough in the elucidation of the role of His18 phosphorylation of 
histidine H4. Expression of the entire histone followed by chemical phosphorylation 
might result in a different outcome in the experiment investigating the PTMs that are 
applied to the lysines that bind the DNA. Also, the pull-down peptide probes that 
were prepared with building block 7 and 128 failed to identify proteins that interact 
with phospho-histidine. Here, a similar remark can be made, that the chosen peptide 
sequence might be too small and using an entire Histone H4 protein, equipped with a 
non-hydrolysable phospho-histidine mimic, will represent a better ‘bate’ in fishing for 
phospho-histidine interacting partners. However, this is not a trivial target. Obtaining 
such a protein would require a chemical ligation approach. 
 
Finally, the study of the protein-protein interacting dynamics of the enzyme remains 
an undiscovered part of the enzyme’s function. The role of the loosely attached C 
terminal end is unknown. It has been established that the C terminal Tyr125 is a target 
for phosphorylation and the X-ray structure generated in-house shows how closely 
this residue can reach the catalytic site. Is this residue prone to get auto-
phosphorylated by this protease? Or is an attached phosphate a target for 
autocatalytic cleavage? The fluorescence assay that uses DiFMUP shows that the 
enzyme has some phospho-phenol cleaving activity. A phospho-tyrosine can also 
serve as a docking site for other proteins. To study these possibilities, the preparation 
of the phosphorylated enzyme is required. Also, deletion of the C terminal end will 
yield a protein that with likely have altered properties, e.g. catalytic activity. Further 
investigation of this C-terminal end represents the most promising direction for 
continuation of this research. 
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9.1 General Materials and Remarks 
 
 
Microbiology 
 
Used machines 
 
PCR      Eppendorf Mastercycler ep gradient S 
Centrifuge     Eppendorf 5810 R Tabletop 
Electroporation     Biorad Pulse Xcell  
Incubator     Memmert Model 100 
Microfluidizer     Microfluidics Corporation    
Protein purification    GE Healtcare Akta Purifier 
Affinity purification    His‐Trap FF crude Ni2+‐NTA‐(5mL Matrix) 
Gelfiltration     Highload 26/60 Sephadex 75 prep grade 
Protein conc. determination  Thermo Scientific Nanodrop 
UV absorbance and Fluorescence  Tecan Infinite 200Pro instrument. 
 
Cells 
 
OmniMAX and electrocompetent TOP10 cells were kindly supplied by Prof. Dr. Frank 
Schulz (Ruhr-Universität Bochum). 
 
Sequencing 
 
Sequencing was performed by StarSEQ 
 
Media 
 
LB  Yeast extract   5.0  g/L 
  NaCl   10.0  g/L 
  Trypton  10.0  g/L  pH = 7.5 
 
TB  Yeast extract 24.0  g/L 
  Trypton  12.0  g/L 
  Glycine    4.0  mL/L 
  KH2PO4    2.13  g/L 
  K2HPO4  12.54 g/L pH = 7.0 
 
SOB  Yeast extract   5.0 g/L 
  Trypton  20.0 g/L 
  NaCl     0.6 g/L 
  KCl     0.2 g/L 
  MgCl2 (10 mM) 10.0  mL/L 
  MgSO4 (10 mM) 10.0 mL/L 
 
SOC  SOB-medium 
  Glucose  20.0 mM 
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Primers  
 
Obtained from Eurofins MWG 
 
LIC primer forwards:  
CTTTATTTTCAGGGCGCCATGGCAGTGGCGGACCTCGCTC 
LIC primer rev: 
CAAAACAGCCAAGCTCTCGATTATTAGTAGCCGTCGTTAGCCCAGGTG 
 
Enzymes 
 
NcoI   Obtained from New England Biolabs 
XhoI   Obtained from New England Biolabs 
Phu polymerase Obtained from New England Biolabs 
TEV protease  Provided by the Dortmund Protein Facility106 
HindIII  Obtained from Fermentas 
 
Kits 
 
Plasmid isolation Qiagen QIAprep Spin Miniprep Kit 
Gel extraction Qiagen QIAquick Gel Extraction Kit 
 
 
Chemistry 
 
All chemicals were obtained from Acros, Aldrich, Alfa Aesar, Merck or Rapp 
Polymere and were used without further purification except when noted. Solvents 
were used as received; except dichloromethane, which was distilled from CaH2 and 
THF, which was distilled from sodium. 1H, 13C and 31P NMR spectra were recorded on 
Varian Mercury 400- or a Bruker DRX 500 NMR spectrometer. Chemical shifts are 
reported in δ values relative to residual solvent peaks (Abbreviations: s: singlet, bs: 
broad singlet, bd: broad doublet, d: doublet, dd: doublet of doublets, dt: doublet of 
triplets, t: triplet, q: quartet, m: multiplet). Specific optical rotations were measured on 
a Schmidt + Haensch Polartronic HH8 Polarimeter. Column chromatography was 
performed using silica gel for chromatography (0.035-0.070 mm, 60A) purchased 
from Acros Organic. Compounds on TLC were visualized by UV and/or basic KMnO4 
staining. High resolution mass spectra (HR-MS, 70 eV) were measured on a Thermo 
Orbitrap, coupled to a Thermo Accela nano-HPLC machine, using electron spray 
ionization (ESI). Analytical HPLC-MS data were recorded on an Agilent HPLC (1100 
series) coupled to a Finnigan LCQ ESI spectrometer, using a Nucleodur C18 gravity 
column, ID 4 mm, length 125 mm, particle size 3 μm from Macherey-Nagel. A 
gradient was applied beginning at 10% acetonitrile and ending at 90% after 15 min, 
followed by 3 min at 90% acetonitrile; finally, the column was washed for 5 min with 
100% acetonitrile. The column was equilibrated for 3 min with 10% acetonitrile. All 
RP-HPLC solvents contained TFA (0.1% v/v). Preparative HPLC purifications were 
performed with an Agilent 1100 series instrument, connected to an Agilent MSD VL 
mass spectrometer andequipped with a fraction collector. All RP-HPLC solvents 
contained TFA (0.1% v/v) and products with basic amines were isolated as a TFA 
salt. 
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9.2 Cloning and Expression of PHP 
 
The gene encoding for PHP was supplied to us by Prof. Zetterqvist (Dept. Medical 
biochemistry, Uppsala University) in the form of a pBADNK vector. The pBADM 
vectors were supplied to us by Prof. Frank Schultz (Ruhr-Universität Bochum). 
 
PCR  
 
requirements: 
 Buffer solution 5x  20 µL 
 dNTPs   10       µL 
 primer 1 (10pmol/µL)   5       µL 
 primer rev (10pmol/µL)   5       µL 
 Phu polymerase    1.25  µL 
 plasmid     2.5    µL 
 steril water   56.25  µL 
 
The solution was divided over 5 PCR tubes 
program 
1. 98oC – 20 sec 
2. 98oC –   5 sec (30x) 
3. 72oC – 20 sec (30x) 
4. 72oC –   5 min 
5.   4oC -  
 
To the PCR reaction mixture was added loading buffer/color dye (5x) and loaded on 
an agarose gel. The gel was run at 100V constant voltage and the desired DNA was 
cut out and purified using a gel extraction kit. 
 
Plasmid digestion 
The five different pBADM vectors were digested using the enzymes NcoI and XhoI. 
 
 NcoI-HF mix     1.0    µL 
 XhoI mix     1.0    µL 
 pBADM vector  10.0    µL 
 steril water     8.0    µL 
 
 
To the digestion reaction mixture was added loading buffer/color dye (5x) and loaded 
on an agarose gel. The gel was run at 100V constant voltage and the desired DNA 
was cut out and purified using a gel extraction kit. 
 
From the isolated PCR product and the linearized vector solution the concentration 
was determined by nanodrop measurement: 
PCR product  35.0  ng/µL  pBADM-30    9.7 ng/µL 
pBADM-10  10.6 ng/µL  pBADM-40  19.1 ng/µL 
pBADM-20  15.5 ng/µL  pBADM-60  16.8 ng/µL 
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Ligation-independent cloning 
 
100 ng of purified insert and 50 ng of linearized and purified vector were mixed 
together in a total volume of 5 µL. On ice, 5 vial of 50 µL OmniMAX chemically 
competent cells were thawed. The insert/vector mixtures from all five vectors were 
carefully added to and mixed with the cells and incubated for 30 min. on ice. Heat-
shock was applied to the cells for 1 min. and 15 sec. at 42 0C. The cells were places 
on ice for 1 min. and 600 µL SOC medium was added and the mixture was 
transferred to a shaker and incubated for 45 min. at 37 0C. The mixture was divided 
over 3 LB agar plates (with 100 µg/mL ampicillin) with 5/50/500+ division and 
incubated overnight at 37 0C. For all five vectors 5 clear single clones were selected 
and incubated in 10 mL LB medium (100 ug/mL ampicillin) and grown overnight at 37 
0C. The cells were harvested by centrifuge for 15 min. at 4,000 rpm and 4 0C. Vectors 
were isolated by use of a miniprep kit and sequenced. 
 
 
Expression and purification of PHP 
 
1 µL vector solution (pBADM60) was mixed with a 50 µL aliquot of TOP10 
electrocompetent cells on ice. The mixture was then transferred to the electroporation 
cuvette and the reaction was carried out (bacteria\Ecoli\1.8kV). SOC-medium (0.6 
mL) was then added and the cells were transferred back into the eppendorf tube. The 
eppendorf tube was then transferred to a shaker and heated at 37 ºC for 1 hour. The 
resulting solution was plated on plates (LB+100 µg/mL carbenicillin). Incubated at 37 
ºC overnight. 100 mL LB medium with 100 µg/mL ampicillin was inoculated with one 
colony from the plate and incubated at 30 °C and 150 rpm overnight. 2000 mL LB 
medium (100 µg/mL ampicillin) was inoculated with the pre-culture so that the OD600 
was 0,05. The culture was incubated at 37 °C and 150 rpm to an OD600 = 0.8 - 1. The 
culture was cooled to 20 °C and the expression was started by addition of arabinose 
(0.05 % w/v). The culture was further incubated overnight at 20 °C and 150 rpm. The 
cells were harvested by centrifugation for 10 min at 4000 rpm by 4 °C. After re-
suspension in wash buffer (25 mM HEPES, 150 mM NaCl, pH 7.5) in 1/10 of the 
volume of the main culture, the cells were harvested again by centrifugation. The 
cells were re-suspended in lysis buffer (25 mM HEPES, 150 mM NaCl, 50 mM 
imidazole, pH 7.5) (0.5 g pellet per mL buffer) and sonicated (90 % power, 5 x 20 
sec, 1 min on ice in between). The lysed cells were centrifuged for 15 min by 
10,000 rpm at 4 °C. The supernatant was pipetted off and transferred to a fresh tube 
and loaded on a 5 mL HisTrap FF column (GE Healthcare) pre-equilibrated with lysis 
buffer at a rate of 1 mL/min. The column was washed with 50 mL lysis buffer 
(1 mL/min). The protein was eluted with 25 mL elution buffer (25 mM HEPES, 
150 mM NaCl, 250 mM imidazole, pH 7.5) and concentrated with an Amicon tube 
(10 kDa MWCO). The concentrated protein was incubated with TEV protease and 
cleavage was analyzed using SDS PAGE. The sample was directly loaded onto the 
SEC column pre-equilibrated with storage buffer (20 mM HEPES, 20 mM NaCl, 
pH 7.5), eluted and concentrated with an Amicon (10 kDa MWCO) to 25 mg/mL. The 
enzyme solution was used as such for crystallography or was aliquoted as 100 µM 
stock solutions and stored at -80 0C for enzymatic assay purposes. The molecular 
weight was confirmed with mass analysis. 
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Expression and purification of the pBADM-11 PHP-His Tag protein 
 
Expression performed the same way as described for pBADM-60 derived PHP with 
exception that the TEV digestion was not performed. Stored in the same buffer 
(20 mM HEPES, 20 mM NaCl, pH 7.5) at a concentration of 25 mg/mL. 
 
 
 
9.3 Continuous Fluorometric Assay 
 
Synthesis of DiFMUP (13) 
 
 
 
 
 
 
 
 
 
dibenzyl (6,8-difluoro-4-methyl-2-oxo-2H-chromen-7-yl) phosphate (12) 200 mg 
(0.94 mmol) 11 was suspended in 6 mL dry acetonitril under argon in a flame-dried 
flask. 0.46 mL (4.71 mmol) CCl4, 0.34 mL (1.98 mmol) DiPEA and 10 mg DMAP were 
added before cooling the RM to -15 0C. 300 µL (1.37 mmol) dibenzyl phosphite was 
added dropwise and the RM was allowed to reach -5 0C in 2 h. The RM goes from 
bright yellow to almost colorless and TLC indicated full conversion. 2 mL 0.5 M 
K2HPO3-solution was added and the RM was allowed to reach RT over 1 h. Water 
was added and extracted with EtOAc. The EtOAc was washed with brine, dried over 
Na2SO4 and evaporated. Filtration through a plug of silica yielded 398 mg 12. 
1H-
NMR(400 MHz, DMSO-d6) δ: 7.40 – 7.32 (m, 10H), 7.16 (dd, J=2.0, 10.7Hz, 1H), 
6.35 (s, 1H), 5.24 (d, J = 8.4Hz, 4H), 2.39 (d, J = 1.2Hz, 3H). Analytical data in 
agreement with literature.73 
 
 
 
 
 
 
 
 
 
6,8-difluoro-4-methyl-2-oxo-2H-chromen-7-yl dihydrogen phosphate (13) 360 
mg (0.76 mmol) 12 was dissolved in 6 mL ethanol and 3 mL toluene. The flask was 
rinsed with argon before replacing the argon with hydrogen gas. The RM was stirred 
overnight at RT. TLC indicated complete conversion and the RM was filtered through 
celite. Evaporation yielded 210 mg 13 (76 % yield over two steps). 1H-NMR(400 MHz, 
DMSO-d6) δ: 7.60 (dd, J=2.0, 10.7Hz, 1H), 6.46 (s, 1H), 4.30 (bs, 2H), 2.39 (d, J = 
1.2Hz, 3H). Analytical data in agreement with literature.73 
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Determination of KM and Vmax 
 
Assay buffer: 
20 mM Tris 
20 mM NaCl 
0.02% NP40 
pH = 8.0 
 
 
In a 96 well microtiter plate, DiFMUP substrate solution (80 μL in assay buffer, 
endconcentration ranging from 50 to 1000 μM) were mixed with enzyme solution (20 
μL in assay buffer, endconcentration of 100 nM) and the fluorescence at 455 nm 
(excitation wavelength: 358 nm) was measured every 30 seconds for 5 minutes at 37 
°C. The experiment was performed in triplo. The initial velocities were measured and 
by using the software program ‘XL Fit’ a KM of 765 ± 59 μM and Vmax of 8.3 ± 0.6 
μM/s was established. kcat/KM was determined to be 1.08 ± 0.2 .10
5 M-1.s-1. 
 
 
Determination of inhibitor activity 
 
Assay buffer: 
20 mM Tris 
20 mM NaCl 
0.02% NP40 
pH = 8.0 
 
 
In a 96 well microtiter plate, inhibitor solutions (50 μL in assay buffer, 
endconcentration of 100 μM for screening purposes and 10 different concentrations 
around the IC50 for a full curve) were mixed with enzyme solution (20 μL in assay 
buffer, endconcentration of 100 nM) and incubated for 10 minutes at RT (total volume 
was filled to 90 μL with assay buffer for every well). Immediately after addition of the 
DiFMUP substrate solution (10 μL in assay buffer, endconcentration of 200 μM) the 
fluorescence at 455 nm (excitation wavelength: 358 nm) was measured every 30 
seconds for 5 minutes at 37 °C. The relative increase in fluorescence in 5 minutes is 
the measure for inhibition. As a control a reaction with only substrate (background 
experiment with 90 μL assay buffer) and a reaction without inhibitor (positive control 
experiment with 50 μL extra assay buffer) was run in parallel. Every inhibitor was 
tested from the solid material twice and both separate experiments performed in 
duplo. 
 
 
Inhibitor solutions: 
10 mM in DMSO diluted to 200 μM stock in assay buffer (final DMSO concentration is 
1%, should be held constant for all inhibitor concentration solutions for an IC50 
determination). 
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9.4 Continuous Coupled Enzyme Assay 
 
Synthesis of substrate 3-phosphohistidine (15) and MESG (16)  
 
 
 
 
 
 
 
 
 
 
 
3-phosphohistidine (15) 25 mg (0.16 mmol) histidine was dissolved in 2 mL water 
before adding 217 mg (1.6 mmol) potassium phosphoramidate. The RM was stirred 
for 40 hours at RT, filtered and loaded onto a monoQ anion exchange column (0.5 
mL mixture per run diluted with 0.5 mL buffer) equilibrated with 0.5 mL/min 50mM 
NH4HCO3(aq) on an akta system. The product was eluted with a gradient to 50 % 1.5 
M NH4HCO3(aq) in 20 min and in 1 min to 100%. A second purification of the 
obtained product solution was required to obtain highly pure material. The 
concentration was determined (see below for procedure) and diluted with buffer to 
obtain 4.7 mL of 1.0 mM solution. The substrate solution was aliquoted in 100 µL 
amounts, shock frozen and stored at -80 ºC. 31P-NMR(161 MHz, CDCl3) δ: 3.50. 
 
 
 
 
 
 
 
 
 
 
2-amino-6-mercapto-7-methylpurine riboside MESG (16) 200 mg (0.66 mmol) 2-
amino-6-chloropurine riboside (17) was dissolved in 1 mL dry DMF. 0.4 mL (6.4 
mmol) MeI was added and the RM was stirred overnight at RT. The excess MeI was 
removed under vacuum before adding 200 mg thiourea. After 30 minutes the pH was 
corrected from 2 to 7 using methanolic ammonia before drop wise addition of the RM 
into 10 mL acetone. A yellow precipitate was formed, after stirring for 10 minutes 
before the acetone was decanted off. This step was repeated before filtration yielded 
a yellow solid. This material was suspended in MeOH, the MeOH was decanted off 
(repeated 3x). The solid material was dried under vacuum yielding 132 mg 16 as a 
yellowish solid (64 % yield from 17). 1H-NMR(400 MHz, DMSO-d6) δ: 9.64 (s, 1H), 
7.68 (bs, 2H), 5.81 (d, J=2.5Hz, 1H), 5.67 (d, J=6.0Hz, 1H), 5.27 (d, J=6.0Hz, 1H), 
5.17 (t, J=6.0Hz, 1H), 4.35 (m, 1H), 4.22 (s, 3H), 4.14 (q, J=5.0Hz, 1H), 3.97 (dd, 
J=5.7Hz, J=3.2Hz, 1H), 3.75-3.55 (m, 2H). Analytical data in agreement with 
literature.83  
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Expression of Bacillus cereus Purine Nucleoside Phosphorylase (BcPNP) 
 
The gene encoding for PNP was supplied to us by Prof. Steve Ealick (Cornell 
University). 
 
50 µL chemical competent E. coli BL21 DE3 cells were thawed on ice. 2.0 µL plasmid 
solution (pBcPNP2_28) was added and incubated for 30 min. The cells were heated 
to 42 °C for 1 min (heat shock) and immediately cooled for 2 min on ice. After 
addition of 700 µL SOC medium the cells were incubated for 40 min at 37 °C. Cells 
were streaked out on LB agar plates with 50 µg/mL kanamycin and incubated 
overnight at 37 °C. 4 mL LB medium with 50 µg/mL kanamycin was inoculated with 
one colony and incubated over night at 30 °C. The plasmid DNA was isolated by use 
of a miniprep kit and sequenced. The digested DNA (HindIII) was analyzed by 
agarose gel electrophoresis (1 % Agarose (w/v) in TAE buffer, 120 V). 150 mL LB 
medium with 50 µg/mL kanamycin was inoculated with one colony from a LB agar 
plate and incubated at 30 °C and 150 rpm overnight. 
1000 mL LB medium with 50 µg/mL kanamycin was inoculated with the pre-culture 
so that the OD600 was 0.05. The culture was incubated at 37 °C and 150 rpm to an 
OD600 = 0.8 – 1. The culture was cooled to 20 °C and the expression was started by 
addition of IPTG (1 mM in the culture). The culture was further incubated for 18 h 
(overnight) at 20 °C and 150 rpm. The cells were harvested by centrifugation for 
10 min at 4000 rpm by 4 °C. After resuspension in wash buffer (25 mM HEPES, 
150 mM NaCl, pH 7.5) in 1/10 of the volume of the main culture, the cells were 
harvested again by centrifugation. The cells were resuspended in lysis buffer (25 mM 
HEPES, 150 mM NaCl, 50 mM imidazole, pH 7,5) (0,5 g pellet per mL buffer) and 
sonicated (90 % power, 5 x 20 sec, 1 min on ice between). The lysed cells were 
centrifuged for 15 min by 10000 rpm at 4 °C. The protein was in the supernatant 
which was pipetted off and transferred to a fresh tube. The supernatant was loaded 
on a 5 mL HisTrap FF column (GE Healthcare) pre equilibrated with lysis buffer at a 
rate of 1 mL/min. The column was washed with 50 mL lysis buffer (1 mL/min). The 
protein was eluted with 25 mL elution buffer (25 mM HEPES, 150 mM NaCl, 250 mM 
imidazol, pH 7,5) and concentrated with an Amicon (10 kDa MWCO). The buffer was 
changed (wash buffer) by adding several times (at least 3 times) fresh buffer (10 mL) 
to the Amicon. 
 
 
 
Determination of the concentration of phospho-histidine (15) and determination 
of KM and Vmax 
 
 
Assay buffer: 
20 mM Tris 
1 mM MgCl2 
0.02% NP40 
pH = 7.5 
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To determine the concentration of the purified 3-phospho-histidine (15) the enzyme 
reaction was run at various concentrations of phosphate to create a calibration graph. 
In a 96 well microtiter plate, various KH2PO4 solutions (80 μL in assay buffer, 
endconcentration ranging from 2 to 50 μM) were mixed with MESG substrate solution 
(40 μL in assay buffer, endconcentration of 100 µM). PNP solution (80 μL in assay 
buffer, endconcentration of 5 µM) was added and the absorbance at 360 nm was 
measured every 30 seconds for 1 hour at 30 °C. The maximum absorbance reached 
was plotted against the concentration. The experiment was repeated with various 
concentrations of 15 premixed with 500 nM PHP to assure complete hydrolysis. 
Comparison with the generated calibration line revealed a concentration of 1.6 mM. 
 
To determine the KM and Vmax values, PHP (10 μL in assay buffer, endconcentration 
of 100 nM), MESG (40 μL in assay buffer, endconcentration of 100 µM) and PNP (20 
μL in assay buffer, endconcentration of 10 µM) were mixed in a 96 well microtiter 
plate. The volume was filled up to 190 µL with assay buffer and substrate 15 (10 μL 
in assay buffer, endconcentration of 25 µM)  was added and the absorbance at 360 
nm was measured every 30 seconds for 10 minutes at 30 °C. The experiment was 
performed in triplo. The initial velocities were measured and by using the software 
program ‘XL Fit’ a KM of 3.6 ± 0.2 μM and a Vmax of 213 ± 12 μM/s was established. 
kcat/KM was determined to be 5.9 ± 1.2 .108 M-1.s-1.  
 
 
Determination of inhibitor activity 
 
 
Assay buffer: 
20 mM Tris 
1 mM MgCl2 
0.02% NP40 
pH = 7.5 
 
 
In a 96 well microtiter plate, inhibitor solutions (100 μL in assay buffer, 
endconcentration of 100 μM for screening purposes and 10 different concentrations 
around the IC50 for a full curve) were mixed with PHP solution (10 μL in assay buffer, 
endconcentration of 100 nM) and incubated for 10 minutes at RT. MESG (40 μL in 
assay buffer, endconcentration of 100 µM) and PNP (20 μL in assay buffer, 
endconcentration of 10 µM) were added. The volume was filled up to 190 µL with 
assay buffer. The substrate 15 (10 μL in assay buffer, endconcentration of 25 µM)  
was added and the absorbance at 360 nm was measured every 30 seconds for 10 
minutes at 30 °C. The relative increase in absorbance in 5 minutes is the measure for 
inhibition. As a control a reaction without PHP (background) and a reaction without 
inhibitor was run in parallel. Every inhibitor was tested from the solid material twice 
and both separate experiments performed in duplo. Additionally, all inhibitor 
compounds were tested on PNP solely in order to exclude PNP inhibition as the 
mechanism of action. No compound was found to be active on the coupled PNP 
enzyme confirming the inhibitors to be genuine PHP inhibitors. 
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Inhibitor solutions: 
10 mM in DMSO diluted to 200 μM stock in assay buffer (final DMSO concentration is 
1%, should be held constant for all inhibitor concentration solutions for an IC50 
determination). 
 
 
9.5 Determination of Kd with Microscale Thermophoresis 
 
 
PHP fluorescein labeling: 
5 mL (1 mg/mL) PHP solution (in PBS buffer) was treated with 0.5 mL (1.5 mg/mL) 
carboxyfluorescein succinimidyl ester in DMSO. The mixture was allowed to react 
overnight at 4 ºC. The labelled protein was purified by SEC (20 mM Tris/20 mM NaCl, 
pH = 8.0) and concentrated to 0.5 mL. Concentration was determined to be 4 mg/mL. 
 
 
Assay buffer: 
20 mM Tris 
20 mM NaCl 
0.02% NP40 
pH = 8.0 
 
The labelled protein was diluted to correct fluorecence intensity (generally 750 nM) 
and incubated with 12 different inhibitor solutions in a 1:1 dilution row around the Kd 
value. Samples were incubated for 20 min before measurements. Laser-on and -off 
times were adjusted to 30 s and 5 s, respectively. The measurements were carried 
out at 20 ºC and generally performed at 50% LED power and 60% infrared-laser 
power. The measurements were performed on NanoTemper Monolith NT.115 
instruments in standard treated capillaries and analyzed with NanoTemper Analysis 
version 1.2.205 (NanoTemper Technologies GmbH). 
 
 
9.6 PHP Crystallography 
 
A search for new crystal forms for PHP was initialized with both histag labeled and 
label free protein (~30 mg/ml). A full screen was launched using commercially 
available screens and a Mosquito pipetting robot. New crystal forms were obtained in 
Co(II)Cl2 0.01 M, MES 0.1 M, NH4SO4 1.8 M, pH = 6.5 (taken from Core III nr.50). 
After optimization, the best diffracting crystals were grown in Co(II)Cl2 0.01 M, MES 
0.1 M, NH4SO4 1.6-1.8 M, pH = 6.5-8.5. Thicker needles were obtained that showed 
significant diffraction at the Swiss Light Source (SLS, Paul-Scherer Institut Villigen, 
Switzerland). 
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9.7 Synthesis of Building Block 7 
 
 
 
 
 
 
 
1H-imidazole-4-sulfonyl chloride (24) 20.0 g (294 mmol) imidazole (25) was melted 
(theoretical mp = 90 °C / heated to 115 °C) in an argon flushed 250 mL flask. 60.0 
mL (900 mmol) ClSO3H was added drop wise (Caution! the first 15 mL reacted 
violently, with excessive HCl(g) formation). The reaction mixture was heated at 140 
oC for 16 hours. The resulting dark reaction mixture (RM) was cooled to 40 oC before 
adding 22.0 mL (302 mmol) thionyl chloride drop wise over 5 minutes (immediate gas 
evolution visible). The RM was heated until gas evolution ceased, during which time 
the temperature was slowly raised to 125 °C. The RM was allowed to cool to rt before 
pouring it into a slurry of 300 g crushed ice with 20.0 g NaCl. A white precipitate was 
formed and the suspension was filtered after the ice had completely melted. The 
white solid was washed with a small amount of cold water and dried overnight under 
vacuum over KOH. The filtrate was re-filtered once and the collected solid was 
washed with a small amount of water and dried overnight under vacuum over KOH. 
Combining the two solids yielded 30.2 g 24 as a fine white powder (62% yield from 
25). 1H-NMR(400 MHz, DMSO-d6) δ: 14.22 (broad s, 1H), 8.99 (d, J=1.2Hz, 1H), 7.64 
(d, J=1.2Hz, 1H) Analytical data in agreement with literature.120 
 
 
 
 
 
 
 
N,N-bis(2,4-dimethoxybenzyl)-1H-imidazole-4-sulfonamide (26) 4.00 g (24.0 
mmol) 24 was added in small portions to a solution of 6.34 g N,N-bis(2,4-
dimethoxybenzyl)amine (20.0 mmol) in 100 mL DCM with 6.60 mL (5.17 g/40 mmol) 
DIPEA at 0 °C. The RM was stirred at 0 °C for 30 minutes, followed by 2 hours at rt. 
When TLC indicated complete conversion, the RM was poured into 20.0 mL 5% citric 
acid and was shaken once before adding 200 mL sat. NaHCO3(aq) and shaking it 
carefully (gas evolution). The layers where separated and the DCM was washed with 
brine, dried over MgSO4(s), concentrated and dried under vacuum. The product was 
purified by SiO2 column chromatography, eluted with EtOAc to obtain 8.02 g of 26 as 
a pale yellow foam (90% yield from bis(2,4-dimethoxybenzyl)amine). Rf = 0.46 
(DCM/MeOH 9:1); 1H-NMR(400 MHz, CDCl3) δ: 7.92 (d, J=1.2Hz, 1H), 7.23 (d, 
J=1.2Hz, 1H), 7.05 (d, J=8.4Hz, 2H), 6.28 (dd, J=8.4Hz J=2.4Hz, 2H), 9.19 (d, 
J=2.4Hz, 2H), 5.35 (broad s, 2H), 4.34 (s, 4H), 3.66 (s, 6H), 3.54 (s, 6H); 13C-
NMR(101 MHz, CDCl3) δ: 160.3, 158.1, 137.3, 136.4, 130.4, 120.7, 116.6, 104.0, 
97.7, 55.2, 54.9, 46.6; ESI HRMS calculated for  C21H26O6N3S [M+H]
+ = 448.15368. 
Mass found [M+H]+ = 448.15358. 
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(N,N-bis(2,4-dimethoxybenzyl)-1-trityl-1H-imidazole-4-sulfonamide (27) In a 100 
mL round bottom flask, 2.00 g (4.47 mmol) 26 was dissolved in 30.0 mL dry DMF. 
After adding 1.00 g (8.91 mmol) KOtBu (RM became yellow) and allowing it to stir (20 
minutes), 1.87 g (6.71 mmol) trityl-Cl was added at 0 oC and the RM was stirred for 
18 hours at rt. The DMF was evaporated and the residue was suspended in sat. 
NaHCO3(aq) and extracted with EtOAc twice. The combined EtOAc layers were 
washed with brine, dried over MgSO4(s), concentrated and dried under vacuum. The 
product was purified by SiO2 column chromatography, eluted with toluene/EtOAc 
(85:15) to obtain 2.53 g of 27 as a white/yellow foam (83% yield from 26). Rf = 0.69 
(toluene/EtOAc 1:1); 1H-NMR(400 MHz, CDCl3) δ: 7.46 (d, J=1.2Hz, 1H), 7.34 (m, 
10H), 7.20 (d, J=8.4Hz, 2H), 7.05 (m, 6H), 6.33 (dd, J=8.4Hz, J=2.4Hz, 2H), 6.29 (d, 
J=2,4Hz, 1H), 4.48 (s, 4H), 3.74 (s, 6H), 3.62 (s, 6H); 13C-NMR(101 MHz, CDCl3) δ: 
160.2, 158.3, 141.8, 140.2, 140.1, 130.3, 129.9, 128.7, 128.5, 124.8, 117.9, 104.1, 
98.1, 76.5, 55.5, 55.2, 46.3; ESI HRMS calculated for C40H40O6N3S [M+H]
+ = 
690.26323. Mass found [M+H]+ = 690.26366. 
 
 
 
 
 
 
 
 
N,N-bis(2,4-dimethoxybenzyl)-2-formyl-1-trityl-1H-imidazole-4-sulfonamide (23 
2.0 g (2.9 mmol) 27 was dissolved in 20.0 mL dry THF in a flame-dried Schlenk flask. 
The reaction mixture was cooled to -30 oC under argon atmosphere. 2.20 mL (3.52 
mmol) of a 1.6 M n-butyl lithium solution in hexane was added drop wise at -30 oC 
and the RM became  red. After 20 minutes, 1 mL dry DMF (5 equiv.) was added drop 
wise. The RM was allowing the RM to warm up for 1 hour. The RM was poured into 
sat. NaHCO3 solution and was extracted twice with EtOAc. The combined EtOAc 
layers were washed with brine, dried over MgSO4(s), concentrated and dried under 
vacuum. The product was purified by SiO2 column chromatography, eluted with 
toluene/EtOAc (9:1) to obtain 1.89 g of 23 as a white foam (91% yield from 27). Rf = 
0.68 (cyclohexane/EtOAc 1:1); 1H-NMR(400 MHz, CDCl3) δ: 9.23 (d, J=6Hz, 1H), 
7.33 (m, 10H), 7.24 (d, J=8.4Hz, 2H), 7.01 (m, 6H), 6.35 (dd, J=8.4Hz, J=2.4Hz, 2H), 
6.33 (d, J=2,4Hz, 1H), 4.56 (s, 4H), 3.74 (s, 6H), 3.68 (s, 6H); 13C-NMR(101 MHz, 
CDCl3) δ: 178.7, 160.4, 158.6, 145.4, 141.8, 141.5, 130.8, 129.7, 128.7, 128.4, 
128.3, 117.5, 104.1, 98.2, 78.2, 55.5, 55.3, 46.5; ESI HRMS calculated for 
C41H40O7N3S [M+H]
+ = 718.25815. Mass found [M+H]+ = 718.25885. 
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(E)-methyl 3-(4-(N,N-bis(2,4-dimethoxybenzyl)sulfamoyl)-1-trityl-1H-imidazol-2-
yl)-2-formamidoacrylate (22) 820 mg (1.14 mmol) 23 and 105 µL (1.15 mmol) 
methyl isocyanoacetate were dissolved in 8 mL dry THF. 8 mg Cu2O was added and 
the RM was stirred for 1h at RT. 135 mg KOtBu was added at to the RM at 0 oC and 
stirred for 2 hours at RT. The RM was poured into a sat. NaHCO3 and was extracted 
using EtOAc. The EtOAc was dried and evaporated, yielding 350 mg 22 (33% yield 
from 23). Rf = 0.90 (EtOAc); 
1H-NMR(400 MHz, CDCl3) δ: 10.68 (bs, 1H), 8.60 (bs, 
1H), 7.37-7.35 (m, 9H), 7.23-720 (m, 2H), 7.05-7.02 (m, 6H), 6.35-6.32 (m, 4H), 5.60 
(bs, 1H), 4.58 (s, 4H), 3.74 (s, 6H), 3.68 (s, 6H), 3.60 (s, 3H); 13C-NMR(101 MHz, 
CDCl3) δ: 163.9, 160.4, 158.5, 145.4, 141.3, 139.3, 130.8, 129.9, 128.8, 128.7, 
124.6, 117.5, 106.1, 104.0, 98.2, 77.1, 55.5, 55.3, 53.6, 52.7, 46.7; ESI HRMS 
calculated for C45H45O9N4S [M+H]
+ = 817.29018. Mass found [M+H]+ = 817.29039. 
 
 
 
 
 
 
 
 
N,N-bis(2,4-dimethoxybenzyl)-2-iodo-1-trityl-1H-imidazole-4-sulfonamide (29) 
1.0 g (1.45 mmol) 27 was dissolved in 20.0 mL dry THF in a flame-dried Schlenk 
flask. The reaction mixture was cooled to -30 oC under argon atmosphere. 1.20 mL 
(1.74 mmol) of a 1.41M n-butyl lithium solution in hexane was added drop wise at -30 
oC and the RM became dark red. After 20 minutes, 1.00 g iodine (3 equiv.) dissolved 
in 5.00 mL THF was added drop wise. The first equivalent of iodine was consumed 
as seen by disappearance of color. An additional 1 mL of iodine solution was added. 
The RM was stirred at -30 oC for 10 minutes before removing the cooling bath and 
allowing the RM to warm up for 10 minutes. The still relatively cold (-5 °C) RM was 
poured into a sat. Na2S2O3 solution and was extracted twice with EtOAc. The 
combined EtOAc layers were washed with brine, dried over MgSO4(s), concentrated 
and dried under vacuum. The product was purified by SiO2 column chromatography, 
eluted with toluene/EtOAc (95:5) to obtain 1.01 g of 29 as a white foam (85% yield 
from 27). Rf = 0.73 (toluene/EtOAc 1:1); 
1H-NMR(400 MHz, CDCl3) δ: 7.34 (m, 10H), 
7.20 (d, J=8.4Hz, 2H), 7.05 (m, 6H), 6.33 (dd, J=8.4Hz, J=2.4Hz, 2H), 6.29 (d, 
J=2,4Hz, 1H), 4.48 (s, 4H), 3.74 (s, 6H), 3.62 (s, 6H); 13C-NMR(101 MHz, CDCl3) δ: 
160.3, 158.5, 142.1, 141.0, 130.8, 130.6, 128.6, 128.3, 128.2, 117.7, 104.1, 98.1, 
92.1, 78.1, 55.5, 55.3, 46.2; ESI HRMS calculated for C40H39O6N3IS [M+H]
+ = 
816.15988. Mass found [M+H]+ = 816.16011. 
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(S)-methyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-hydroxypropanoate 
(32) 1.88 g (22 mmol) NaHCO3 and 1.43 g (9.0 mmol) Serine-OMe.HCl (31) were 
dissolved in 20 mL water and cooled to 0 0C. 3.05 g (9 mmol) Fmoc-OSu dissolved in 
20 mL dioxane was added dropwize. The resulting suspension was allowed to reach 
RT and was stirred for an additional hour. 10 mL water was added and the RM was 
extracted 4x with EtOAc. The combined EtOAc was washed with 0.2 M HCl solution 
and with brine. Drying and evaporation yielded a transparent oil. Toluene was added 
and evaporated to remove traces of dioxane and 3.07 g (8.9 mmol) 32 was isolated 
as a white powder (98% yield from 31). 1H-NMR(400 MHz, CDCl3) δ: 7.77 (2H, d, J = 
7.2), 7.61 (2H, d, J = 6.8), 7.41 (2H, t, J = 7.6), 7.32 (2H, t, J = 7.6), 5.70 (1H, d, J = 
6.8), 4.44 (3H, m), 4.23 (1H, t, J = 6.8), 3.98 (2H, m), 3.80 (3H, s), 1.86 (1H, br s). 
Analytical data in agreement with literature.121 
 
 
 
 
 
 
 
 
(R)-methyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-iodopropanoate 
(33) 3.0 g 32 was dissolved in 30 mL pyridine. The mixture was cooled to -5 0C 
before adding 3.3 g (2 equiv.) TsCl. The RM was stirred at 4 0C for 40h. The RM was 
poured in ice-water and was extracted using EtOAc. The EtOAc was washed with 1 
M citric acid (3x), sat NaHCO3, 1 M HCl (2x), sat NaHCO3 and sat NaCl. The organic 
layer was dried and evaporated. To the oil was added ether and a crystaline solid 
was formed that was dried under vacuum overnight. The solid was dissolved in 20 
mL acetone and the flask flushed with argon. A solution of 2.42g (2equiv.) NaI in 10 
mL acetone was added dropwise and the RM was stirred overnight at RT (flask was 
wrapt in alumina foil). The RM was filtered and the filtrate was concentrated. The 
residue was suspended in chloroform and washed with water, sat. Na2S2O3 and 
NaHCO3.. The chloroform was dried and evaporated. The solid material was 
redissolved in 200 mL 1:1 Ethanol/petroleum ether and the volume was reduced with 
vacuum and the concentrated solution was stored at 4 0C overnight. The solid 
material was filtered off yielding 3.3 g 33 as a white powder (90% yield from 32). 1H-
NMR(400 MHz, CDCl3) δ: 7.77 (2H, d, J 7.5), 7.62 (2H, d, J 7.5), 7.41 (2H, t, J 7.5), 
7.35-7.32 (2H, m), 5.66 (1H, d, J 7.0), 4.65-4.56 (1H, m), 4.45-4.36 (2H, m), 4.25 
(1H, t, J 7.5), 3.83 (3H, s), 3.62-3.59 (2H, m). Analytical data in agreement with 
literature.122 
 
 
 
 
 - 141 - 
 
 
 
 
 
 
 
 
 
 
 
(S)-methyl-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(4-(N,N-bis(2,4-
dimethoxybenzyl)-sulfamoyl)-1-trityl-1H-imidazol-2-yl)propanoate (34) 65 mg (1 
mmol) Zn(0) (dust) was weighted into a pear-shaped flask and flame-dried. 20 mg I2 
dissolved in 3 mL dry DMF was added (the yellow color disappeared after approx. 1 
minute). 160 mg (0.36 mmol) (R)-methyl 2-(((9H-fluoren-9-yl)methoxy)-
carbonylamino)-3-iodopropanoate 33 together with 20 mg iodine was added and the 
RM was stirred until TLC indicated full consumption of 33.25 The stirring was stopped 
and the unreacted Zn was allowed to precipitate. 2 mL of the supernatant was taken 
out in a syringe and directly added to a pre-stirred solution of 6 mg (0.006 mmol) 
Pd2(dba)3, 6 mg (0.012 mmol) Xphos and 100 mg (0.12 mmol) 29 suspended in 1 mL 
dry DMF. The RM was aged for 2 hours at 40  oC, poured into sat. NaHCO3(aq) and 
extracted twice with EtOAc. The combined EtOAc layers were washed with sat 
NaCl(aq), dried over MgSO4(s), concentrated and dried under vacuum. The product 
was purified by SiO2 column chromatography, eluted with toluene/EtOAc (9:1) to 
obtain 66 mg of 34 as a pale yellow foam (53% yield from 29). Rf = 0.63 
(toluene/EtOAc 1:1).  +22.2° (c = 0.4, CHCl3); 
1H-NMR(400 MHz, CDCl3) δ: 7.73 
(d, J=8.0Hz, 2H), 7.58 (t, J=8.0Hz, 2H), 7.35 (m, 11H), 7.22 (m, 5H), 7.06 (m, 6H), 
6.45 (d, J=8.8Hz, 1H), 6.39 (dd, J=8.4Hz, J=2.4Hz, 2H), 6.28 (d, J=2.4Hz, 1H), 4.60 
(d, 16.0Hz, 1H), 4.45 (d, 16.0Hz, 1H), 4.39 (m, 2H), 4.20 (m, 2H), 3.74 (s, 6H), 3.71 
(s, 3H), 3.58 (s, 6H), 2.57 (dd, J=17.2Hz, J=4.0Hz, 1H) ), 2.07 (dd, J=17.2Hz, 
J=4.0Hz, 1H); 13C-NMR(101 MHz, CDCl3) δ: 171.7, 160.2, 158.4, 156.5, 149.2, 
144.2, 144.0, 141.4, 141.4, 141.1, 137.7, 130.5, 130.1, 128.7, 128.6, 127.9, 127.8, 
127.4, 127.4, 125.6, 125.5, 125.0, 120.1, 117.9, 104.3, 98.1, 76.3, 67.6, 55.5, 55.2, 
52.7, 51.7, 47.3, 46.5, 32.8; ESI HRMS calculated for C59H57O10N4S [M+H]
+ = 
1013.37899. Mass found [M+H]+ = 1013.37950. 
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(S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(4-(N,N-bis(2,4-
dimethoxybenzyl)sulfamoyl)-1-trityl-1H-imidazol-2-yl)propanoic acid (7) 500 mg 
(0.49 mmol) 34 was dissolved in 10 mL DCE. 894 mg (5.0 mmol) Sn(Me)3OH was 
added. The RM was heated at 65 °C for 18 hours, when TLC indicated complete 
disappearance of SM. The RM was poured into citric acid and extracted with DCM 
(2x 20 mL). The DCM was dried over MgSO4(s), concentrated and dried under 
vacuum. The product was purified by SiO2 column chromatography, eluted with 
toluene/EtOAc (1:1) to obtain 425 mg of 7 as a pale yellow foam (86% yield from 34). 
Rf = 0.20 (toluene/EtOAc 1:1);  +19.8° (c = 0.3, CHCl3). 
1H-NMR(400 MHz, 
CDCl3) δ: 7.76 (d, J=8.0Hz, 2H), 7.56 (d, J=8.0Hz, 1H), 7.51 (d, J=8.0Hz, 1H), 7.35 
(m, 11H), 7.22 (m, 5H), 7.06 (m, 6H), 6.45 (d, J=8.8Hz, 1H), 6.39 (dd, J=8.4Hz, 
J=2.4Hz, 2H), 6.28 (d, J=2.4Hz, 1H), 4.60 (d, 16.0Hz, 1H), 4.45 (d, 16.0Hz, 1H), 4.39 
(m, 2H), 4.20 (m, 2H), 3.74 (s, 6H), 3.71 (s, 3H), 3.58 (s, 6H), 2.57 (dd, J=17.2Hz, 
J=4.0Hz, 1H) ), 2.07 (dd, J=17.2Hz, J=4.0Hz, 1H). 13C-NMR(101 MHz, CDCl3) δ: 
172.2, 160.4, 158.5, 155.6, 148.9,  144.1, 144.0, 141.5, 141.4, 140.6, 137.0, 130.8, 
130.0, 128.8, 128.1, 128.0, 127.5, 127.3, 125.4, 125.3, 124.9, 120.2, 117.5, 104.3, 
98.3, 67.4, 55.5, 55.4, 53,7, 51.7, 47.2, 46.6, 34.2, 29.9; ESI HRMS calculated for  
C58H55O10N4S [M+H]
+ = 999.36334. Mass found [M+H]+ = 999.36386. 
 
 
Peptides 37 and 38 Synthesized manually on Tentagel Rink-amide resin preloaded 
with glycine (0.25 mmol/g). Coupling of the Fmoc-amino acids (10 equiv) was carried 
out using standard HBTU/HOBt activation, except for the protected sulfonamide 
building block 7 (2 equiv.), which was coupled employing HATU/HOAt as activating 
reagents. Cleavage from the resin, as well as global deprotection, was carried out by 
applying a mixture of trifluoroacetic acid (TFA)/triisopropylsilane (TIPS)/H2O (90:5:5). 
After filtration from the resin, an additional 10% H2O was added to the cleavage 
mixture, which was allow to stir for 30 min. to ensure complete hydrolysis of the 
DMB-protective groups from the sulfonamide moiety. Concentration under reduced 
pressure at ambient temperature and trituration with diethyl ether yielded the crude 
peptide. After preparative reverse phase HPLC purification (C18) and subsequent 
lyophilization the peptides 37 and 38 were isolated as white solids.  
 
 
 
 
 
 
 
 
 
 
 
 
Peptide 37; Isolated was 88 mg (42% yield from 1.0 g resin). ESI HRMS calculated 
for C25H36O7N9S [M+H]
+ = 606.24529. Mass found [M+H]+ = 606.24433.  
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Peptide 38; Isolated was 82 mg (59% yield from 0.43 g resin). ESI HRMS calculated 
for C26H51O7N16S [M+H]
+ = 731.38419. Mass found [M+H]+ = 731.38311. 
  
 
 
 
 
 
 
 
 
(S)-2-amino-3-(4-sulfamoyl-1H-imidazol-2-yl)propanoic acid (39) 100 mg 7 (0.1 
mmol) was treated with 4 mL piperidine/DMF 2:8  for 30 min. The RM was 
evaporated to dryness and was co-evaporated with toluene (2x) before dissolving in 
4 mL TFA/water/TiPS 90:5:5 and was stirred for 4 hours. The solvents were 
evaporated and the residue was taken up in methanol, filtered and was purified with 
prep HPLC yielding 23 mg 39 (66% yield from 7). Rf = 0.45 (EtOAc/MM 1:2);  
+9.9° (c = 0.2, CHCl3) ; 
1H-NMR(400 MHz, D2O) δ: 7.80 (s, 1H), 4.49 (t, J=..Hz, 1H), 
3.52 (m, 2H); 13C-NMR(101 MHz, CD3OD) δ: 168.6, 144.8, 138.8, 120.3, 50.6, 27.2; 
ESI HRMS calculated for  C6H11O4N4S [M+H]
+ = 235.04955. Mass found [M+H]+ = 
235.04960.  
 
 
 
9.8 Synthesis and evaluation of Sulfonamide-Imidazole PHP Inhibitors   
 
General procedure A 150 mg (0.22 mmol) 27 was dissolved in 3 mL dry THF and 
treated dropwise with 0.2 mL 1.6 M BuLi solution (1.5 equiv) at -30 0C under argon. 
The red solution was stirred at this temperature for 20 minutes before 2 equiv of the 
appropriate electrophile dissolved in a minimum of dry THF was added dropwise. The 
RM was stirred for 30 minutes at -30 0C before pouring into a saturated solution of 
NaHCO3 (Na2S2O3 for entries: 53b, 53e, 53f and 86). The water layer was extracted 
2x with EtOAc and the combined organic layers were washed with saturated NaCl 
solution. The EtOAc was dried over anhydrous Na2SO4 and evaporated to dryness. 
The residue was taken up in 2 mL TFA/water/TiPS 90:5:5 and stirred overnight. The 
solvent was removed under vacuum and the residue was suspended in MeOH, 
filtered and purified using preparative HPLC. 
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1H-imidazole-4-sulfonamide 2,2,2-trifluoroacetate (53a) Synthesized according to 
the TFA deprotection step from general procedure A from compound 27, imidazole 
53a was obtained as a sticky oil (18.3 mg, 32% yield from 27). Rf = 0.12 (DCM/MeOH 
9:1); 1H-NMR(400 MHz, CD3OD) δ: 8.21 (d, J=1.2Hz, 1H), 7.74 (d, J=1.2Hz, 1H); 
13C-NMR(101 MHz, CD3OD) δ: 139.9, 136.7, 119.8; ESI HRMS calculated for 
C3H6O2N3S [M+H]
+ = 148.01752. Mass found [M+H]+ = 148.01737.  
 
 
 
 
 
 
 
 
2-iodo-1H-imidazole-4-sulfonamide 2,2,2-trifluoroacetate (53b) Synthesized 
according to the TFA deprotection step from general procedure A from compound 27, 
imidazole 53b was obtained as an off-white solid (42.0 mg, 60% yield from 27). Rf = 
0.34 (DCM/MeOH 9:1); 1H-NMR(400 MHz, CD3OD) δ: 7.60 (s, 1H); 
13C-NMR(101 
MHz, CD3OD) δ: 144.8, 123.3, 110.0; ESI HRMS calculated for C3H5O2N3IS [M+H]
+ = 
273.91417. Mass found [M+H]+ = 273.91407.  
 
 
 
 
 
 
 
 
2-methyl-1H-imidazole-4-sulfonamide 2,2,2-trifluoroacetate (53c) According to 
general procedure A and MeI as electrophile, imidazole 53c was obtained as a sticky 
oil (35,0 mg, 58% yield from 27). Isolated as a mixture of two isomers (2- and 5-
methyl). Rf = 0.15 (DCM/MeOH 9:1); 
1H-NMR(400 MHz, CD3OD) δ: 8.39/7.72 (s, 1H), 
2.57/2.51 (s, 3H); 13C-NMR(101 MHz, CD3OD) δ: 147.1, 137.1, 134.1, 132.9, 131.2, 
119.9, 10.9, 8.8; ESI HRMS calculated for C4H8O2N3S [M+H]
+ = 162.03317. Mass 
found [M+H]+ = 162.03306.  
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2-ethyl-1H-imidazole-4-sulfonamide 2,2,2-trifluoroacetate (53d) According to 
general procedure A and EtI as electrophile, imidazole 53d was obtained as a white 
solid (25.4 mg, 40% yield from 27). Rf = 0.2 (DCM/MeOH 9:1); 
1H-NMR(400 MHz, 
CD3OD) δ: 7.71 (s, 1H), 2.91 (q, J=8.0Hz, 2H) 1.36 (t, J=8.0, 3H); 
13C-NMR(101 
MHz, CD3OD) δ: 151.9, 137.5, 119.8, 20.1, 10.9; ESI HRMS calculated for 
C5H10O2N3S [M+H]
+ = 176.04882. Mass found [M+H]+ = 176.04864.  
 
 
 
 
 
 
 
 
 
 
2-chloro-1H-imidazole-4-sulfonamide 2,2,2-trifluoroacetate (53e) According to 
general procedure A and NCS as electrophile, imidazole 53e was obtained as a 
white solid (21,0 mg, 32% yield from 27). Rf = 0.18 (DCM/MeOH 9:1); 
1H-NMR(400 
MHz, CD3OD) δ: 7.68 (s, 1H), 2.91 (q, J=8.0Hz, 2H) 1.36 (t, J=8.0, 3H); 
13C-
NMR(101 MHz, CD3OD) δ: 135.13; ESI HRMS calculated for C3H5O2N3ClS [M+H]
+ = 
181.97855. Mass found [M+H]+ = 181.97844.  
 
 
 
 
 
 
 
 
2-bromo-1H-imidazole-4-sulfonamide 2,2,2-trifluoroacetate (53f) According to 
general procedure A and CBr4 as electrophile, imidazole 53f was obtained as a white 
solid (42,8 mg, 57% yield from 27). Rf = 0.28 (DCM/MeOH 9:1); 
1H-NMR(400 MHz, 
CD3OD) δ: 7.77 (s, 1H); 
13C-NMR(101 MHz, CD3OD) δ: 141.4, 122.4, 119.1; ESI 
HRMS calculated for C3H5O2N3BrS [M+H]
+ = 225.92804/227.92599. Mass found 
[M+H]+ = 225.92837/227.92624.  
 
 
General procedure B 150 mg (0.18 mmol) iodine 29 was dissolved in 3 mL dioxane 
and 0.3 mmol boronic acid, 0.5 mL 2M K2CO3 solution and 10 mg Pd(PPh3)4 were 
added under argon atmosphere. The mixture was stirred at 80 0C till TLC indicated 
complete conversion of the starting material. The mixture was poured into a saturated 
solution of NaHCO3. The water layer was extracted with EtOAc (2x) and the 
combined organic layers were washed with saturated NaCl solution. The EtOAc was 
dried over anhydrous Na2SO4 and evaporated to dryness. The residue was taken up 
in TFA/water/TiPS 90:5:5 and stirred overnight. The solvent was removed under 
vacuum and the residue was suspended in MeOH, filtrated and purified using 
preparative HPLC. 
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2-phenyl-1H-imidazole-4-sulfonamide 2,2,2-trifluoroacetate (56a) According to 
general procedure B and using phenylboronic acid, imidazole 56a was obtained as a 
white solid (38,0 mg, 51% yield from 29). Rf = 0.80 (DCM/MeOH 9:1); 
1H-NMR(400 
MHz, CD3OD) δ: 7.94-7.89 (m, 2H), 7.80 (s, 1H), 7.56-7.51 (m, 3H); 
13C-NMR(101 
MHz, CD3OD) δ: 148.1, 140.7, 130.8, 129.2, 127.0, 126.4, 120.7; ESI HRMS 
calculated for C9H10O2N3S [M+H]
+ = 224.04882. Mass found [M+H]+ = 224.04888.  
 
 
 
 
 
 
 
 
 
 
2-(furan-2-yl)-1H-imidazole-4-sulfonamide 2,2,2-trifluoroacetate (56b) According 
to general procedure B and using 2-furanylboronic acid, imidazole 56b was obtained 
as a white solid (12.0 mg, 17% yield from 29). Rf = 0.77 (DCM/MeOH 9:1); 
1H-
NMR(400 MHz, CD3OD) δ: 7.69 (m, 1H), 7.66 (s, 1H), 7.05 (m, 1H), 6.62 (m, 1H); 
13C-NMR(101 MHz, CD3OD) δ: 144.4, 143.7, 141.8, 140.4, 119.8, 111.9, 109.9; ESI 
HRMS calculated for C7H8O3N3S [M+H]
+ = 214.02809. Mass found [M+H]+ = 
214.02819.  
 
 
 
 
 
 
 
 
 
 
 
2-(pyridin-3-yl)-1H-imidazole-4-sulfonamide 2,2,2-trifluoroacetate (56c) 
According to general procedure B and using 3-pyridinylboronic acid, imidazole 56c 
was obtained as a white solid (4.2 mg, 6% yield from 29). Rf = 0.33 (DCM/MeOH 
9:1); 1H-NMR(400 MHz, CDCl3) δ: 9.21 (d, J=2.0Hz, 1H), 8.71 (dd, J=2.0Hz, 
J=5.0Hz, 1H), 8.62 (dt, J=2.0Hz, J=8.0Hz, 1H), 7.82 (m, 1H), 7.78 (s, 1H); ESI HRMS 
calculated for C8H9O2N4S [M+H]
+ = 225.04407. Mass found [M+H]+ = 225.04342.  
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2-benzyl-1H-imidazole-4-sulfonamide 2,2,2-trifluoroacetate (56d) 52 mg (0.8 
mmol) Zn(0) (dust) was weighted into a pear-shaped flask and flame-dried. 18 mg I2 
dissolved in 2 mL dry DMF was added (the yellow color disappeared after approx. 1 
minute). 65 mg (0.33 mmol) benzyl iodine together with 18 mg iodine was added and 
the RM was stirred until TLC indicated full consumption. The stirring was stopped and 
the unreacted Zn was allowed to precipitate. 2 mL of the supernatant was taken out 
in a syringe and directly added to a pre-stirred solution of 8 mg (0.006 mmol) 
PdCl2(PPh3)2 and 200 mg (0.18 mmol) iodine 29 suspended in 1.5 mL dry DMF. The 
RM was aged for 2 hours at 40 oC, poured into sat. NaHCO3 (aq) and extracted (2x) 
with EtOAc. The combined EtOAc layers were washed with sat NaCl (aq), dried over 
MgSO4 (s), concentrated and dried under vacuum. The residue was taken up in 
TFA/water/TiPS 90:5:5 and stirred overnight. The solvent was removed under 
vacuum and the residue was purified using preparative HPLC. Imidazole 56d was 
obtained as a white solid (16 mg, 18% yield from 29). Rf = 0.60 (DCM/MeOH 9:1); 
1H-NMR(400 MHz, D2O) δ: 7.74 (s, 1H), 7.35-7.20 (m, 5H), 4.24 (s, 2H); 
13C-
NMR(101 MHz, D2O ) δ: 149.9, 134.2, 133.4, 129.5, 129.1, 128.3, 121.7, 32.1; ESI 
HRMS calculated for C10H12O2N3S [M+H]
+ = 238.06447. Mass found [M+H]+ = 
238.06459.  
 
 
 
 
 
 
 
2N,N-bis(2,4-dimethoxybenzyl)-2-(hydroxymethyl)-1-trityl-1H-imidazole-4-
sulfonamide (58) 1.2 g (1.67 mmol) 23 was suspended in 22 mL dry MeOH and 
warmed to 45 0C. The solid dissolved and 126 mg (3.34 mmol) NaBH4 was added 
and the RM stirred for 2 hours at 45 0C. The RM was diluted with DCM and was 
washed with sat NaHCO3, dried over Na2SO4 and evaporated to obtain alcohol 58 as 
an off-white foam (1.15 g, 96% yield from 23). Rf = 0.45 (cyclohexane/EtOAc 1:1); 
1H-NMR(400 MHz, CDCl3) δ: 7.37-7.33 (m, 10H), 7.27 (d, J=8.4Hz, 2H), 7.03 (m, 
6H), 6.37 (dd, J=8.4Hz, J=2.4Hz, 2H), 6.33 (d, J=2,4Hz, 1H), 4.51 (s, 4H), 3.74 (s, 
6H), 3.66 (s, 6H), 3.57 (s, 2H), 2.85 (bs, 1H); 13C-NMR(101 MHz, CDCl3) δ: 160.3, 
158.5, 151.3, 141.1, 137.9, 130.7, 129.9, 128.8, 128.7, 125.1, 117.8, 104.1, 98.1, 
76.2, 59.3, 55.5, 55.3, 46.1; ESI HRMS calculated for C41H42O7N3S [M+H]
+ = 
720.27380. Mass found [M+H]+ = 720.27378.  
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2-(1-hydroxyethyl)-1H-imidazole-4-sulfonamide 2,2,2-trifluoroacetate (60a) 100 
mg (0.14mmol) 23 was dissolved in 2 mL dry THF and cooled to 0 0C. 75 µL (0.22 
mmol) MeMgBr (3M in ether) was added dropwize and the RM was allowed to stir for 
30 min. at 0 0C and 1 hour ar RT. The RM was diluted with DCM and washed with 
sat. NaHCO3 solution. The DCM was dried over MgSO4 and evaporated. 
Deprotection was performed according to the TFA deprotection step from general 
procedure A and imidazole 60a was obtained as an off-white solid (23 mg, 54% yield 
from 23). Rf = 0.10 (DCM/MeOH 9:1); 
1H-NMR(400 MHz, CD3OD) δ: 7.69 (s, 1H), 
5.00 (q, J=8.0Hz, 1H), 1.55 (d, J=8.0Hz, 3H); 13C-NMR(101 MHz, CD3OD) δ: 154.0, 
138.7, 119.7, 62.9, 21.6; ESI HRMS calculated for C5H10O3N3S [M+H]
+ = 192.04374. 
Mass found [M+H]+ = 192.04368.  
 
 
 
 
 
 
 
 
 
2-(hydroxymethyl)-1H-imidazole-4-sulfonamide 2,2,2-trifluoroacetate (60c) 
Synthesized according to the TFA deprotection step from general procedure A from 
compound 58, imidazole 60c was obtained as an off-white solid (18 mg, 44% yield 
from 58). Rf = 0.08 (DCM/MeOH 9:1); 
1H-NMR(400 MHz, D6-DMSO) δ: 12.40 (bs, 
1H), 7.44 (s, 1H), 7.06 (bs, 2H), 4.45 (s, 2H); 13C-NMR(101 MHz, D6-DMSO) δ: 
149.9, 142.5, 119.1, 57.4; ESI HRMS calculated for C4H8O3N3S [M+H]
+ = 178.02809. 
Mass found [M+H]+ = 178.02798.  
 
 
 
 
 
 
 
 
 
2-(methoxymethyl)-1H-imidazole-4-sulfonamide 2,2,2-trifluoroacetate (60d) 100 
mg (0.14 mmol) 23 was reduced as described for 58 and the solid material was 
dissolved in 5 mL dry THF, cooled to 0 0C and 28 mg (0.7 mmol) NaH was added. 
The RM was stirred for 30 min. at 0 0C and 30 min. at RT. 35 µL MeI (0.56 mmol) 
was added and the RM was allowed to stir overnight. The RM was diluted with DCM 
and washed with sat. NaHCO3 solution. The DCM was dried over MgSO4 and 
evaporated. Deprotection was performed according to the TFA deprotection step 
from general procedure A and imidazole 60d was obtained as an oil (45 mg, 42% 
yield from 23). Rf = 0.22 (DCM/MeOH 9:1); 
1H-NMR(400 MHz, CD3OD) δ: 7.70 (s, 
1H), 4.58 (s, 2H), 3.43 (s, 2H); 13C-NMR(101 MHz, CD3OD) δ: 147.2, 139.8, 120.1, 
65.7, 58.1; ESI HRMS calculated for C5H10O3N3S [M+H]
+ = 192.04374. Mass found 
[M+H]+ = 192.04361.  
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4-(N,N-bis(2,4-dimethoxybenzyl)sulfamoyl)-1H-imidazole-2-carboxylic acid (61)  
500 mg (0.72 mmol) 27 was dissolved in 10 mL dry THF and cooled to -30 0C. 0.68 
mL (1.5 equiv) 1.6 M BuLi solution was added dropwise and the RM was stirred for 
20 min. before transferring it through a cannula into a suspension of crushed CO2 
pallets in 5 mL dry THF. The mixture was allowed to reach RT over 2 hours and was 
taken up in diluted 5% citric acid solution. The product was extracted using EtOAc 
(3x) and the combined organic layers were washed with sat NaHCO3 solution, dried 
over Na2SO4(s) and concentrated. The product was purified by SiO2 column 
chromatography, eluted with DCM/MeOH (from 98:2 to 9:1) to obtain 330 mg of 61 as 
an off-white foam (93% yield from 27). Rf = 0.13 (DCM/MeOH 9:1); 
1H-NMR(400 
MHz, CD3OD) δ: 7.71 (s, 1H), 7.05 (d, J=8.4Hz, 2H), 6.36-6.30 (m 4H), 4.49 (s, 4H), 
3.73 (s, 6H), 3.64 (s, 6H); 13C-NMR(101 MHz, CD3OD) δ: 160.8, 159.6, 158.5, 136.2, 
130.4, 128.3, 116.9, 104.0, 97.6, 54.6, 54.4, 46.9; ESI HRMS calculated for 
C22H26O8N3S [M+H]
+ = 492.14351. Mass found [M+H]+ = 492.14294.  
 
 
 
 
 
 
 
 
4-sulfamoyl-1H-imidazole-2-carboxylic acid (62) Synthesized according to the 
deprotection step from general procedure A from 60 mg (0.12 mmol) carboxylic acid 
61, imidazole 62 was obtained as a sticky oil (16 mg, 44% yield from 61). Rf = 0.03 
(DCM/MeOH 9:1); 1H-NMR(400 MHz, D6-DMSO) δ: 13.40 (bs, 1H), 7.70 (s, 1H), 7.28 
(bs, 2H); 13C-NMR(101 MHz, D6-DMSO) δ: 175.1, 171.9, 136.7, 73.1; ESI HRMS 
calculated for C4H6O4N3S [M+H]
+ = 192.00735. Mass found [M+H]+ = 192.00735.  
 
 
General procedure C 90 mg (0.18 mmol) 61 was dissolved in 1 mL dry DMF and the 
appropriate amine (0.22 mmol), 112 mg (0.22 mmol) PyBOP and 38 µL DiPEA (0.36 
mmol) were added. The RM was stirred till TLC indicated complete conversion before 
concentration under vacuum. The residue was dissolved in EtOAc and washed with a 
saturated solution of NaHCO3. The organic layer was washed with saturated 
NaCl(aq) solution. The EtOAc was dried over anhydrous Na2SO4 and evaporated to 
dryness. The residue was taken up in 2 mL TFA/water/TiPS 90:5:5 and stirred 
overnight. The solvent was removed under vacuum and the residue was suspended 
in MeOH, filtered and purified using prep HPLC. 
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4-sulfamoyl-1H-imidazole-2-carboxamide 2,2,2-trifluoroacetate (64a) According 
to general procedure C and N,N-bis(2,4-dimethoxybenzyl)amine as nucleophile, 
imidazole 64a was obtained as a white solid (12 mg, 22% yield from 61). Rf = 0.21 
(DCM/MeOH 9:1); 1H-NMR(400 MHz, CD3OD) δ: 8.08 (bs, 1H), 7.82 (bs, 2H), 7.62 
(s, 1H); ESI HRMS calculated for C4H7O3N4S [M+H]
+ = 191.02334. Mass found 
[M+H]+ = 191.02331.  
 
 
 
 
 
 
 
 
 
 
 
N-methyl-4-sulfamoyl-1H-imidazole-2-carboxamide 2,2,2-trifluoroacetate (64b) 
According to general procedure C and methylamine HCl as nucleophile, imidazole 
64b was obtained as a white solid (43 mg, 75% yield from 61). Rf = 0.08 
(DCM/MeOH 9:1); 1H-NMR(400 MHz, D6-DMSO) δ: 13.40 (bs, 1H), 8.53 (bs, 1H), 
7.83 (s, 1H), 7.62 (bs, 2H), 2.79 (s, 3H); 13C-NMR(101 MHz, D6-DMSO) δ: 107.63, 
26.54; ESI HRMS calculated for C5H9O3N4S [M+H]
+ = 205.03899. Mass found 
[M+H]+ = 205.03910.  
 
 
 
 
 
 
 
 
 
N,N-dimethyl-4-sulfamoyl-1H-imidazole-2-carboxamide 2,2,2-trifluoroacetate 
(64c) According to general procedure C and N,N-dimethylamine HCl as nucleophile, 
imidazole 64c was obtained as a white solid (37 mg, 62% yield from 61). Rf = 0.15 
(DCM/MeOH 9:1); 1H-NMR(400 MHz, CD3OD) δ: 7.98 (s, 1H), 3.09 (s, 3H), 3.00 (s, 
3H); 13C-NMR(101 MHz, CD3OD) δ: 162.5, 136.4, 136.1, 128.2, 37.9, 34.2; ESI 
HRMS calculated for C6H11O3N4S [M+H]
+ = 219.05464. Mass found [M+H]+ = 
219.05464.  
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1-((benzyloxy)methyl)-1H-imidazole-4-sulfonyl chloride (66) 5.0 g (30.0 mmol) 24 
was dissolved in 100 mL acetonitrile and 4.5 mL (33.0 mmol) BOM-Cl was added and 
the RM was stirred overnight at RT. The RM was concentrated, resuspended in DCM 
and loaded onto a silica column. The product was eluted with cyclohexane/EtOAc 2:1 
to 1:1 and 6.8 g 66 was obtained as a transparent oil that turns solid upon freezer 
storage (79% yield from 24). Rf = 0.55 (chex/EtOAc 1:1); 
1H-NMR(400 MHz, CDCl3) 
δ: 7.76 (s, 1H), 7.70 (s, 1H), 7.41-7.27 (m, 5H), 5.40 (s, 2H), 4.56 (s, 2H); 13C-
NMR(101 MHz, CDCl3) δ: 144.2, 138.9, 135.3, 129.2, 129.1, 128.3, 124.0, 76.3, 71.7.  
 
 
 
 
 
 
 
 
 
 
1-((benzyloxy)methyl)-2-bromo-1H-imidazole-4-sulfonyl chloride (68) 2.0 g (7.0 
mmol) 66 was dissolved in 50 mL chloroform and 1.4 g NBS (7.87 mmol) was added. 
The reaction was stirred for 4 hours at 50 0C. The RM was concentrated to an oil and 
loaded onto a silica column. The product was eluted with cyclohexane/EtOAc 4:1 to 
2:1 and 1.1 g 68 was obtained as a transparent oil that turns solid upon freezer 
storage (43% yield from 66). Rf = 0.67 (chex/EtOAc 1:1); 
1H-NMR(400 MHz, CDCl3) 
δ: 7.75 (s, 1H), 7.41-7.28 (m, 5H), 5.41 (s, 2H), 4.61 (s, 2H); 13C-NMR(101 MHz, 
CDCl3) δ: 143.8, 135.4, 129.11, 129.07, 128.2, 126.3, 122.9, 77.1, 72.2.  
 
 
General procedure D 100 mg (0.27 mmol) 68 was dissolved in 1.5 mL DCM and the 
appropriate amine (0.5 mmol) and 175 µL (1.0 mmol) DiPEA were added. The RM 
was stirred overnight at RT. The RM was washed with sat NaHCO3 solution, dried 
over Na2SO4(s) and evaporated the residue was taken up in 1 mL TFA and 1 mL 
48% HBr in water and stirred overnight. The solvent was removed and the residu 
purified with prep HPLC. 
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2-bromo-N-methyl-1H-imidazole-4-sulfonamide 2,2,2-trifluoroacetate (69a) 
According to general procedure D and using methylamine HCl, imidazole 69a was 
obtained as a white solid (33 mg, 35% yield from 68). Rf = 0.50 (DCM/MeOH 9:1); 
1H-NMR(400 MHz, CD3OD) δ: 7.76 (s, 1H), 2.61 (s, 1H); 
13C-NMR(101 MHz, 
CD3OD) δ: 138.5, 124.0, 119.4, 28.1; ESI HRMS calculated for C4H7O2N3BrS [M+H]
+ 
= 239.94369. Mass found [M+H]+ = 239.94380.  
 
 
 
 
 
 
 
2-bromo-N,N-dimethyl-1H-imidazole-4-sulfonamide 2,2,2-trifluoroacetate (69b) 
According to general procedure D and using N,N-dimethylamine HCl, imidazole 69b 
was obtained as a white solid (57 mg, 57% yield from 68). Rf = 0.70 (DCM/MeOH 
9:1); 1H-NMR(400 MHz, CD3OD) δ: 7.48 (s, 1H), 2.76 (s, 6H); 
13C-NMR(101 MHz, 
CD3OD) δ: 137.0, 124.6, 119.5, 38.0; ESI HRMS calculated for C5H9O2N3BrS [M+H]
+ 
= 253.95934. Mass found [M+H]+ = 253.95950.  
 
 
 
 
 
 
 
2-bromo-N-(2-methoxyethyl)-1H-imidazole-4-sulfonamide 2,2,2-trifluoroacetate 
(69c) According to general procedure D and using 2-methoxyethylamine, imidazole 
69c was obtained as a white solid (48 mg, 45% yield from 68). Rf = 0.60 
(DCM/MeOH 9:1); 1H-NMR(400 MHz, CD3OD) δ: 7.64 (s, 1H), 3,41 (t, J=5.6Hz, 2H), 
3.29 (s, 3H), 3.12 (t, J=5.6Hz, 2H); 13C-NMR(101 MHz, CD3OD) δ: 140.87, 123.49, 
118.92, 71.08, 57.70, 42.55; ESI HRMS calculated for C6H11O3N3BrS [M+H]
+ = 
283.96990. Mass found [M+H]+ = 283.97001.  
 
 
 
 
 
 
 
 
N-allyl-2-bromo-1H-imidazole-4-sulfonamide 2,2,2-trifluoroacetate (69d) 
According to general procedure D and using allylamine, imidazole 69d was obtained 
as a white solid (25 mg, 24% yield from 68). Rf = 0.54 (DCM/MeOH 9:1); 
1H-
NMR(400 MHz, CD3OD) δ: 7.64 (s, 1H), 5.76 (m, 1H), 5.18 (m, 1H), 5.05 (m, 1H), 
3.58 (m, 2H); 13C-NMR(101 MHz, CD3OD) δ: 140.78, 134.04, 123.62, 118.98, 
115.84, 45.38; ESI HRMS calculated for C6H9O2N3BrS [M+H]
+ = 265.95934. Mass 
found [M+H]+ = 265.95946.  
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2-bromo-N-phenyl-1H-imidazole-4-sulfonamide 2,2,2-trifluoroacetate (69e) 
According to general procedure D and using aniline, imidazole 69e was obtained as 
a white solid (52 mg, 46% yield from 68). Rf = 0.57 (DCM/MeOH 9:1); 
1H-NMR(400 
MHz, CD3OD) δ: 7.57 (s, 1H), 7.22 (dt, J=1.2Hz, J=8.8Hz, 2H), 7.13 (dd, J=1.2Hz, 
J=8.8Hz, 2H), 7.04 (tt, J=1.2Hz, J=8.8Hz, 1H); 13C-NMR(101 MHz, CD3OD) δ: 
137.56, 128.84, 124.71, 124.42, 120.88, 119.02; ESI HRMS calculated for 
C9H9O2N3BrS [M+H]
+ = 301.95934. Mass found [M+H]+ = 301.95938.  
 
 
 
 
 
 
 
N-benzyl-2-bromo-1H-imidazole-4-sulfonamide 2,2,2-trifluoroacetate (69f) 
According to general procedure D and using benzylamine, imidazole 69f was 
obtained as a white solid (40 mg, 43% yield from 68). Rf = 0.58 (DCM/MeOH 9:1); 
1H-NMR(400 MHz, CD3OD) δ: 7.54 (s, 1H), 7.27-7.18 (m, 5H), 4.15 (s, 2H); 
13C-
NMR(101 MHz, CD3OD) δ: 140.93, 137.50, 128.14, 127.72, 127.21, 123.65, 118.91, 
46.68; ESI HRMS calculated for C10H11O2N3BrS [M+H]
+ = 315.97499. Mass found 
[M+H]+ = 315.97517.  
 
 
General procedure E 50 mg (0.13 mmol) 68, 34 mg (0.26 mmol) Na2SO3 and 23 mg 
(0.26 mmol) NaHCO3 were suspended in 0.5 mL water. The RM was allowed to run 
for 3 hours during which the sulfonylchloride slowly goes into solution. 4.2 mg (0.013 
mmol) tetra-n-butylammonium bromide and 0.20 mmol halide was added and the RM 
was stirred overnight. The RM was evaporated, the residue was taken up in 1 mL 
TFA and 1 mL 48% HBr in water and the mixture was stirred overnight at RT. The 
solvent was removed and the residu purified with prep HPLC. 
 
 
 
 
 
 
2-bromo-4-(methylsulfonyl)-1H-imidazole 2,2,2-trifluoroacetate (70a) According 
to general procedure E and using iodomethane, imidazole 70a was obtained as a 
white solid (25 mg, 53% yield from 68). Rf = 0.37 (DCM/MeOH 9:1); 
1H-NMR(400 
MHz, CD3OD) δ: 7.79 (s, 1H), 3.12 (s, 3H); 
13C-NMR(101 MHz, CD3OD) δ: 141.50, 
124.39, 119.66, 42.16; ESI HRMS calculated for C4H6O2N2BrS [M+H]
+ = 224.93279. 
Mass found [M+H]+ = 224.93299.  
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4-(allylsulfonyl)-2-bromo-1H-imidazole 2,2,2-trifluoroacetate (70b) According to 
general procedure E and using allylbromide,  imidazole 70b was obtained as a white 
solid (18 mg, 35% yield from 68). Rf = 0.50 (DCM/MeOH 9:1); 
1H-NMR(400 MHz, 
CD3OD) δ: 7.77 (s, 1H), 5.79 (m, 1H), 5.34 (m, 1H), 5.23 (m, 1H), 3.97 (m, 2H); 
13C-
NMR(101 MHz, CD3OD) δ: 139.19, 126.10, 124.93, 123.67, 119.76, 58.92; ESI 
HRMS calculated for C6H8O2N4BrS [M+H]
+ = 250.94844. Mass found [M+H]+ = 
250.94804.  
 
 
 
 
 
 
 
4-(benzylsulfonyl)-2-bromo-1H-imidazole 2,2,2-trifluoroacetate (70c) According 
to general procedure E and using benzylbromide,  imidazole 70c was obtained as a 
white solid (29 mg, 50% yield from 68). Rf = 0.60 (DCM/MeOH 9:1); 
1H-NMR(400 
MHz, CD3OD) δ: 7.50 (s, 1H), 7.33-7.27 (m, 3H), 7.21-7.17 (m, 2H), 4.50 (s, 2H); 
13C-
NMR(101 MHz, CD3OD) δ: 138.50, 130.87, 128.55, 128.53, 128.34, 126.38, 119.83, 
60.69; ESI HRMS calculated for C10H10O2N2BrS [M+H]
+ = 300.96409. Mass found 
[M+H]+ = 300.96418.  
 
 
 
 
 
 
 
1-methyl-1H-imidazole-4-sulfonyl chloride (75) 24.1 g (294 mmol) N-
methylimidazole (74) was melted in an argon flushed 250 mL flask. 60.0 mL (900 
mmol) ClSO3H was added drop wise (Caution! the first 15 mL reacted violently, with 
excessive HCl(g) formation). The reaction mixture was heated at 140 oC for 16 hours. 
The resulting dark reaction mixture (RM) was cooled to 40 oC before adding 22.0 mL 
(302 mmol) thionyl chloride drop wise over 5 minutes (immediate gas evolution 
visible). The RM was heated until gas evolution ceased, during which time the 
temperature was slowly raised to 125 °C. The RM was allowed to cool to RT before 
pouring it into a slurry of 300 g crushed ice with 20.0 g NaCl. A white precipitate was 
formed and the suspension was filtered after the ice had completely melted. The 
white solid was washed with a small amount of cold water and dried overnight under 
vacuum over KOH. The filtrate was re-filtered once and the collected solid was 
washed with a small amount of water and dried overnight under vacuum over KOH. 
Combining the two solids yielded 16.2 g 75 as a fine white powder (31% yield from 
74). 1H-NMR(400 MHz, DMSO-d6) δ: 8.93 (d, J=1.2Hz, 1H), 7.68 (d, J=1.2Hz, 1H) 
Analytical data in agreement with literature.115  
 
 - 155 - 
 
 
 
 
 
 
 
 
 
 
N,N-bis(2,4-dimethoxybenzyl)-1-methyl-1H-imidazole-4-sulfonamide (76) 1.0 g 
(5.54 mmol) 75 was added in portions to a solution of 1.27 g (4.0 mmol) N,N-bis(2,4-
dimethoxybenzyl)amine in 40 mL DCM with 2.1 mL (12.0 mmol) DiPEA at 0 0C. The 
RM was stirred at 0 0C for 30 min. before allowing it to warm to RT. The RM was 
stirred at RT overnight. The RM was washed with NaHCO3, dried over MgSO4(s), 
concentrated and dried under vacuum. The product was purified by SiO2 column 
chromatography, eluted with toluene/EtOAc (1:1 to 1:3) to obtain 1.52 g of 76 as a 
white foam (82% yield from 75). Rf = 0.15 (toluene/EtOAc 1:1); 
1H-NMR(400 MHz, 
CDCl3) δ: 7.40 (d, J=1.2Hz, 1H), 7.23 (d, J=8.4Hz, 2H), 7.12 (d, J=1.2Hz, 1H), 6.35 
(dd, J=8.4Hz, J=2.4Hz, 2H), 6.24 (d, J=2,4Hz, 1H), 4.46 (s, 4H), 3.75 (s, 6H), 3.61 (s, 
6H), 3.60 (s, 3H); 13C-NMR(101 MHz, CDCl3) δ: 160.3, 158.4, 141.5, 138.7, 130.8, 
123.8, 117.9, 103.9, 97.9, 55.6, 55.2, 47.1, 33.9; ESI HRMS calculated for 
C22H28O6N3S [M+H]
+ = 462.16933. Mass found [M+H]+ = 462.16875.  
 
 
 
 
 
 
 
 
 
 
 
N,N-bis(2,4-dimethoxybenzyl)-2,5-diiodo-1-methyl-1H-imidazole-4-sulfonamide 
(77) 400 mg (0.87 mmol) 76 was suspended in 10 mL dry THF and 2 mL HMPA in a 
flame dried Schlenk flask. The reaction mixture was cooled to -30 0C under argon. 
1.1 mL (1.76 mmol) 1.6 M BuLi solution is added dropwize. The RM becomes dark 
blue. After 10 min. at -30 0C 400 mg iodine (1.76 mmol) dissolved in 3 mL dry THF 
was added dropwize. The RM was stirred at -30 0C for 10 min and allowed to reach 
RT when it was poured into a sat. Na2S2O3 solution and was extracted twice with 
EtOAc. The combined EtOAc layers were washed with brine, dried over MgSO4(s), 
concentrated and dried under vacuum. The product was purified by SiO2 column 
chromatography, eluted with toluene/EtOAc (4:1) to obtain 514 mg of 77 as a white 
foam (83% yield from 76). Rf = 0.75 (EtOAc); 
1H-NMR(400 MHz, CDCl3) δ: 7.21 (d, 
J=8.4Hz, 2H), 6.35 (dd, J=8.4Hz, J=2.4Hz, 2H), 6.28 (d, J=2,4Hz, 1H), 4.51 (s, 4H), 
3.76 (s, 6H), 3.68 (s, 6H), 3.59 (s, 3H); 13C-NMR(101 MHz, CDCl3) δ: 160.3, 158.4, 
148.2, 130.9, 117.7, 104.0, 97.9, 92.3, 55.6, 55.3, 47.2, 39.0; ESI HRMS calculated 
for C22H26O6N3I2S [M+H]
+ = 713.96262. Mass found [M+H]+ = 713.96321.  
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2-iodo-1-methyl-1H-imidazole-4-sulfonamide 2,2,2-trifluoroacetate (71) 
Synthesized according to the deprotection step from general procedure A from 100 
mg 77, imidazole 71 was obtained as a sticky oil (23 mg, 41% from 77). Rf = 0.18 
(DCM/MeOH 9:1); 1H-NMR(400 MHz, CD3OD) δ: 9.15 (s, 1H), 3.89 (s, 3H); 
13C-
NMR(101 MHz, CD3OD) δ: 139.32, 138.58, 82.92, 37.58; ESI HRMS calculated for 
C4H7O2N3IS [M+H]
+ = 287.92982. Mass found [M+H]+ = 287.92969. 
 
 
 
 
 
 
 
1-methyl-1H-imidazole-5-sulfonyl chloride (78) 3 g (18 mmol) 24 was suspended 
in 10 mL 78% formic acid. 1.8 mL (19 mmol) Me2SO4 was added and the RM was 
stirred overnight at RT. The RM was poored carefully into a saturated NaHCO3 
solution and extracted with DCM (3x). The DCM was dried over Na2SO4(s) and 
evaporated to dryness giving 2.1 g 78 as a white powder (58% yield from 24). 1H-
NMR(400 MHz, DMSO-d6) δ: 9.02 (d, J=1.2Hz, 1H), 7.63 (d, J=1.2Hz, 1H), 3.89 (s, 
3H). Analytical data in agreement with literature.116 
 
 
 
 
 
 
 
5-methyl-1H-imidazole-4-sulfonyl chloride (83) 20 g (244 mmol) 4(5)-
methylimidazole (82) was melted in an argon flushed 250 mL flask. 60.0 mL (900 
mmol) ClSO3H was added drop wise (Caution! the first 15 mL reacted violently, with 
excessive HCl(g) formation). The reaction mixture was heated at 140 oC for 16 hours. 
The resulting dark reaction mixture (RM) was cooled to 40 oC before adding 22.0 mL 
(302 mmol) thionyl chloride drop wise over 5 minutes (immediate gas evolution 
visible). The RM was heated until gas evolution ceased, during which time the 
temperature was slowly raised to 125 °C and was stirred for 6 hours. The RM was 
allowed to cool to RT before pouring it into a slurry of 300 g crushed ice with 20.0 g 
NaCl. A white precipitate was formed and the suspension was filtered after the ice 
had completely melted. The white solid was washed with a small amount of cold 
water and dried overnight under vacuum over KOH. The filtrate was re-filtered once 
and the collected solid was washed with a small amount of water and dried overnight 
under vacuum over KOH. Combining the two solids yielded 17.1 g 83 as a fine white 
powder (39% yield from 82). 1H-NMR(400 MHz, DMSO-d6) δ: 12.24 (bs, 1H), 8.83 (s, 
1H), 2.32 (s, 3H). 
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1-((benzyloxy)methyl)-5-methyl-1H-imidazole-4-sulfonyl chloride (84) 5.0 g (27.7 
mmol) 83 was dissolved in 150 mL acetonitrile and 4.12 mL (30.0 mmol) BOM-Cl was 
added and the RM was stirred overnight at RT. The RM was concentrated, 
resuspended in DCM and loaded onto a silica column. The product was eluted with 
cyclohexane/EtOAc 2:1 to 1:1 and 4.2 g 84 was obtained as a transparent oil that 
turns solid upon freezer storage (50 % from 83). Rf = 0.45 (chex/EtOAc 1:1); 
1H-
NMR(400 MHz, CDCl3) δ: 7.56 (bs, 1H), 7.42-7.25 (m, 5H), 5.34 (s, 2H), 4.54 (s, 2H), 
2.60 (s, 3H); 13C-NMR(101 MHz, CDCl3) δ: 140.5, 138.3, 135.5, 135.1, 129.1, 129.0, 
128.3, 74.8, 71.4, 9.7. 
 
 
 
 
 
 
 
 
 
2-iodo-5-methyl-1H-imidazole-4-sulfonamide (85) 1.0 g (3,3 mmol) 84 was 
dissolved in 25 mL CHCl3 and 700 mg NBS (3.9 mmol) was added. The reaction 
mixture was stirred for 3 hours at 50 ºC. The RM was poured into a sat. Na2S2O3 
solution and was extracted twice with DCM. The DCM was dried over Na2SO4(s) and 
evaporated to dryness. The solid material was dissolved in 5 mL DCM and added 
dropwise to a solution of 1.27 g (4.0 mmol) N,N-bis(2,4-dimethoxybenzyl)amine and 
0.9 mL (1.0 mmol) DiPEA in 30 mL DCM at 0 0C. The RM was for 3 hours at RT and 
was poured into a sat. NaHCO3 (aq) solution and was extracted twice with DCM. The 
combined DCM layers were washed with brine, dried over MgSO4(s), concentrated 
and dried under vacuum. The residue was taken up in DCM and purified using silica 
chromatography (cyclohexane/EtOAc 4:1 to 1:1) obtaining 356 mg imidazole 85 as a 
white solid (16 % yield from 84). Rf = 0.60 (chex/EtOAc 1:1); 1H-NMR(400 MHz, 
CDCl3) δ: 7.33 (m, 5H), 7.22 (d, J=8.4Hz, 2H), 6.34 (dd, J=8.4Hz, J=2.4Hz, 2H), 6.26 
(d, J=2,4Hz, 2H), 5.24 (s, 2H), 4.49 (s, 2H), 3.73 (s, 6H), 3.66 (s, 6H), 2.41 (s, 3H); 
13C-NMR(101 MHz, CDCl3) δ: 160.26, 158.41, 138.34, 136.32, 134.66, 130.67, 
128.87, 128.59, 127.96, 119.91, 117.84, 103.93, 97.92, 74.12, 70.96, 55.53, 55.23, 
47.12, 10.11; ESI HRMS calculated for C30H35O7N3BrS [M+H]
+ = 660.13736. Mass 
found [M+H]+ = 660.13747  
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2-iodo-5-methyl-1H-imidazole-4-sulfonamide 2,2,2-trifluoroacetate (73) 
Synthesized according to the deprotection step from general procedure A from 200 
mg (0.30 mmol) 85. Imidazole 73 was obtained as a white solid (53 mg, 50% yield 
from 85). Rf = 0.40 (DCM/MeOH 9:1); 
1H-NMR(400 MHz, DMSO-d6) δ: 13.12 (bs, 
1H), 7.12 (bs, 2H), 2.31 (s, 3H); 13C-NMR(101 MHz, DMSO-d6) δ: 139.5, 132.1, 
115.5, 10.8; ESI HRMS calculated for C58H55O10N4S [M+H]
+ = 239.94369. Mass 
found [M+H]+ = 239.94380.  
 
 
 
 
 
 
 
 
 
2-mercapto-1H-imidazole-4-sulfonamide (86) According to general procedure A 
and S8 as electrophile (added as a suspension in dry THF). Imidazole 86 was 
obtained as a white solid ( 18 mg, 12% yield from 27). Rf = 0.27 (DCM/MeOH 9:1); 
1H-NMR(400 MHz, DMSO-d6) δ: 12.78 (bs, 1H), 12.43 (bs, 1H), 7.43 (bs, 2H), (t, 
J=2.4Hz, 1H); 13C-NMR(101 MHz, CD3OD) δ: 163.5, 131.1, 118.5; ESI HRMS 
calculated for C3H6O2N3S2 [M+H]
+ = 179.98959. Mass found [M+H]+ = 179.98944. 
 
 
 
 
9.9 Synthesis and evaluation of Phosphonate and Amide/Carbonic Acid  
      Derivatives as PHP Inhibitors 
 
 
 
 
 
 
 
4-iodo-1-trityl-1H-imidazole (92) 5.0 g (25.8 mmol) 91 and 7.5 g (27.1 mmol) TrCl 
were suspended in 50 mL THF. After stirring for 10min. 9.4 mL (57 mmol) DiPEA was 
added. The RM was stirred for 30 min. before raising the temp to 60 0C and was 
stirred overnight. The RM was evaporated to dryness, the residue was redissolved in 
chloroform and washing with 10% Na2CO3 (aq), water and sat. NaCl. The chloroform 
was dried over Na2SO4 and evaporation afforded solid material that was suspended 
in 5 mL MeOH and 50 mL diethyl ether and stirred for 1 hour. The white solid was 
filtered off and washed with diethyl ether. The filtrate was concentrated and co-
evaporated with toluene before re-suspension in 1 mL MeOH and 10 mL diethyl 
ether. After stirring for one hour the solvent was decanted and the white solid was 
washed with ether. The solids were combined and 9.45 g 92 was obtained as an off-
white solid (84% yield from 91). 1H-NMR(400 MHz, CDCl3) δ: 7.36-7.32 (m, 10H), 
7.13-7.09 (m, 6H), 6.91 (d, J=1.4Hz, 1H). Analytical data in agreement with 
literature.123  
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dibenzyl (1-trityl-1H-imidazol-4-yl)phosphonate (93) 4.0 g (9.2 mmol) 92 was 
dissolved in 50 mL dry THF under argon. The RM was cooled to 0 0C and 7.4 mL i-
PrMgCl:LiCl 1.3M in THF (9.6 mmol) was added dropwise. The RM was stirred for 20 
min. at 0 0C and 20 min. at RT before cooling to -78 0C. 2.4 g (10 mmol) 
bis(diethylamino)phosphine chloride was added dropwise and the RM was stirred for 
1 hour at -78 0C before allowing the RM to reach RT and letting it stir for 1 addition 
hour. The THF was evaporated and under argon 5.0 g benzyl alcohol (40 mmol) and 
30 mL dry acetonitril was added. The mixture was cooled to 0 0C and 2 mL tetrazole 
0.45 M in acetonitrile (0.9 mmol) was added and the RM was stirred overnight at RT. 
The yellow suspension was cooled to 0 0C and 4 mL (35.3 mmol) 30% hydrogen 
peroxide was added dropwise. The RM was stirred for 2 hours at 0 0C and 30 min. at 
RT. 50 mL 5% Na2CO3 and 50 mL EtOAc were added and stirred for 10 min. The 
layers were separated and the water was extracted with EtOAc (2x). The combined 
organic layers were washed with water and sat. NaCl(aq) solution, dried over 
Na2SO4(s) and evaporated to dryness. The product was purified by SiO2 column 
chromatography (cyclohexane/EtOAc 4:1 to 3:5) to obtain 2.8 g of 93 as a sticky oil 
(53% yield from 92). 1H-NMR(400 MHz, CDCl3) δ: 7.58-7.53 (m, 1H), 7.53-7.50 (m, 
1H), 7.36-7.29 (m,4H), 7.29-7.15 (m, 15H), 7.10-6.97 (m, 6H), 5.20-5.04 (m, 4H). 
Analytical data in agreement with literature.67 
 
 
 
 
 
 
 
 
(1H-imidazol-4-yl)phosphonic acid (97) Synthesized according to the TFA 
deprotection step from general procedure A from 93, imidazole 97 was obtained as a 
sticky oil (17 mg, 29% yield from 93). Rf = 0.25 (DCM/MeOH 8:2); 
1H-NMR(400 MHz, 
DMSO-d6) δ: 8.83 (s, 1H), 7,57 (s, 1H), 5.75-4.25 (bs); 
13C-NMR(101 MHz, DMSO-
d6) δ: 135.70, 132.12, 130.09; 
31P-NMR(161 MHz, DMSO-d6) δ: -7.60; ESI HRMS 
calculated for C3H6O3N2P [M+H]
+ = 149.01106. Mass found [M+H]+ = 149.01090.  
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dibenzyl (2-iodo-1-trityl-1H-imidazol-4-yl)phosphonate (94) To 1.6 g (2.3 mmol) 
93 dissolved in 10 mL freshly distilled THF in a flame dried flask at -100 0C was 
added 1.47 mL 1.7 M t-BuLi (2.5 mmol) dropwize. The red solution was stirred for 2 
min. at -100 0C and a solution of 760 mg (3.0 mmol) I2 in 4 mL dry THF was added 
dropwize and the RM was stirred for 5 min. at -100 0C. The cold RM was poured 
directly into saturated Na2S2O3 solution  and was extracted with EtOAc (3x), the 
combined EtOAc was washed with sat. NaCl(s) solution, dried over Na2SO4(s) and 
evaporated to dryness. The product was purified by SiO2 column chromatography 
(toluene/EtOAc (3:1) to obtain 1.0 g of 94 as a white powder (62% yield from 93). Rf 
= 0.30 (toluene/EtOAc 1:1); 1H-NMR(400 MHz, CDCl3) δ: 7.43 (d, J=0.8Hz, 1H), 
7.38-7.29 (m, 19H), 7.10-7.07 (m, 6H), 5.19-5.09 (m, 4H); 13C-NMR(101 MHz, CDCl3) 
δ: 147.1, 141.1, 136.4, 136.3, 134.8, 134.4, 132.7, 130.8, 130.3, 129.9, 128.7, 128.6, 
128.52, 128.46, 128.30, 128.26, 128.20, 128.15, 128.13, 127.5, 93.9, 93.7, 77.9, 
68.30, 68.24; 31P-NMR(161 MHz, CDCl3) δ: 11.42; ESI HRMS calculated for 
C36H3103N2IP [M+H]
+ = 687.11115. Mass found [M+H]+ = 697.11097.  
 
  
 
 
 
 
 
 
 
(2-iodo-1H-imidazol-4-yl)phosphonic acid (88) Synthesized according to the TFA 
deprotection step from general procedure A from compound 94 imidazole 88 was 
obtained as a white solid (35 mg, 64% yield from 94). Rf = 0.40 (DCM/MeOH 8:2); 
1H-NMR(400 MHz, DMSO-d6) δ: 11.00-8.00 (bs), 7.57 (s, 1H), 7.45 (s, 1H); 
13C-
NMR(101 MHz, DMSO-d6) δ: 188.90, 146.67, 146.47; 
31P-NMR(161 MHz, DMSO-d6) 
δ: -11.34; ESI HRMS calculated for C3H5O3N2IP [M+H]
+ = 274.90770. Mass found 
[M+H]+ = 274.90707.  
 
 
 
 
 
 
 
 
1-trityl-1H-imidazole-4-carboxylic acid (105) A suspension of 224 mg 104 (2.0 
mmol) and 613 mg trityl chloride (2.2 mmol) in 3 mL pyridine and 6 mL DMF was 
stirred at RT overnight. The RM was poured into water and extracted with EtOAc 
(2x). The combined organic layers were washed with 10% citric acid and sat NaCl 
solution, dried over Na2SO4 and concentrating . The residue was washed with EtOAc 
to afford 520 mg 105 as a white powder (73% yield from 104). 1H-NMR(400 MHz, 
CDCl3) δ: 7.65 (d, J=1.4Hz, 1H), 7.51 (d, J=1.4Hz, 1H), 7.38-7.33 (m, 9H), 7.12-7.08 
(m, 6H); Analytical data in agreement with literature.124  
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2-iodo-1H-imidazole-4-carboxylic acid (89) 100 mg (0.28 mmol) 105 was dissolved 
in 3 mL dry THF with 1 mL HMPA and cooled to -100 0C. 0.2 mL (0.34 mmol, 1.7M) 
tBuLi was added dropwize and the RM was stirred for 2 minutes. 125 mg (0.5 mmol) 
I2 dissolved in 2 mL dry THF was added dropwize and the RM was stirred for 5 min. 
at -100 0C. The cold RM was poured directlly into sat. Na2S2O3(aq) solution and was 
extracted with EtOAc (3x), the combined EtOAc was washed with sat. NaCl(s) 
solution, dried over Na2SO4(s) and evaporated to dryness. The residue was taken up 
in 2 mL TFA/water/TiPS 90:5:5 and stirred overnight. The solvent was removed 
under vacuum and the residue was purified using preparative HPLC. Imidazole 89 
was obtained as a white solid (44 mg, 45% yield from 105). Rf = 0.15 (DCM/MeOH 
8:2); 1H-NMR(400 MHz, CDCl3) δ: 8.18 (s, 1H); 
13C-NMR(101 MHz, CDCl3) δ: 
139.76, 129.12, 127.76; ESI HRMS calculated for C4H4O2N2I [M+H]
+ = 238.93120. 
Mass found [M+H]+ = 238.93114.  
 
 
 
 
 
 
 
 
N,N-bis(2,4-dimethoxybenzyl)-1-trityl-1H-imidazole-4-carboxamide (106) 1.2 g 
105 (3.4 mmol) and 1.27 g N,N-bis(2,4-dimethoxybenzyl)amine (4.0 mmol) were 
dissolved in 25 mL DMF. 460 mg HOBt (3.4 mmol) was added and the RM was 
cooled to 0 0C before adding 127 mg EDC.HCl (6.0 mmol) and 2.2 mL DiPEA (12 
mmol)  and the RM was stirred for 2 hours at RT under argon. The solvent was 
removed under vacuum and the product was purified by SiO2 column 
chromatography, eluted with cyclohexane/EtOAc (1:1 to 100% EtOAc) to obtain 2.1 g 
of 106 as a white foam (95% yield from 105). Rf = 0.20 (cyclohexane/EtOAc 1:1); 
1H-
NMR(400 MHz, CDCl3) δ: 7.50 (d, J=1.4Hz, 1H), 7.35-7.26 (m, 11H), 7.11-7.07 (m, 
7H), 6.45-6.37 (m, 4H), 5.20 (bs, 2H), 4.57 (bs, 2H), 3.78 (bs, 6H), 3.71 (bs, 3H), 
3.65 (bs, 3H); 13C-NMR(101 MHz, CDCl3) δ: 165.1, 160.0, 158.7, 158.7, 158.5, 
142.3, 138.1, 137.2, 130.0, 128.4, 128.3, 126.9, 119.2, 118.7, 104.2, 104.0, 98.5, 
75.9, 55.6, 55.3, 53.6, 46.7, 43.7; ESI HRMS calculated for C41H40O5N3 [M+H]
+ = 
654.29625. Mass found [M+H]+ = 654.29638.  
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2-iodo-1H-imidazole-4-carboxamide (90) 100 mg (0.15 mmol) 106 was dissolved in 
2 mL dry THF and cooled to -100 0C. 0.12 mL (0.19 mmol) 1.7M tBuLi was added 
dropwize and the RM was stirred for 2 min. 75 mg (0.3 mmol) I2 dissolved in 1 mL dry 
THF was added dropwize and the RM was stirred for 5 min. at -100 0C. The cold RM 
was poured directly into saturated Na2S2O3(aq) solution and was extracted with 
EtOAc (3x), the combined EtOAc was washed with sat. NaCl(aq) solution, dried over 
Na2SO4(s) and evaporated to dryness. The residue was taken up in 2 mL 
TFA/water/TiPS 90:5:5 and stirred overnight. The solvent was removed under 
vacuum and the residue was purified using preparative HPLC. Imidazole 90 was 
obtained as a white solid (20 mg, 38% yield from 106). Rf = 0.38 (DCM/MeOH 8:2); 
1H-NMR(400 MHz, CD3OD) δ: 8.23 (s, 1H); 
13C-NMR(101 MHz, CDCl3); 162.58, 
139.13, 132.75, 114.53; ESI HRMS calculated for C4H5ON3I [M+H]
+ = 237.94718. 
Mass found [M+H]+ = 237.94736.  
 
 
 
9.10 Synthesis of 3,5-diphenyl isothiazolidine 1,1-dioxide 
 
 
 
 
 
 
 
 
 
 
N-(2-chloro-1-phenylethyl)-1-phenylmethanesulfonamide (111) 0.55 g (14.5 
mmol) LiAlH4 was weight in a flask (carefully not to make a dust cloud). The flask was 
flushed with argon before adding 20 mL of THF. The suspension was cooled to 0 0C 
and 1.0 g (6.6 mmol) 114 was added in portions. The RM was stirred for one hour at 
RT and at 50 0C overnight. The RM was cooled to 0 0C and 0.5 mL water was added 
dropwise. The RM became thick and 10 mL THF was added before 3 mL 2M 
K2CO3(aq) solution was added. Filtration and evaporation of the solvent gave a 
yellow solid that was dissolved in 25 mL THF and 2 mL TEA was added. The RM 
was cooled to 0 0C. and 2.86 g (15 mmol) 112 was added portion wise. The ice bath 
was removed and the RM was stirred at RT for 8 hours. The precipitated salt was 
filtered off and washed with EtOAc. The filtrate was evaporated to dryness and 
dissolved in 16 mL DMF. 0.6 g NaCl(s) was added and the RM was stirred overnight 
at 80 0C. The RM was allowed to cool before adding water and was extracting with 
EtOAc (3x). The combined EtOAc was washed with 1M HCl and sat. NaCl(aq) 
solution. Drying over Na2SO4 and evaporation yielded a yellow solid that was purified 
by SiO2 column chromatography, eluted with cyclohexane/EtOAc (8:2) to obtain 1540 
mg of 111 as an off-white solid (68% yield from 114). Rf = 0.38 (cyclohexane/EtOAc 
1:1); 1H-NMR(400 MHz, CDCl3) δ: 7.42-7.17 (m, 10H), 5.11 (d, J=8.0Hz, 2H), 4.66 (q, 
J=8.0Hz, 2H), 4.11 (m, 2H), 3.73 (m, 2H); 13C-NMR(101 MHz, CDCl3) δ: 138.2, 
131.0, 129.2, 129.0, 128.91, 128.88, 127.2, 60.4, 59.0, 48.8; ESI HRMS calculated 
for C15H17O2NClS [M+H]
+ = 310.06630. Mass found [M+H]+ = 310.06641.  
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3,5-diphenylisothiazolidine 1,1-dioxide (107) 600 mg chloride 111 (1.94 mmol) and 
68 µL (0.49 mmol) diisopropylamine were dissolved in 20 mL dry THF and cooled to -
70 oC. 2.8 mL 1.6 M BuLi solution (4.36 mmol) was added dropwise and the reaction 
mixture was allowed to warm to 0 0C over 1 hour. The mixture was stirred at 0 0C for 
2 hours and quenched with a 1.0 M HCl solution. The reaction mixture was extracted 
with EtOAc (3x). The combined organic layers were washed with sat. NaCl(aq) 
solution, dried over MgSO4 and concentrated to dryness. The residue was purified by 
SiO2 column chromatography, eluted with cyclohexane/EtOAc (1:1) to obtain 188 mg 
of 107 isomer 1 and 153 mg of 107 isomer 2 as off-white solids (64% total yield from 
111). Isomer 1: Rf = 0.25 (cyclohexane/EtOAc 1:1); 
1H-NMR(400 MHz, CDCl3) δ: 
7.50-7.34 (m, 10H), 4.89 (m, 1H), 4.77 (bd, 1H), 4.52 (m, 1H) 3.19 (m, 1H) 2.70 (m, 
1H); 13C-NMR(101 MHz, CDCl3) δ: 141.5, 130.5, 129.44, 129.41, 129.2, 129.1, 
128.6, 61.3, 55.1, 37.4; ESI HRMS calculated for C15H16O2NS [M+H]
+ = 274.08963. 
Mass found [M+H]+ = 274.08985. Isomer 2: Rf = 0.15 (cyclohexane/EtOAc 1:1); 
1H-
NMR(400 MHz, CDCl3) δ: 7.50-7.31 (m, 10H), 5.02 (bd, 1H), 4.78 (m, 1H), 4.51 (m, 
1H) 2.94 (m, 1H) 2.70 (m, 1H); 13C-NMR(101 MHz, CDCl3) δ: 140.7, 129.9, 129.5, 
129.20, 129.17, 129.15, 128.6, 65.4, 56.0, 38.3; ESI HRMS calculated for 
C15H16O2NS [M+H]
+ = 274.08963. Mass found [M+H]+ = 274.08989.  
 
 
 
9.11 Synthesis of Prodrugs 121 and 122 
 
 
 
 
 
 
 
 
(4-sulfamoyl-1H-imidazol-2-yl)methyl acetate (121) 50 mg (0.07 mmol) 58 was 
dissolved in 0.5 mL dry DCM and 0.5 mL pyridine was added before cooling the RT 
to 0 0C. 6 µL acetyl chloride (0.08 mmol) was added and the RM was stirred for 2 
hour at RT. The solvent was evaporated and the residue was suspended in 2 mL 
TFA with 50 µL TiPS and 50 µL water and stirred overnight at RT. The solvent was 
evaporated and the residue taken up in MeOH and purified using prep HPLC yielding 
13 mg 121 (56% yield from 58). Rf = 0.40 (DCM/MeOH 9:1); 
1H-NMR(400 MHz, 
CD3OD) δ: 7.60 (s, 1H), 5.14 (s, 2H), 2.10 (s, 3H); 
13C-NMR(101 MHz, CD3OD) δ: 
170.8, 144.9, 141.9, 120.1, 58.1, 19.2; ESI HRMS calculated for C6H10O4N3S [M+H]
+ 
= 220.03865. Mass found [M+H]+ = 220.03859.  
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(4-sulfamoyl-1H-imidazol-2-yl)methyl benzoate (122) 50 mg (0.07 mmol) 58 was 
dissolved in 0.5 mL dry DCM and 0.5 mL pyridine was added before cooling the RT 
to 0 0C. 10 µL benzoyl chloride (0.08 mmol) was added and the RM was stirred for 2 
hour at RT. The solvent was evaporated and the residue was suspended in 2 mL 
TFA with 50 µL TiPS and 50 µL water and stirred overnight at RT. The solvent was 
evaporated and the residue taken up in MeOH and purified using prep HPLC yielding 
21 mg 122 (76% yield from 58). Rf = 0.55 (DCM/MeOH 9:1); 
1H-NMR(400 MHz, 
CD3OD) δ: 8.04 (dt, J=8.4Hz, J=2.4Hz, 1H), 7.64 (s, 1H), 7.61 (dd, J=2.4Hz, 
J=8.4Hz, 2H),  7.48 (dt, J=2.4Hz, J=8.4Hz, 2H),  5.4 (s, 2H)); 13C-NMR(101 MHz, 
CD3OD) δ: 166.1, 144.8, 141.9, 133.5, 129.6, 129.4, 128.5, 120.3, 58.5; ESI HRMS 
calculated for C11H12O4N3S [M+H]
+ = 282.05430. Mass found [M+H]+ = 282.05422. 
 
 
 
 
9.12 Synthesis of TAMRA labeled Probe 123 
 
 
 
 
 
 
 
 
2-(2-(2-azidoethoxy)ethoxy)ethanol (125) 38.6 g (257 mmol) triethylene glycol 
(124) was dissolved in 250 mL anhydrous THF under argon atmosphere and cooled 
to 0 0C. 5.0 mL methanesulfonyl chloride (64.4 mmol) and 9.0 mL TEA (64.4 mmol) 
were added dropwise. The RM was allowed to stir at room temperature overnight 
under an argon atmosphere. The reaction mixture was concentrated and the residue 
was dissolved in 250 mL dry ethanol. 20.9 g sodium azide (322.0 mmol) was added 
and the reaction mixture was heated to reflux for 6 hours. After cooling to room 
temperature the mixture was concentrated and dissolved in water. The product was 
extracted with DCM (3x), and the combined organic fractions were dried over 
magnesium sulfate, filtered, and concentrated to yield 5.1 g 125 as a sticky oil (45% 
yield from methanesulfonyl chloride). Rf = 0.20 (100% EtOAc); 
1H-NMR(400 MHz, 
CDCl3) δ: 3.77 (t, J = 5.8 Hz, 2H), 3.72 – 3.66 (m, 6H), 3.64 (t, J = 5.8 Hz, 2H), 3.39 
(t, J = 5.0 Hz, 2H), 1.57 (s, 1H). Analytical data in agreement with literature.117  
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2-(2-(2-azidoethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (126) 5.0 g (28.5 
mmol) 125 was dissolved in 50 mL DCM and 50 mL pyridine and 6.0 g (31.5 mmol) 
4-toluenesulfonyl chloride was added. The RM was stirred overnight at RT. The RM 
was evaporated to dryness and the residue was taken up in DCM and washed with 
sat. NaCl solution. The DCM was evaporated to dryness and the residue taken up in 
DCM. After washing the organic layer with sat. NaCl solution, the solvent was 
removed by evaporation. The product was purified by SiO2 column chromatography, 
eluted with EtOAc (100%) to obtain 6.2 g of 126 (66% yield from 125). Rf = 0.20 
(100% EtOAc); 1H-NMR(400 MHz, CDCl3) δ: 7.80 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 8.0 
Hz, 2H), 4.19 – 4.15 (m, 2H), 3.79 – 3.61 (m, 8H), 3.41 – 3.33 (m, 2H), 2.45 (s, 3H). 
Analytical data in agreement with literature.117  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2-((2-(2-(2-azidoethoxy)ethoxy)ethoxy)methyl)-N,N-bis(2,4-dimethoxybenzyl)-1-
trityl-1H-imidazole-4-sulfonamide (127) 50 mg (0.07 mmol) 58 was dissolved in 0.5 
mL dry DMF and 3.0 mg (0.08 mmol) NaH 60 % dispersion in mineral oil was added 
and the mixture was stirred for 30 min. 33 mg (0.10 mmol) 126 dissolved in 0.5 mL 
DMF was added dropwise and the RM was stirred overnight at RT. The RM was 
concentrated and diluted with DCM and washed with sat NaHCO3. The DCM was 
dried over Na2SO4(s) and evaporated. The product was purified by SiO2 column 
chromatography, eluted with cyclohexane/EtOAc (7:3 to 1:1) to obtain 25 mg 127 
(41% yield from 58). Rf = 0.20 (toluene/EtOAc 1:3); 
1H-NMR(400 MHz, CDCl3) δ: 
7.35-7.30 (m, 9H), 7.24 (d, J=8.2Hz, 1H), 7.17 (s, 1H), 7.06-7.02 (m, 6H), 6.36 (dd, 
J=2.6Hz, J=8.2Hz, 2H), 6.31 (d, J=2.6Hz, 2H), 4.5 (s, 4H), 3.75 (s, 6H), 3.74 (s, 2H), 
3.65 (s, 6H), 3.64-3.53 (m, 6H), 3.44 (t, J=4.8Hz, 2H), 3.36-3.32 (m, 4H); 13C-
NMR(101 MHz, CDCl3) δ: 160.2, 158.4, 148.3, 141.7, 138.5, 130.6, 129.9, 128.52, 
128.49, 124.9, 117.9, 104.2, 98.0, 76.4, 71.4, 70.8, 70.71, 70.66, 70.56, 70.2, 70.1, 
66.2, 55.5, 55.3, 50.9, 46.1, 42.9; ESI HRMS calculated for C47H53O9N6S [M+H]
+ = 
877.35892. Mass found [M+H]+ = 877.35963.  
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3',6'-bis(dimethylamino)-3-oxo-N-(2-(2-(2-((4-sulfamoyl-1H-imidazol-2-
yl)methoxy)ethoxy)ethoxy)ethyl)-3H-spiro[isobenzofuran-1,9'-xanthene]-5/6-
carboxamide (123) 25 mg (0.028 mmol) 127 was dissolved in 0.5 mL THF and 9.0 
mg (0.034 mmol) PPh3 was added and stirred for 6 hours. 10 uL water was added 
and the RM was stirred overnight. The solvent was evaporated and the residue was 
dissolved in 1 mL DMF and 14.8 mg (0.028 mmol) TAMRA-OSu was added and after 
addition of 4.0 µL (0.029 mmol) TEA stirred overnight at RT in a dark vial. The RM 
was diluted with 2 mL EtOAc and was washed with sat. NaHCO3(aq) and evaporated 
to dryness.The residue was suspended in 2 mL TFA with 50 µL TiPS and 50 µL 
water and stirred at RT for 2 hours. The solvent was evaporated and the residue 
taken up in MeOH and purified using prep HPLC yielding 2.0 mg 123 (10% yield from 
127). ESI HRMS calculated for C35H41O9N6S [M+H]
+ = 721.26502. Mass found 
[M+H]+ = 721.26491.  
 
 
 
9.13 Synthesis of Histone H4 Peptide Probes 
 
 
 
 
 
 
 
 
 
tert-butyl 3-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)propanoate (135) 51.2 mL 
(376 mmol) triethyleneglycol 124 was dissolved in 200 mL dry THF and 80 mg (1.8 
mmol) sodium was added under argon. The sodium was allowed to dissolve before 
adding 19.2 mL (132 mmol) tertbutylacrylate and stirring overnight at RT. 3.0 mL 1M 
HCl(aq) was added to the RM before removing the solvent. The oily residu was taken 
up in 150 mL saturated NaCl(aq) solution and extracted with EtOAc 3x. The 
combined EtOAc was washed with saturated NaCl(aq), dried over anhydrous 
Na2SO4(s), evaporated and extensively dried under high vacuum, yielding 30.0 g 135 
(29% yield from 124). 1H-NMR(400 MHz, CDCl3) δ: 3.76 – 3.56 (m, 14H), 2.50 (t, J = 
6.6 Hz, 2H), 2.40 (s, 1H), 1.44 (s, 9H). Analytical data in agreement with literature.118  
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tert-butyl 3-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)propanoate (136) 29.0 g (104 
mmol) 135 was dissolved in 40 mL dry DCM before adding 35 mL (251 mmol) TEA. 
The RM was cooled with an icebath before adding 16.4 mL (214 mmol) mesyl 
chloride dropwise. The icebath was removed and the RM was stirred for 4 hours. The 
RM was filtered over celite before washing the DCM with icecold water (2x). The 
DCM was washed with sat. NaCl(aq) solution and dried over anhydrous MgSO4(s) 
before removing the solvent through evaporation. The resulting oil was taken up in 40 
mL DMF and 40.0 g (615 mmol) NaN3 was added. The suspension was stirred 
overnight at 60 ºC. The DMF was removed by vacuum and the resulting solid 
material was dissolved in water and extracted with diethylether (2x). De combined 
organic layers were washed with sat. NaCl(s) solution, dried over anhydrous 
MgSO4(s) and evaporated. The product was purified by SiO2 column 
chromatography, eluted with petroleum ether/ethyl ether (3:1) to obtain 27.6 g 136 
(87% yield from 135). 1H-NMR(400 MHz, CDCl3) δ: 3.76 – 3.56 (m, 12H), 3.39 (t, J = 
5.1 Hz, 2H), 2.50 (t, J = 6.6 Hz, 2H), 1.45 (s, 9H). Analytical data in agreement with 
literature.119  
 
 
 
 
 
 
 
 
 
 
 
tert-butyl 19-((4R,5S)-5-methyl-2-oxoimidazolidin-4-yl)-14-oxo-4,7,10-trioxa-13-
azanonadecan-1-oate (137) 334 mg (1.1 mmol) 136 was dissolved in 4 mL 
dioxane/water (9:1) and 317 mg (1.2 mmol) triphenylphosphine was added and the 
RM was stirred overnight. The RM was evaoprated to dryness and coevaporated with 
toluene (3x). The residue was dissolved in 1 mL DMF and a solution of 250 mg 
(1.16mmol) desthiobiotin, 232 mg (1.2 mmol) EDC.HCl and 28 mg (0.23 mmol) 
DMAP in 4 mL DMF was added. The RM was stirred overnight at RT and the DMF 
was evaporated. The residue was purified by SiO2 column chromatography 
(DCM/MeOH 98:2 - 9:1) yielding 225 mg 137 (43% yield from 136). Rf = 0.60 
(DCM/MeOH 1:9); 1H-NMR(400 MHz, CDCl3) δ: 6.62 (bs, 1H), 5.86 (bs, 1H), 5.05 
(bs, 1H), 3.77 (m, 1H), 3.68 (m, 3H), 3.59 (s, 10H), 3.53 (t, J = 5.9 Hz, 2H), 3.39 (m, 
2H), 2.47 (t, J = 6.0 Hz, 2H), 2.16 (t, J = 6.0 Hz, 2H), 1.63 (m, 2H), 1.52 – 1.20 (m, 
13H), 1.08 (d, J = 8.0 Hz, 3H). ESI HRMS calculated for C23H44O7N3 [M+H]
+ = 
474.3174. Mass found [M+H]+ = 474.3166. 
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(S)-25-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-1-((4R,5S)-5-methyl-2-
oxoimidazolidin-4-yl)-6,19-dioxo-10,13,16-trioxa-7,20-diazahexacosan-26-oic 
acid (134) 140 mg (0.30 mmol) 137 was dissolved in 3 mL DCE. 1 mL TFA was 
added dropwise and the RM was stirred for 30 min. The solvent was evaporated and 
the residue was taken up in DCE and evaporated to dryness. The residue was 
coevaporated with toluene (2x) and dried overnight under vacuum yielding 120 mg 
138. The oily material was redissolved in 2 mL DCM and 101 mg (0.88 mmol) N-
Hydroxysuccinimide was added. After cooling the RM to 0 ºC, 191 mg (1.0 mmol) 
EDC.HCl was added under an argon atmosphere. The icebath was removed and the 
RM was stirred overnight. The RM was evaporated to dryness and redissolved in a 
ice cooled solution of 5 mL dioxane/NaHCO3 (sat.) 1:1. 648 mg (1.6 mmol) Fmoc-
Lys-OH was added (suspended in 10 mL dioxane/NaHCO3 (sat.) 1:1) and the RM 
was stirred under argon atmosphere for 3 hours at RT. The RM was made acidic (pH 
3) with KHSO4(s) before evaporation to dryness.  The solid was suspended in CHCl3 
with 10% ethanol added and stirred for 2 hours before decanting of the liquid (done 
twice). The combined liquid was evaporated and the oily material was purified using 
prep HPLC yielding 71 mg 134 (31% yield from 137). Rf = 0.24 (DCM/MeOH 8:2); 
1H-
NMR(400 MHz, CD3OD) δ: 12.50 (s, 1H), 7.87 (d, J = 7.5 Hz, 2H), 7.83 – 7.75 (m, 
2H), 7.71 (d, J = 7.4 Hz, 2H), 7.57 (d, J = 7.9 Hz, 1H), 7.40 (t, J = 7.4 Hz, 2H), 7.31 (t, 
J = 7.2 Hz, 2H), 6.26 (s, 1H), 6.08 (s, 1H), 4.31 – 4.15 (m, 3H), 3.89 (td, J = 9.1, 4.6 
Hz, 1H), 3.57 (q, J = 6.6 Hz, 3H), 3.46 (d, J = 5.0 Hz, 9H), 3.36 (t, J = 5.9 Hz, 2H), 
3.15 (q, J = 5.8 Hz, 2H), 3.06 – 2.95 (m, 2H), 2.27 (t, J = 6.5 Hz, 2H), 2.03 (t, J = 7.4 
Hz, 2H), 1.75 – 1.51 (m, 2H), 1.32 (tdd, J = 50.4, 19.8, 13.0 Hz, 13H), 0.93 (d, J = 6.4 
Hz, 3H); ESI HRMS calculated for C40H58O10N5 [M+H]
+ = 768.41782. Mass found 
[M+H]+ = 768.41760  
 
 
Peptides 131, 132 and 133 Synthesized like was described for peptides 37 and 38 
but with an automated peptide synthesizer on Tentagel Rink-amide (0.24 mmol/g) 
resin. Before cleavage of the peptides from the resin, the alloc on the lysine was 
removed using 50 mol% Pd(PPh3)4 in piperidine/DMF (performed 2x) and 138 was 
coupled using standard HOAt/HATU conditions (performed 2x). Cleavage from the 
resin and global deprotecting was performed as described for peptides 37 and 38. 
After preparative reverse phase HPLC purification (C18) and subsequent 
lyophilization the peptides 131, 132 and 133 were isolated as white solids. 
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Peptide 131; Isolated was 47 mg (22 % yield from 0.25 g resin). ESI HRMS 
calculated for C118H214O35N43P [M+2H]
2+ = 1412.30071. Mass found [M+2H]2+ = 
1412.29920. 
 
 
 
 
 
 
Peptide 132; Isolated was 42 mg (20 % yield from 0.25 g resin). ESI HRMS 
calculated for C118H216O32N43 [M+5H]
5+ = 549.53138. Mass found [M+5H]5+ = 
549.53107. 
 
 
 
 
 
 
Peptide 133; Isolated was 37 mg (17 % yield from 0.25 g resin). ESI HRMS 
calculated for C118H217O34N44S [M+5H]
5+ = 565.32594. Mass found [M+5H]5+ = 
565.32579 
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(S)-tert-butyl 2-((tert-butoxycarbonyl)amino)-4-((4-nitrophenyl)amino)-4-
oxobutanoate (147) 1.0 g (3.5 mmol) 146 was dissolved in 10 mL DCM at 0 0C. 0.61 
g (4.5 mmol) HOAt and 1.0 g (5.24 mmol) EDC.HCl were added. The RM was 
allowed to reach RT and was stirred overnight. The RM was washed with 5% citric 
acid solution, saturated NaCl(aq) solution and dried over anhydrous Na2SO4(s) and 
evaporated to dryness. The residue was dissolved in 20 mL dry DCM. The RM was 
cooled to 0 0C and 370 mg (2.68 mmol) 4-nitroaniline and 73 µL (0.49 mmol) DBU 
were added and the RM was stirred overnight at 35 0C. The RM was washed with a 
saturated NaHCO3(aq) solution, dried over anhydrous Na2SO4(s) and evaporated to 
dryness. The product was purified by SiO2 column chromatography (hexane/EtOAc 
8:2 to 100%) to obtain 440 mg 147 (44% yield from 146). Rf = 0.65 (EtOAc); 
1H-
NMR(400 MHz, CDCl3) δ: 8.48 (bs, 1H), 8.28 – 8.14 (m, 2H), 7.82 – 7.65 (m, 2H), 
7.26 (s, 2H), 5.60 (s, 1H), 4.49 (dt, J = 7.7, 5.3 Hz, 1H), 3.11 – 2.84 (m, 2H), 1.48 (s, 
9H), 1.45 (s, 10H). 
 
 
 
 
 
 
 
 
 
(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-((4-nitrophenyl)amino)-4-
oxobutanoic acid (145) 400 mg (0.98 mmol) 147 was dissolved in 10 mL DCM. 10 
mL TFA and 2 mL H2O were added and the RM was stirred for 4 hours. The solvent 
was removed by vacuum and the residue was redissolved in 10 mL dioxane and 10 
mL water. 300 mg (2.0 mmol) NaHCO3(s) was added and the RM was cooled to 0 
0C. 600 mg (1.1 mmol) Fmoc-OSu was added and the RM was stirred at RT 
overnight. The RM was poured into EtOAc and washed with a 5% citric acid solution 
and with a sat. NaCl(aq) solution. The EtOAc was dried over anhydrous Na2SO4(s) 
and evaporated. The product was purified by SiO2 column chromatography 
(DCM/MeOH 99:1 to 9:1) to obtain 256 mg 145 (57% yield from 147). Rf = 0.38 
(DCM/MeOH 8:2); 1H-NMR(400 MHz, DMSO-d6) δ: 11.03 (s, 1H), 8.12 (d, J = 8.9 Hz, 
2H), 7.82 (dd, J = 13.5, 8.4 Hz, 4H), 7.65 (d, J = 7.2 Hz, 2H), 7.36 (m, 3H), 7.27 (q, J 
= 8.3, 7.3 Hz, 2H), 4.42 – 4.29 (m, 1H), 4.21 (m, 3H), 3.16 (s, 1H), 3.00 – 2.88 (m, 
1H), 2.87 (s, 1H), 2.79 – 2.67 (m, 3H), 2.48 (dt, J = 3.6, 1.8 Hz, 1H); 13C-NMR(101 
MHz, DMSO-d6) δ: 170.74, 162.99, 156.38, 146.22, 144.51, 142.57, 141.35, 128.25, 
127.72, 125.91, 125.50, 120.74, 119.33, 66.30, 47.33, 36.46, 31.46; ESI HRMS 
calculated for C25H22O7N3S [M+H]
+ = 476.14523. Mass found [M+H]+ = 476.14465.  
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Peptides 143 Synthesized like was described for peptides 37 and 38 but with an 
automated peptide synthesizer on Tentagel Rink-amide resin (0.24 mmol/g). 
Cleavage from the resin and global deprotecting was performed as described for 
peptides 37 and 38. After preparative reverse phase HPLC purification (C18) and 
subsequent lyophilization, 240 mg peptide 143 was isolated as a white solid (31 % 
yield from 1.0 g resin). ESI HRMS calculated for C97H167O25N39 [M+2H]
2+ = 
1140.15759. Mass found [M+2H]2+ = 1140.15741. 
 
 
 
 
 
 
Peptide 144 10 mg (0.0044 mmol) 143 was dissolved in 2 ml H2O. 5.9 mg (0.044 
mmol) potassium phosphoramidate and 4.2 mg (0.053 mmol) NH4HCO3(s) were 
added. The mixture was stirred for 7 days at RT. The RM was purified by Source 15S 
cation exchange column chromatography using a gradient of NH4HCO3 salt solution 
50 to 1500 mM). The fractions containing product were run a second type to obtain 
5.0 mg of chemically pure material (….% yield from 143). 31P-NMR(161 MHz, CDCl3) 
δ: -3.73; MALDI-TOF calculated for C97H167O28N39P [M-1H]
- = 2357.25804. Mass 
found [M-1H]- = 2357.6. 
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